

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPIINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPIINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family searching
NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:17:30 ON 05 JUN 2008

FILE 'REGISTRY' ENTERED AT 11:17:38 ON 05 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JUN 2008 HIGHEST RN 1025498-38-7
DICTIONARY FILE UPDATES: 4 JUN 2008 HIGHEST RN 1025498-38-7

New CAS Information Use Policies. enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10518496.str



```

chain nodes :
 11 12 13 14 15
ring nodes :
 1 2 3 4 5 6 7
chain bonds :
 11-12 12-13 12-14 13-15
ring bonds :
 1-2 1-6 1-7 2-3 3-4 4-5 4-7 5-6
exact/norm bonds :
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 11-12 12-13 12-14 13-15


```

exact bonds :
1-7
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 11:CLASS 12:CLASS
13:CLASS 14:CLASS 15:Atom 16:CLASS

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 full
FULL SEARCH INITIATED 11:17:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 21366 TO ITERATE

100.0% PROCESSED 21366 ITERATIONS 1016 ANSWERS
SEARCH TIME: 00.00.01

L2 1016 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
 178.36 178.57

FILE 'CAPLUS' ENTERED AT 11:18:05 ON 05 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 5 Jun 2008 VOL 148 ISS 23
FILE LAST UPDATED: 4 Jun 2008 (20080604/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12 full
L3 50 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008121112 CAPLUS

DOCUMENT NUMBER: 148:192110

TITLE: Quinuclidine derivatives as M3 antagonists

INVENTOR(S): Amari, Gabriele; Rizzi, Andrea; Patacchini, Riccardo; Cenacchi, Valentina; Villetti, Gino; Catena Ruiz, Juan Lorenzo; Masip Masip, Isabel

PATENT ASSIGNEE(S): Chiesi Farmaceutici S.p.A., Italy

SOURCE: PCT Int. Appl., 25pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2008012290 | A2 | 20080131 | WO 2007-EP57585 | 20070723 |
| WO 2008012290 | A3 | 20080313 | | |
| W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OR | | | | |
| EP 1882691 | A1 | 20080130 | EP 2006-117883 | 20060726 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| US 20080039493 | A1 | 20080214 | US 2007-881146 | 20070725 |
| PRIORITY APPLN. INFO.: | | | EP 2006-117883 | A 20060726 |
| OTHER SOURCE(S): MARPAT 148:192110 | | | | |
| GI | | | | |



AB Quinuclidine derivs., such as I [R1 = H, F, Cl, Br, iodo, C1-C4-alkyl; R2 = optionally substituted 2- or 3-thienyl, or substituted phenyl; R3 = (CH2)1-4-COR4 or (CH2)1-4-S(O)nR4; R4 = optionally substituted Ph or

optionally substituted 2- or 3-thienyl; n = 0, 1 or 2; X- = pharmaceutically acceptable anion] in the form of single enantiomers or mixts. thereof, were prepared for therapeutic use as muscarinic M3 receptor antagonists for the treatment or prevention of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema. Thus, quinuclidine derivative II was prepared via a quaternization reaction of (3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester with 2-bromo-1-(2-thienyl)ethanone in MeCN and CHCl3. The prepared quinuclidines were tested for M3 receptor antagonist activity using isolated guinea pig trachea as indication of action against acetylcholine induced bronchospasm.

IT 1004312-95-1P 1004312-96-2P 1004312-97-3P

1004312-98-4P 1004312-99-5P 1004313-00-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of quinuclidine derivs. for therapeutic use


as

M3 antagonists)

RN 1004312-99-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1004312-96-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1004312-97-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)((3,4,5-trifluorophenyl)methyl)amino]carbonyl}oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1004312-98-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(4-fluorophenyl)-2-oxoethyl]-3-[{[(3-fluorophenyl)((3,4,5-trifluorophenyl)methyl)amino]carbonyl}oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1004312-99-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-fluorophenyl)((3,4,5-trifluorophenyl)methyl)amino]carbonyl}oxy]-1-[2-(phenylthio)ethyl]bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 1004313-00-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)((3,4,5-trifluorophenyl)methyl)amino]carbonyl}oxy]-1-[(phenylthio)methyl]bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


IT 1004312-94-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 preparation of quinuclidine derivs. for therapeutic use as M3 antagonists)

RN 1004312-94-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl}oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 552860-82-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 preparation of quinuclidine derivs. for therapeutic use as M3 antagonists)

RN 552860-82-9 CAPLUS

CN Carbanic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 385367-47-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinuclidine derivs. for therapeutic use as M3 antagonists)

RN 385367-47-5 CAPLUS

CN Carbanic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 2007:999179 CAPLUS

DOCUMENT NUMBER: 147:323165

TITLE: Cytisine and acetylcholine analogs and methods of
treating mood disordersINVENTOR(S): Picciotto, Marina; Gundisch, Daniela; Munoz, Lenka;
Andra, Matthias; Mineur, YannPATENT ASSIGNEE(S): Yale University, USA; Rheinische Friedrich-Wilhelms-
Universitat BonnSOURCE: PCT Int. Appl., 124pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2007100430 | A2 | 20070907 | WO 2007-US2297 | 20070126 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: US 2006-763197P P 20060127

OTHER SOURCE(S): MARPAT 147:323165

GI



AB Cytisine derivs., such as I [R = H, alkyl, acyl, carboxyl; R3, R5 = H, halogen, alkyl, alkenyl, alkynyl, substituted- or unsubstituted-phenyl, heteroaryl, etc.], and acetylcholine analogs were prepared for use in pharmaceutical compns. which modulate nicotinic acetylcholine receptor (nAChR) activity. These compds. were claimed for therapeutic use in the treatment of mood disorders, such as major depressive disorder, bipolar disorder, unipolar disorder, dysthymia (dysthymic disorder), postpartum depression, seasonal affective disorder or schizoaffective disorder. These compds. were also claimed for use in combination with tricyclic antidepressants, such as amitriptyline, clomipramine, desipramine, dothiepin hydrochloride, doxepin, imipramine, leoperamine, nortriptyline, protriptyline or trimipramine, with MAO inhibitors, such as isocarboxazid, phenelzine or tranylcypromine, and with serotonin reuptake inhibitors,


such as escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline or fluoxetine. Thus, 3-phenylcytisine I ($R = R_5 = H$, $R_3 = Ph$) was prepared via isolation of cytisine I ($R = R_3 = R_5 = H$) from seeds of Laburnum anagyroides and L. watereri, N-protection of cytisine and subsequent bromination to give intermediate bromide I ($R = CO_2CMe_3$, $R_3 = Br$, $R_5 = H$), and finally, a cross-coupling/deprotection reaction of the bromide with $PhB(OH)_2$ using Na_2CO_3 and $Pd(PPh_3)_4$ in DME and H_2O to form the target cytisine derivative. The prepared compds. were assayed in mice for binding affinity for a number of nAChR subtypes.

IT 753026-70-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cytisine derivs. and acetylcholine analogs as nicotinic acetylcholine receptor ligands for therapeutic use in treatment of mood disorders)

RN 753026-70-9 CAPLUS

CN Carbamic acid, N-(3-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)




IT 195191-11-8P 753026-71-0P 753026-73-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cytisine derivs. and acetylcholine analogs as nicotinic acetylcholine receptor ligands for therapeutic use in treatment of mood disorders)


RN 195191-11-8 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-3-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)




RN 753026-71-0 CAPLUS

CN Carbamic acid, N-(3-methylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)



IT 753026-73-2 CAPLUS

CN Carbamic acid, N-[3-(2-phenylethenyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)



ACCESSION NUMBER: 2007:702698 CAPLUS

DOCUMENT NUMBER: 147:125811

TITLE: Combination comprising cyclooxygenase and
lipoxygenase inhibitor for managing inflammation and
associated disorders

INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand

PATENT ASSIGNEE(S): Panacea Biotech Ltd., India

SOURCE: PCT Int. Appl., 37pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2007072503 | A2 | 20070628 | WO 2006-IN496 | 20061218 |
| WO 2007072503 | A3 | 20071101 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |

PRIORITY APPLN. INFO.:

IN 2005-DE3431 A 20051221


AB This invention relates to pharmaceutical compns. comprising at least one analgesic and anti-inflammatory compound(s) that inhibits both cyclooxygenase (COX) and lipoxygenase (LOX) as active agent in combination with at least one another active agent(s) optionally with other pharmaceutically, acceptable excipients is provided. Also described are process for preparation of such compns. and method of using such compns. for the management of inflammation and pain and/or other associated disorders. Thus, tablet was prepared containing licofelone 200 mg, nimesulide 100 mg, AvicelPH 101 50 mg, lactose monohydrate 35 mg, starch 1500 30 mg, sodium lauryl sulfate 20 mg, croscarmellose sodium 15 mg, silicone dioxide 5 mg, starch 20 mg, magnesium stearate 5 mg, talc 5 mg and purified water as needed.

IT 171722-81-9, YM-46303

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination comprising cyclooxygenase and lipoxygenase inhibitor for
managing inflammation and associated disorders)

RN 171722-81-9 CAPLUS


CN Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 4 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:60686 CAPLUS
DOCUMENT NUMBER: 146:333161
TITLE: Novel Chemical Enhancers of Heat Shock Increase Thermal Radiosensitization through a Mitotic Catastrophe Pathway
AUTHOR(S): Sekhar, Konjeti R.; Sonar, Vijayakumar N.; Muthusamy, Venkatraj; Sasi, Soumya; Laszlo, Andrei; Sawani, Jamil; Horikoshi, Nobuo; Higashikubo, Ryujii; Bristow, Robert G.; Borrelli, Michael J.; Crooks, Peter A.; Lepock, James R.; Roti Roti, Joseph L.; Freeman, Michael L.
CORPORATE SOURCE: Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
SOURCE: Cancer Research (2007), 67(2), 695-701
CODEN: CNRAE8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Radiation therapy combined with adjuvant hyperthermia has the potential to provide outstanding local-regional control for refractory disease. However, achieving therapeutic thermal dose can be problematic. In the current investigation, we used a chemical-driven approach with the goal of designing and synthesizing novel small mols. that could function as thermal radiosensitizers. (Z)-(-)-2-(1-Benzenesulfonylindol-3-ylmethylene)-1-azabicyclo[2.2.2]octan-3-ol was identified as a compound that could lower the threshold for Hsfl activation and thermal sensitivity. Enhanced thermal sensitivity was associated with significant thermal radiosensitization. We established the structural requirements for activity: the presence of an N-benzenesulfonylindole or N-benzylindole moiety linked at the indolic 3-position to a 2-(1-azabicyclo[2.2.2]octan-3-ol) or 2-(1-azabicyclo[2.2.2]octan-3-one) moiety. These small mols. functioned by exploiting the underlying biophys. events responsible for thermal sensitization. Thermal radiosensitization was characterized biochem. and found to include loss of mitochondrial membrane potential, followed by mitotic catastrophe. These studies identified a novel series of small mols. that represent a promising tool for the treatment of recurrent tumors by ionizing radiation.
IT 929256-72-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chemical enhancers of heat shock increase thermal radiosensitization through mitotic catastrophe pathway)
RN 929256-72-4 CAPLUS
CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-[(1-(phenylsulfonyl)-1H-indol-3-yl)methylene]-, 3-(N-phenylcarbamate), (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:676969 CAPLUS

DOCUMENT NUMBER: 145:117429

TITLE: Use of 3-substituted-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octanes for treating MRG-X1 receptor-mediated diseases

INVENTOR(S): Kunapuli, Priya; Strulovici, Berta

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2006074146 | A2 | 20060713 | WO 2006-US55 | 20060103 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 1855678 | A2 | 20071121 | EP 2006-717280 | 20061003 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| US 20080027095 | A1 | 20080131 | US 2007-794400 | 20070627 |
| PRIORITY APPLN. INFO.: | | | US 2005-642230P | P 20050107 |
| | | | WO 2006-US55 | W 20060103 |

OTHER SOURCE(S): MARPAT 145:117429

AB The invention discloses a method for treating a disease or condition mediated by the human MRG-X1 receptor, e.g. as nociception, hyperalgesia, allodynia, pain related to central hypersensitivity conditions, somatic pain, visceral pain, acute pain, chronic pain, post-operative pain, headache, inflammatory pain, neurop. pain, musculoskeletal pain, cancer-related pain or vascular pain, in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of a 3-substituted-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof. The invention is also directed to the use of these compds. as mol. tools to directly explore the role of the MRG-X1 receptor in pain perception.

IT 887109-81-1 887109-82-2 887109-88-8

887109-89-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(diphenylmethyl azabicyclo[2.2.2]octane derivs. for treatment of MRG-X1 receptor-mediated diseases)

RN 887109-81-1 CAPLUS


CN Carbamic acid, 1-naphthalenyl-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 887109-82-2 CAPLUS
 CN Carbamic acid, (2-chlorophenyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 887109-88-8 CAPLUS
 CN Carbamic acid, (3-nitrophenyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 887109-89-9 CAPLUS
 CN Carbamic acid, (2-chlorophenyl)-, (3S)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 6 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:259381 CAPLUS

DOCUMENT NUMBER: 144:480368

TITLE: Identification of small molecule antagonists of the human mas-related gene-X1 receptor

AUTHOR(S): Kunapuli, Priya; Lee, Seungtaek; Zheng, Wei; Alberts, Melissa; Kornienko, Oleg; Mull, Rebecca; Kreamer, Anthony; Hwang, Jong-Ik; Simon, Melvin I.; Strulovici, Berta

CORPORATE SOURCE: Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA, 19454, USA

SOURCE: Analytical Biochemistry (2006), 351(1), 50-61
CODEN: ANBCA2; ISSN: 0003-2697

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The recently identified mas-related-gene (MRG) family of receptors, located primarily in sensory neurons of the dorsal root ganglion, has been implicated in the perception of pain. Thus, antagonists of this class of receptors have been postulated to be useful analgesics. Toward this end, we developed a cell-based beta-lactamase (BLA) reporter gene assay to identify small mol. antagonists of the human MRG-X1 receptor from a library of compds. Single-cell clones expressing functional receptors were selected using the BLA reporter gene technol. The EC50 for the MRG agonist peptide, BAM15, appeared to be comparable between the BLA assay and the intracellular Ca²⁺ transient assays in these cells. Ultra high-throughput screening of approx. 1 million compds. in a 1.8-μl cell-based BLA reporter gene assay was conducted in a 3456-well plate format. Compds. exhibiting potential antagonist profile in the BLA assay were confirmed in the second messenger Ca²⁺ transient assay. A cell-based receptor trafficking assay was used to further validate the mechanism of action of these compds. Several classes of compds., particularly the 2,3-disubstituted azabicyclo-octanes, appear to be relatively potent antagonists at the human MRG-X1 receptors, as confirmed by the receptor trafficking assay and radioligand binding studies. Furthermore, the structure-activity relationship reveals that within this class of compds., the diphenylmethyl moiety is constant at the 2-substituent, whereas the 3-substituent is directly correlated with the antagonist activity of the compound.


IT 887109-81-1 887109-82-2 887109-88-8
887109-89-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification of small mol. antagonists of human mas-related gene-X1 receptor)

RN 887109-81-1 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-82-2 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-88-8 CAPLUS

CN Carbamic acid, (3-nitrophenyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-89-9 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (3S)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:99752 CAPLUS

DOCUMENT NUMBER: 144:171147

TITLE: Process for preparing quinuclidinium carbamate derivatives

INVENTOR(S): Prat Quinones, Maria; Busquets Baque, Nuria; Puigol

de Santacana, Miquel; Bocanegra, Noquera, Ferran; Ibarzo Casamia,

PATENT ASSIGNEE(S): Almirall Prodesfarma,

SOURCE: PCT Int. Appl.

CODEN:



DOCUMENT TYPE:

DOCUMENT TYPE:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2006010452 | A1 | 20060202 | WO 2005-EP7424 | 20050708 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| ES 2246170 | A1 | 20060201 | ES 2004-1880 | 20040729 |
| ES 2246170 | B1 | 20070401 | | |
| EP 1781651 | A1 | 20070509 | EP 2005-762590 | 20050708 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| CN 101018786 | A | 20070815 | CN 2005-80024812 | 20050708 |
| JP 2008508203 | T | 20080321 | JP 2007-522953 | 20050708 |
| PRIORITY APPLN. INFO.: | | | ES 2004-1880 | A 20040729 |
| | | | WO 2005-EP7424 | W 20050708 |

OTHER SOURCE(S): MARPAT 144:171147

61



AB This invention relates to a new process for preparing carbamate derivs., such as I [R = $(CH_2)_m-A-(CH_2)_n-B$; R1 = CH2Ph, 2-, 3-furanyl, 2-, 3-thienyl, 2-, 3-furanylmethyl, 2-, 3-thienylmethyl, etc.; R2 = Ph, CH2Ph, alkyl, alkenyl, alkynyl, cycloalkyl, 2-, 3-furanylmethyl, 2-, 3-thienylmethyl, etc.; A = linking group, such as CH₂, CH:CH, CO, O, S, SO, SO₂, NH, etc.;

B = CN, NO₂, alkyl, alkoxy cycloalkylmethyl, aryl, heteroaryl, etc.; m = 0-8; n = 0-4), by reacting, in a first step, a corresponding azabicyclic alc. with a compound W-(CH₂)_m-A-(CH₂)_n-B (W = leaving group, such as Br) and reacting the product of this first step with an acylating agent G-CO NR₂ (G = leaving group, such as Cl). Thus, quinuclidinium carbamate II was prepared via refluxing Ph(CH₂)₃Br with (3R)-3-quinuclidinol in THF to form (3R)-3-hydroxy-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide in 100% yield, and subsequently, reacting the intermediate quinuclidinium alc. with PhCH₂N(Ph)COCl using NaH in DMF and mineral oil to give the desired quinuclidinium carbamate with 46% yield for the carbamoylation step.


IT 439908-03-9P 439908-55-1P 439908-92-6P
637744-69-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(process for preparing quinuclidinium carbamate derivs. useful as
intermediates in pharmaceutical synthesis)

RN 439908-03-9 CAPLUS

CN 1-Azonabiacyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-55-1 CAPLUS

CN 1-Azonabiacyclo[2.2.2]octane, 3-[[[butylphenylamino]carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




● Br⁻

RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{(butylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-69-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy}-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:286359 CAPLUS

DOCUMENT NUMBER: 143:19236

TITLE: 2-(Arylmethyl)-3-substituted quinuclidines as selective α_7 nicotinic receptor ligands

AUTHOR(S): Mazurov, Anatoly; Klucik, Jozef; Miao, Lan; Phillips, Teresa Y.; Seamans, Angela; Schmitt, Jeffrey D.; Hauser, Terry A.; Johnson, Raymond T.; Miller, Craig
Medicinal Chemistry, Targacept, Inc., Winston-Salem, NC, 27101, USA

CORPORATE SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(8), 2073-2077

SOURCE: CODEN: BMCL8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:19236

AB A series of 2-(arylmethyl)-3-substituted quinuclidines was developed as α_7 neuronal nicotinic acetylcholine receptor (nAChR) agonists based on a putative pharmacophore model. The series is highly selective for the α_7 over other nAChRs (e.g., the $\alpha_4\beta_2$ of the CNS, and the muscle and ganglionic subtypes) and is functionally tunable at α_7 . One member of the series, (+)-N-(1-azabicyclo[2.2.2]oct-3-yl)benzo[b]furan-2-carboxamide, has potent agonistic activity for the α_7 nAChR (EC₅₀ = 33 nM, I_{max} = 1.0), at concns. below those that result in desensitization.

IT 852475-90-2P 852475-91-3P 852475-92-4P
852475-93-5P 852475-94-6P 852475-95-7P
852475-96-8P 852475-97-9P 852475-98-0P
852475-99-1P 852476-00-7P 852476-01-8P
852476-02-9P 852476-03-0P 852476-04-1P
852476-05-2P 852476-06-3P 852476-08-5P
852476-09-6P 852476-10-9P 852476-12-1P
852476-14-3P 852476-16-5P 852476-65-4P
874635-04-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(arylmethyl-substituted quinuclidines as selective α_7 nicotinic receptor ligands)

RN 852475-90-2 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-91-3 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(6-methoxy-3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-92-4 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(6-phenoxy-3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-93-5 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(5-methoxy-3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-94-6 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(5-(1-methylethoxy)-3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-95-7 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(2-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-96-8 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(5-pyrimidinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-97-9 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(3-quinolinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-98-0 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(phenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-99-1 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[{(4-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-00-7 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[{(4-dimethylamino)phenyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-01-8 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(4-fluorophenyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-02-9 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(4-(methylsulfonyl)phenyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-03-0 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(1H-imidazol-4-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-04-1 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(3-thienylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-05-2 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(2-furanylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-06-3 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(2-benzofuranylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-08-5 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-09-6 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-10-9 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2R,3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-12-1 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-14-3 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-16-5 CAPLUS

CN Carbamic acid, (2-phenylcyclopropyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-65-4 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874635-04-8 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 195190-96-6P 195191-06-1P 852477-07-7P


852477-08-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(arylmethyl-substituted quinuclidines as selective α_7 nicotinic receptor ligands)

RN 195190-96-6 CAPLUS


CN Carbamic acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 195191-06-1 CAPLUS
CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 852477-07-7 CAPLUS
CN Carbamic acid, [4-(phenylthio)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 852477-08-8 CAPLUS
CN Carbamic acid, [4-(phenylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

34

THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:710489 CAPLUS

DOCUMENT NUMBER: 141:235681

TITLE: Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors

AUTHOR(S): Guendisch, Daniela; Andrae, Matthias; Munoz, Lenka; Tilotta, Maria Cristina

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Rhein.

Friedr.-Wilhelm-University, Bonn, D-53115, Germany
SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(18), 4953-4962

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:235681


AB Phenylcarbamate derivs. were synthesized and evaluated in radioligand binding assays for different nicotinic acetylcholine receptor (α nAChR) subtypes. Carbamate derivs. bearing a pyrrolidine or piperidine moiety 8-20 exhibited much lower affinity for $\alpha 7^*$ nAChR than the analogs in the quinuclidine series 21-25, although the same structural elements are present. Furthermore, in contrast to the quinuclidine analogs 21-25, all (S)-pyrrolidine derivs. 8-12 and the piperidine analogs 15 and 16 exhibited higher affinities for $\alpha 4\beta 2\gamma 2$ nAChR.

IT 195191-06-1P 195191-11-8P 753026-69-6P
753026-70-9P 753026-71-0P 753026-72-1P
753026-73-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and evaluation of phenylcarbamate derivs. as ligands for nicotinic acetylcholine receptors)


RN 195191-06-1 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 195191-11-8 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-3-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)




RN 753026-69-6 CAPLUS


CN Carbamic acid, (3-fluorophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 753026-70-9 CAPLUS
CN Carbamic acid, N-(3-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)




RN 753026-71-0 CAPLUS
CN Carbamic acid, N-(3-methylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)



RN 753026-72-1 CAPLUS
CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 753026-73-2 CAPLUS
CN Carbamic acid, N-[3-(2-phenylethenyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)





REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:353186 CAPLUS
 DOCUMENT NUMBER: 140:375177
 TITLE: Preparation of melanocortin-4 receptor binding compounds
 INVENTOR(S): Vos, Tricia J.; Solomon, Michael E.; Claiborne, Christopher F.; Maguire, Martin P.; Dai, Mingshi; Patane, Michael; Marsilje, Thomas H.
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of U.S. 6,699,873.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|---|--|
| US 20040082779 | A1 | 20040429 | US 2003-462436 | 20030616 |
| US 7375125 | B2 | 20080520 | | |
| US 6699873 | B1 | 20040302 | US 2001-778468 | 20010207 |
| CA 2529445 | A1 | 20051222 | CA 2004-2529445 | 20040615 |
| WO 2005121100 | A1 | 20051222 | WO 2004-US19124 | 20040615 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004320025 | A1 | 20060119 | AU 2004-320025 | 20040615 |
| EP 1644337 | A1 | 20060412 | EP 2004-776621 | 20040615 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| JP 2006527776 | T | 20061207 | JP 2006-521070
US 1999-147288P
US 2000-223277P
US 2000-632309
US 2001-778468
US 2003-462436
WO 2004-US19124 | 20040615
P 19990804
P 20000803
B2 20000804
A2 20010207
A 20030616
W 20040615 |
| PRIORITY APPLN. INFO.: | | | | |

OTHER SOURCE(S):
 GI

MARPAT 140:375177



II

AB The title compds. of formula B-Z-E [wherein B = an anchor moiety; Z = a central moiety; E = an MC4-R interacting moiety], e.g. I [wherein P1-P4 = (un)substituted C, wherein one of P1-R4 is optionally replaced by N atom, or the ring bearing P1-P4 is thiophene ring wherein P3R4 together are replaced by a S atom; Z1-Z5 = (un)substituted CH; L2 = a bond, (un)substituted C1-2 alkylene, 2 carbon carbonyl chain, wherein one of the carbons is optionally replaced by O, NH, S; t = CH₂, CHR₃, CR₃R₄; s = CH₂, CHR₅, CR₅R₆, or t-s taken together = CH:CH, CR₃:CH, CH:CR₅, CR₃:CR₅; R₃-R₆ = alkyl, alkylcarbonyl, alkoxyacarbonyl, etc.; R = H, alkyl, alkylcarbonyl], were prepared and tested as melanocortin-4 receptor (MC4-R) binding agonists and antagonists. For example, α -tolunitrile in THF was added to a solution of diisopropylamine in THF, which had been cooled to -78°C and treated with BuLi. HMPA and 1-chloromethylnaphthalene in THF were added, the reaction cooled and stirred for 1 h, and the reaction quenched with H₂O to give 2-(2-naphthalen-1-ylethyl)benzonitrile. Treatment with H₂S and 1,3-diaminopropane, followed by heating to 80°C for 72 h and work up, gave II. In a scintillation proximity assay (SPA) using high-throughput receptor binding screening, II showed exemplary inhibition of MC4-R. The invention compds., primarily 2-(2-aryalkylsulfanylphenyl)-4,5-dihydro-1H-imidazole and 1,4,5,6-tetrahydropyrimidine derivs., are useful in the treatment of disorders associated with weight loss (no data). The pharmaceutical composition comprising the title compds. is claimed.

IT 326486-03-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(inactive as MC4-R binding compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and pyrimidines and analogs)


RN 326486-03-7 CAPLUS

CN Carbanic acid, (2-ethoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326486-02-6

CMF C16 H22 N2 O3



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

IT 325826-44-6P, [2-(Naphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 325826-51-5P,
 [2-(2-Methylnaphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid
 1-azabicyclo[2.2.2]oct-3-yl ester 326484-34-8P
 326484-38-2P 326484-48-4P 326484-49-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (target compound; preparation and high throughput MC4-R receptor binding
 screening of arylalkylsulfanylphenyl-substituted imidazoles and
 pyrimidines and analogs)


RN 325826-44-6 CAPLUS

CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-,
 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 325826-51-5 CAPLUS

CN Carbamic acid, [2-[(2-methyl-1-naphthalenyl)methylthio]phenyl]-,
 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 326484-34-8 CAPLUS

CN Carbamic acid, [2-[(1-naphthalenylmethyl)thiophenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-44-6

CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 326484-38-2 CAPLUS

CN Carbamic acid, [2-[(5-bromo-2-methoxyphenyl)methyl]thiophenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-37-1

CMF C22 H25 Br N2 O3 S



CM 2


CRN 64-18-6
CMF C H2 O2



RN 326484-48-4 CAPLUS
CN Carbamic acid, [2-[(2-naphthalenylmethyl)thio]phenyl]-,
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-47-3
CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6
CMF C H2 O2




RN 326484-49-5 CAPLUS
CN Carbamic acid, [2-[(2-methyl-1-naphthalenyl)methyl]thio]phenyl-,
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-51-5

CMF C26 H28 N2 O2 S



CM 2



CRN 64-18-6
CMF C H2 O2



L3 ANSWER 11 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:176560 CAPLUS
 DOCUMENT NUMBER: 140:217656
 TITLE: Preparation of aryl-substituted tetrahydropyrimidines
 and related compounds as melanocortin-4 receptor
 binding compounds
 INVENTOR(S): Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: U.S., 216 pp., Cont.-in-part of U.S. Ser. No. 632309.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|-----------------|-----------------|----------|
| US 6699873 | B1 | 20040302 | US 2001-778468 | 20010207 |
| WO 2002062766 | A2 | 20020815 | WO 2002-US3566 | 20020207 |
| WO 2002062766 | A3 | 20021003 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2002250029 | A1 | 20020819 | AU 2002-250029 | 20020207 |
| EP 1363890 | A2 | 20031126 | EP 2002-718920 | 20020207 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 20040082779 | A1 | 20040429 | US 2003-462436 | 20030616 |
| US 7375125 | B2 | 20080520 | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 1999-147288P | P | 19990804 |
| | | US 2000-223277P | P | 20000803 |
| | | US 2000-632309 | A2 | 20000804 |
| | | US 2001-778468 | A | 20010207 |
| | | WO 2002-US3566 | W | 20020207 |

OTHER SOURCE(S): MARPAT 140:217656
 GI



AB The title compds. [I and related compds.; A = CH, CF, CCl, C(alkyl), etc.;

B = CH, CF, CCl, C(alkyl), etc.; C = CH, CCl, S, etc.; G, H = CH₂, S; D = CH₂; E, F = (un)substituted CH₂; X = C(alkoxy); Y = CH, C(C.tpbond.CH), CCl, CBr, CCl, CF; Z = CH; or pharmaceutically acceptable salts thereof] were prepared for treating a melanocortin-4 receptor (MC4-R) associated state in a mammal. For example, stirring a solution of α -tolunitrile with diisopropylamine and BuLi in hexanes at -78° under nitrogen for 1 h, followed by addition of HMPA and 1-chloromethylnaphthalene in THF, afforded 2-(2-naphthalen-1-ylethyl)benzonitrile. Heating the benzonitrile with 1,3-diaminopropane in the presence of H₂S at 80° for 72 h gave the tetrahydropyrimidinyl cycloaddn. product II. The latter exhibited exemplary inhibition of MC4-R in a scintillation proximity assay. I are useful for the treatment of disorders associated with pigmentation, bones, or weight loss (no data).

IT 326484-34-8P 326484-38-2P 326484-48-4P

326484-49-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MC4-R binding compound; preparation of aryl-substituted tetrahydropyrimidines and related compds. as melanocortin-4 receptor binding compds. for treatment of pigmentation, bone, and weight loss disorders)


RN 326484-34-8 CAPLUS

CN Carbanic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-44-6

CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2




RN 326484-38-2 CAPLUS

CN Carbanic acid, [2-[(5-bromo-2-methoxyphenyl)methyl]thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-37-1
CMF C22 H25 Br N2 O3 S




CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 326484-48-4 CAPLUS
CN Carbamic acid, [2-[(2-naphthalenylmethyl)thio]phenyl]-,
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1
CRN 326484-47-3
CMF C25 H26 N2 O2 S




CM 2
CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 326484-49-5 CAPLUS
CN Carbamic acid, [2-[(2-methyl-1-naphthalenyl)methyl]thio]phenyl]-,
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-51-5
CMF C26 H28 N2 O2 S



CM 2

CRN 64-18-6
CMF C H2 O2


O=CH-OH

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:3665 CAPLUS
 DOCUMENT NUMBER: 140:77298
 TITLE: Preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of treatment using these compounds
 INVENTOR(S): Mazurov, Anatoly A.; Klucik, Jozef; Miao, Lan;
 Seamans, Angela S.; Phillips, Teresa Youngpeter;
 Schmitt, Jeffrey Daniel; Miller, Craig Harrison
 PATENT ASSIGNEE(S): Targacept, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S.
 Ser. No. 162,129.
 CODEN: USXKC0
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|-------------|
| US 20040002513 | A1 | 20040101 | US 2003-372642 | 20030221 |
| US 6953855 | B2 | 20051011 | | |
| US 6432975 | B1 | 20020813 | US 1998-210113 | 19981211 |
| US 20030045523 | A1 | 20030306 | US 2002-162129 | 20020604 |
| AU 2004215386 | A1 | 20040910 | AU 2004-215386 | 20040220 |
| CA 2514135 | A1 | 20040910 | CA 2004-2514135 | 20040220 |
| WO 2004076449 | A2 | 20040910 | WO 2004-US5044 | 20040220 |
| WO 2004076449 | A3 | 20041216 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1594869 | A2 | 20051116 | EP 2004-713356 | 20040220 |
| EP 1594869 | B1 | 20071219 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2004007708 | A | 20060214 | BR 2004-7708 | 20040220 |
| CN 1751041 | A | 20060322 | CN 2004-80004736 | 20040220 |
| JP 2006518746 | T | 20060817 | JP 2006-503737 | 20040220 |
| AT 381563 | T | 20080115 | AT 2004-713356 | 20040220 |
| NZ 541794 | A | 20080328 | NZ 2004-541794 | 20040220 |
| US 20050255040 | A1 | 20051117 | US 2005-157119 | 20050620 |
| ZA 2005006515 | A | 20060628 | ZA 2005-6515 | 20050815 |
| MX 2005PA08926 | A | 20051005 | MX 2005-PA8926 | 20050822 |
| IN 2005KN01718 | A | 20070323 | IN 2005-KN1718 | 20050829 |
| NO 2005004052 | A | 20051021 | NO 2005-4052 | 20050831 |
| US 20060247270 | A1 | 20061102 | US 2006-458231 | 20060718 |
| PRIORITY APPLN. INFO.: | | | US 1998-210113 | A1 19981211 |
| | | | US 2002-162129 | A2 20020604 |
| | | | US 2003-372642 | A 20030221 |
| | | | WO 2004-US5044 | A 20040220 |
| | | | US 2005-157119 | A1 20050620 |

OTHER SOURCE(S): MARPAT 140:77298
 GI



AB The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes I [A1 = (CH₂)_n; A2 = (CH₂)_m; A3 = (CH₂)_p; m, n = 1, 2; p = 1 - 4; X = O, NR'; Z = NR', covalent bond, A; A = CR'R'', CR'R''CR'R'', CR':CR', C.tpbond.C (wherein, when Z = bond or A, X = N); Ar = (un)substituted carbocyclic, heterocyclic monocyclic or fused polycyclic aryl; Cy = (un)substituted 5- or 6-membered heteroarom. ring; wavy lines = relative or absolute stereochem. (cis or trans, R or S); R', R'' = H, (un)branched C1-8-alkyl, C3-8-cycloalkyl, heterocyclyl, aryl, arylalkyl (wherein, substituents = alkyl, alkenyl, heterocyclyl, cycloalkyl, (un)substituted aryl, (un)substituted arylalkyl, F, Cl, Br, I, OR', NR'R'', CF₃, CN, NO₂, C.tpbond.CR', SR', N3, C(:O)NR'R'', NR'C(:O)R'', C(:O)R', C(:O)R', OC(:O)R', O(CR'R')rC(:O)R', O(CR'R')rN(R'C(:O)R', O(CR'R')rNR'SO₂R', OC(:O)NR'R'', NR'C(:O)R'', SO₂R', SO₂NR'R'', NR'SO₂R'); R'R'' = ring; r = 1 - 6] and II, methods of preparing the compds. and methods of treatment using the compds. The azabicycloalkanes generally are azabicyclooctanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroarom., preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compds. exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

IT 639494-40-9P 639494-43-2P 639494-46-5P


639494-49-8P 639494-53-4P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)

RN 639494-40-9 CAPLUS


CN Carbamic acid, (4-bromophenyl)-, 2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 639494-43-2 CAPLUS
 CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 639494-46-5 CAPLUS
 CN Carbamic acid, (4-fluorophenyl)-, 2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 639494-49-8 CAPLUS
 CN Carbamic acid, (4-methoxyphenyl)-, 2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 639494-53-4 CAPLUS
 CN Carbamic acid, [4-(methylthio)phenyl]-, 2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



| | | | |
|----|--------------|--------------|--------------|
| IT | 639483-23-1P | 639483-24-2P | 639483-25-3P |
| | 639483-26-4P | 639483-27-5P | 639483-28-6P |
| | 639483-29-7P | 639483-30-0P | 639483-31-1P |
| | 639483-32-2P | 639483-33-3P | 639483-34-4P |
| | 639483-35-5P | 639483-36-6P | 639483-37-7P |
| | 639483-38-8P | 639483-39-9P | 639483-40-2P |
| | 639483-41-3P | 639483-42-4P | 639483-43-5P |
| | 639483-44-6P | 639483-45-7P | 639483-46-8P |
| | 639483-47-9P | 639483-48-0P | 639483-49-1P |
| | 639483-50-4P | 639483-51-5P | 639483-52-6P |
| | 639483-53-7P | 639483-54-8P | 639483-55-9P |
| | 639483-56-0P | 639483-57-1P | 639483-59-3P |
| | 639483-60-6P | 639483-61-7P | 639483-62-8P |
| | 639483-63-9P | 639483-65-1P | 639483-66-2P |
| | 639483-67-3P | 639483-68-4P | 639483-69-5P |
| | 639483-70-8P | 639483-71-9P | 639483-72-0P |
| | 639483-73-1P | 639483-74-2P | 639483-75-3P |
| | 639483-76-4P | 639483-77-5P | 639483-78-6P |
| | 639483-79-7P | 639483-80-0P | 639483-81-1P |
| | 639483-82-2P | 639483-83-3P | 639483-84-4P |
| | 639483-85-5P | 639483-86-6P | 639483-87-7P |
| | 639483-88-8P | 639483-89-9P | 639483-90-2P |
| | 639483-91-3P | 639483-92-4P | 639483-93-5P |
| | 639483-94-6P | 639483-95-7P | 639483-96-8P |
| | 639483-97-9P | 639483-98-0P | 639483-99-1P |
| | 639484-00-7P | 639484-01-8P | 639484-02-9P |
| | 639484-03-0P | 639484-04-1P | 639484-05-2P |
| | 639484-06-3P | 639484-07-4P | 639484-08-5P |
| | 639484-09-6P | 639484-10-9P | 639484-11-0P |
| | 639484-12-1P | 639484-13-2P | 639484-14-3P |
| | 639484-15-4P | 639484-16-5P | 639484-17-6P |
| | 639484-18-7P | 639484-19-8P | 639484-20-1P |
| | 639484-21-2P | 639484-22-3P | 639484-23-4P |
| | 639484-24-5P | 639484-25-6P | 639484-26-7P |
| | 639484-27-8P | 639484-28-9P | 639484-29-0P |
| | 639484-30-3P | 639484-31-4P | 639484-32-5P |
| | 639484-33-6P | 639484-34-7P | 639484-35-8P |
| | 639484-36-9P | 639484-37-0P | 639484-38-1P |
| | 639484-39-2P | 639484-40-5P | 639484-41-6P |
| | 639484-42-7P | 639484-43-8P | 639484-44-9P |
| | 639484-45-0P | 639484-46-1P | 639484-47-2P |
| | 639484-48-3P | 639484-49-4P | 639484-50-7P |
| | 639484-51-8P | 639484-52-9P | 639484-53-0P |
| | 639484-54-1P | 639484-55-2P | 639484-56-3P |
| | 639484-57-4P | 639484-58-5P | 639484-60-9P |
| | 639484-61-0P | 639484-62-1P | 639484-63-2P |
| | 639484-64-3P | 639484-65-4P | 639484-66-5P |
| | 639484-67-6P | 639484-68-7P | 639484-69-8P |
| | 639484-70-1P | 639484-71-2P | 639484-72-3P |
| | 639484-73-4P | 639484-74-5P | 639484-75-6P |
| | 639484-76-7P | 639484-77-8P | 639484-78-9P |
| | 639484-79-0P | 639484-80-3P | 639484-81-4P |
| | 639484-82-5P | 639484-83-6P | 639484-84-7P |

639484-85-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-substituted-2-(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)

RN 639483-23-1 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-24-2 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-25-3 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-26-4 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-27-5 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-28-6 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-29-7 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-30-0 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2*S*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-31-1 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, (2*R*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-32-2 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, (2*R*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-33-3 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, (2*S*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-34-4 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, (2*S*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-35-5 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2*R*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-36-6 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-37-7 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-38-8 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-39-9 CAPLUS

CN Carbamic acid, (3-fluorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-40-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-41-3 CAPLUS

CN Carbamic acid, (3-fluorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-42-4 CAPLUS

CN Carbamic acid, (3-fluorophenyl)-, (2*S*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-43-5 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (2*R*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-44-6 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (2*R*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-45-7 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (2*S*,*3R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-46-8 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (2*S*,*3S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-47-9 CAPLUS

CN Carbamic acid, (3-bromophenyl)-, (2*R*,*3R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-48-0 CAPLUS

CN Carbamic acid, (3-bromophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-49-1 CAPLUS

CN Carbamic acid, (3-bromophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-50-4 CAPLUS

CN Carbamic acid, (3-bromophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-51-5 CAPLUS

CN Carbamic acid, (2-fluorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-52-6 CAPLUS

CN Carbamic acid, (2-fluorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-53-7 CAPLUS

CN Carbamic acid, (2-fluorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-54-8 CAPLUS

CN Carbamic acid, (2-fluorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-55-9 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-56-0 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-57-1 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-59-3 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-60-6 CAPLUS

CN Carbamic acid, (2-bromophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-61-7 CAPLUS

CN Carbamic acid, (2-bromophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-62-8 CAPLUS

CN Carbamic acid, (2-bromophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-63-9 CAPLUS

CN Carbamic acid, (2-bromophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-65-1 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-66-2 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-67-3 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-68-4 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-69-5 CAPLUS

CN Carbamic acid, (2-methylphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-70-8 CAPLUS

CN Carbamic acid, (2-methylphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-71-9 CAPLUS

CN Carbamic acid, (2-methylphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-72-0 CAPLUS

CN Carbamic acid, (2-methylphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-73-1 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-74-2 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-75-3 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-76-4 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-77-5 CAPLUS

CN Carbamic acid, (3-methylphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-78-6 CAPLUS

CN Carbamic acid, (3-methylphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-79-7 CAPLUS

CN Carbamic acid, (3-methylphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-80-0 CAPLUS

CN Carbamic acid, (3-methylphenyl)-, (2*S*,*3S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-81-1 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-3-yl-, (2*R*,*3R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-82-2 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-3-yl-, (2*R*,*3S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-83-3 CAPLUS

CN Carbanic acid, [1,1'-biphenyl]-3-yl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-84-4 CAPLUS

CN Carbanic acid, [1,1'-biphenyl]-3-yl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-85-5 CAPLUS

CN Carbanic acid, (4-methylphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-86-6 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, (2*R*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-87-7 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, (2*S*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-88-8 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, (2*S*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-89-9 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-90-2 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-91-3 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-92-4 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-93-5 CAPLUS

CN Carbamic acid, (2-cyanophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-94-6 CAPLUS

CN Carbamic acid, (2-cyanophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-95-7 CAPLUS

CN Carbamic acid, (2-cyanophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-96-8 CAPLUS

CN Carbamic acid, (2-cyanophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-97-9 CAPLUS

CN Carbamic acid, (3-cyanophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-98-0 CAPLUS

CN Carbamic acid, (3-cyanophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-99-1 CAPLUS

CN Carbamic acid, (3-cyanophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-00-7 CAPLUS

CN Carbamic acid, (3-cyanophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-01-8 CAPLUS

CN Carbamic acid, (4-cyanophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-02-9 CAPLUS

CN Carbamic acid, (4-cyanophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-03-0 CAPLUS

CN Carbamic acid, (4-cyanophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-04-1 CAPLUS

CN Carbamic acid, (4-cyanophenyl)-, (2*S*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-05-2 CAPLUS

CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, (2*R*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-06-3 CAPLUS


CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, (2*R*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-07-4 CAPLUS
 CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-08-5 CAPLUS
 CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639484-09-6 CAPLUS
 CN Carbamic acid, [4-(dimethylamino)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-10-9 CAPLUS

CN Carbamic acid, [4-(dimethylamino)phenyl]-, (2*R*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-11-0 CAPLUS

CN Carbamic acid, [4-(dimethylamino)phenyl]-, (2*S*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-12-1 CAPLUS

CN Carbamic acid, [4-(dimethylamino)phenyl]-, (2*S*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-13-2 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-14-3 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-15-4 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-16-5 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-17-6 CAPLUS

CN Carbamic acid, (2-phenoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-18-7 CAPLUS

CN Carbamic acid, (2-phenoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-19-8 CAPLUS

CN Carbamic acid, (2-phenoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-20-1 CAPLUS

CN Carbamic acid, (2-phenoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-21-2 CAPLUS

CN Carbamic acid, [2-(methylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-22-3 CAPLUS

CN Carbamic acid, [2-(methylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-23-4 CAPLUS

CN Carbamic acid, [2-(methylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-24-5 CAPLUS

CN Carbamic acid, [2-(methylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-25-6 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-26-7 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-27-8 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-28-9 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-29-0 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-30-3 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-31-4 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-32-5 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-33-6 CAPLUS

CN Carbamic acid, (3-phenoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-34-7 CAPLUS

CN Carbamic acid, (3-phenoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-35-8 CAPLUS

CN Carbamic acid, (3-phenoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-36-9 CAPLUS

CN Carbamic acid, (3-phenoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-37-0 CAPLUS

CN Carbamic acid, [3-(methylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-38-1 CAPLUS

CN Carbamic acid, [3-(methylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-39-2 CAPLUS

CN Carbamic acid, [3-(methylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-40-5 CAPLUS

CN Carbamic acid, [3-(methylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-41-6 CAPLUS

CN Carbamic acid, [3-(phenylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-42-7 CAPLUS

CN Carbamic acid, [3-(phenylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-43-8 CAPLUS

CN Carbamic acid, [3-(phenylthio)phenyl]-, (2*S*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-44-9 CAPLUS

CN Carbamic acid, [3-(phenylthio)phenyl]-, (2*S*,3*S*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-45-0 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2*R*,3*R*)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-46-1 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-47-2 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-48-3 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-49-4 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-50-7 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-51-8 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-52-9 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-53-0 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-54-1 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-55-2 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-56-3 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-57-4 CAPLUS

CN Carbamic acid, [4-(phenylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-58-5 CAPLUS

CN Carbamic acid, [4-(phenylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-60-9 CAPLUS

CN Carbamic acid, [4-(phenylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-61-0 CAPLUS

CN Carbamic acid, [4-(phenylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-62-1 CAPLUS

CN Carbamic acid, (2,4-dimethoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-63-2 CAPLUS

CN Carbamic acid, (2,4-dimethoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-64-3 CAPLUS

CN Carbamic acid, (2,4-dimethoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-65-4 CAPLUS

CN Carbamic acid, (2,4-dimethoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-66-5 CAPLUS

CN Carbamic acid, 2-thienyl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-67-6 CAPLUS

CN Carbamic acid, 2-thienyl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-68-7 CAPLUS

CN Carbamic acid, 2-thienyl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-69-8 CAPLUS

CN Carbamic acid, 2-thienyl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-70-1 CAPLUS

CN Carbamic acid, 2-thienyl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-71-2 CAPLUS

CN Carbamic acid, 3-thienyl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-72-3 CAPLUS

CN Carbamic acid, 3-thienyl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-73-4 CAPLUS

CN Carbamic acid, 3-thienyl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-74-5 CAPLUS

CN Carbamic acid, benzo[b]thien-3-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-75-6 CAPLUS

CN Carbamic acid, benzo[b]thien-3-yl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-76-7 CAPLUS

CN Carbamic acid, benzo[b]thien-3-yl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-77-8 CAPLUS

CN Carbamic acid, benzo[b]thien-3-yl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-78-9 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-79-0 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-80-3 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-81-4 CAPLUS


CN Carbamic acid, 1-naphthalenyl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-82-5 CAPLUS
 CN Carbamic acid, 2-naphthalenyl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-83-6 CAPLUS
 CN Carbamic acid, 2-naphthalenyl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639484-84-7 CAPLUS
 CN Carbamic acid, 2-naphthalenyl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-85-8 CAPLUS

CN Carbamic acid, 2-naphthalenyl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 195190-96-6 195191-06-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)


RN 195190-96-6 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 195191-06-1 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT:

59

THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:2883 CAPLUS

DOCUMENT NUMBER: 140:59820

TITLE: Preparation of novel quinuclidine derivatives for therapeutic use in medicinal compositions as M3 muscarinic receptor antagonists

INVENTOR(S): Prat Quinones, Maria; Buil Albero, Maria Antonia;

Fernandez Forner, Maria Dolors

PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004000840 | A2 | 20031231 | WO 2003-EP6472 | 20030618 |
| WO 2004000840 | A3 | 20071115 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| ES 2203327 | A1 | 20040401 | ES 2002-1439 | 20020621 |
| ES 2203327 | B1 | 20050616 | | |
| CA 2490082 | A1 | 20031231 | CA 2003-2490082 | 20030618 |
| AU 2003279384 | A1 | 20040106 | AU 2003-279384 | 20030618 |
| EP 1515968 | A2 | 20050323 | EP 2003-740284 | 20030618 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003012169 | A | 20050329 | BR 2003-12169 | 20030618 |
| CN 1675206 | A | 20050928 | CN 2003-819327 | 20030618 |
| JP 2005533799 | T | 20051110 | JP 2004-514785 | 20030618 |
| NZ 537252 | A | 20060728 | NZ 2003-537252 | 20030618 |
| RU 2321588 | C2 | 20080410 | RU 2005-101409 | 20030618 |
| MX 2004PA12272 | A | 20050408 | MX 2004-PA12272 | 20041207 |
| ZA 2004010211 | A | 20050906 | ZA 2004-10211 | 20041217 |
| NO 200500217 | A | 20050318 | NO 2005-217 | 20050113 |
| US 20060094751 | A1 | 20060504 | US 2005-518496 | 20050519 |
| PRIORITY APPLN. INFO.: | | | ES 2002-1439 | A 20020621 |
| | | | WO 2003-EP6472 | W 20030618 |

OTHER SOURCE(S): MARPAT 140:59820

GI



AB Quinuclidine derivs., such as I and II [R = (CH₂)_m-A-(CH₂)_n-B; R₁ = unsubstituted, halo substituted, alkyl substituted, or cyano substituted]

Ph, 2-thienylmethyl, 2-thienyl, 2-furylmethyl, 2-furyl, 3-thienylmethyl, 3-thienyl, 3-furylmethyl, 3-furyl; R₂ = benzyl, phenethyl, 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl or 3-thienylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbons atoms, or a cycloalkyl group of 3 to 6 carbon atoms; A = CH₂, R_{3C}:CH, CH:CR₃, CO, O, S, SO₂, NR₃, CR₃R₄; B = O₂CR₃, CO₂R₃, cyano, etc.; R₃, R₄ = H, alkyl, R₃R₄ = alicyclic ring; X⁻ = anion, such as Cl⁻, Br⁻, I⁻ or F₃CCO₂⁻; m = 0-8, n = 0-4], and pharmaceutical compns. comprising them were prepared for use in therapy as antagonists of M₃ muscarinic receptors (no biol. testing data presented) and are claimed for use in the treatment of respiratory, urol. and gastrointestinal diseases. Thus, butylphenylcarbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester was prepared in 22% yield by refluxing (R)-3-quinuclidinol in toluene with sodium for 2 h and then adding butylphenylcarbamoyl chloride and refluxing for an addnl. 1 h. Pharmaceutical compns. containing the prepared quinuclidines were presented.

IT 385367-13-5P 385367-28-2P 385367-46-4P
 385367-47-5P 439909-77-0P 439910-43-7P
 637744-75-3P 637744-77-5P 637744-79-7P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of novel quinuclidine derivs. for therapeutic use in medicinal compns. as M₃ muscarinic receptor antagonists)

RN 385367-13-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 385367-28-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-46-4 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-47-5 CAPLUS

CN Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-77-0 CAPLUS


CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439910-43-7 CAPLUS


CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.1]hept-4-yl ester (9CI) (CA INDEX NAME)



RN 637744-75-3 CAPLUS

CN Carbamic acid, [(5-bromo-2-thienyl)methyl](2,4,5-trifluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-77-5 CAPLUS

CN Carbamic acid, (4-fluoro-2-methylphenyl)[(3-methyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-79-7 CAPLUS

CN Carbamic acid, (3-fluoro-4-methoxyphenyl)(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



| | | | |
|----|--------------|--------------|--------------|
| IT | 17656-14-3P | 17656-16-5P | 385367-14-6P |
| | 385367-68-0P | 385367-71-5P | 385367-72-6P |
| | 385367-73-7P | 385367-74-8P | 385367-75-9P |
| | 385367-76-0P | 439907-53-6P | 439907-55-8P |
| | 439907-57-0P | 439907-58-1P | 439907-59-2P |
| | 439907-61-6P | 439907-63-8P | 439907-65-0P |
| | 439907-67-2P | 439907-69-4P | 439907-71-8P |
| | 439907-73-0P | 439907-75-2P | 439907-77-4P |
| | 439907-79-6P | 439907-81-0P | 439907-83-2P |
| | 439907-85-4P | 439907-87-6P | 439907-89-8P |
| | 439907-90-1P | 439907-92-3P | 439907-94-5P |
| | 439907-95-6P | 439907-97-8P | 439907-99-0P |
| | 439908-00-6P | 439908-01-7P | 439908-02-8P |
| | 439908-03-9P | 439908-04-0P | 439908-06-2P |
| | 439908-08-4P | 439908-10-8P | 439908-12-0P |
| | 439908-14-2P | 439908-16-4P | 439908-18-6P |
| | 439908-20-0P | 439908-22-2P | 439908-24-4P |
| | 439908-26-6P | 439908-28-8P | 439908-30-2P |
| | 439908-32-4P | 439908-34-6P | 439908-36-8P |
| | 439908-38-0P | 439908-40-4P | 439908-42-6P |
| | 439908-43-7P | 439908-45-9P | 439908-47-1P |
| | 439908-50-6P | 439908-52-8P | 439908-54-0P |
| | 439908-55-1P | 439908-56-2P | 439908-58-4P |
| | 439908-60-8P | 439908-62-0P | 439908-64-2P |
| | 439908-66-4P | 439908-68-6P | 439908-70-0P |
| | 439908-72-2P | 439908-74-4P | 439908-76-6P |
| | 439908-78-8P | 439908-80-2P | 439908-82-4P |
| | 439908-84-6P | 439908-86-8P | 439908-87-9P |
| | 439908-88-0P | 439908-89-1P | 439908-90-4P |
| | 439908-91-5P | 439908-92-6P | 439908-93-7P |
| | 439908-94-8P | 439908-95-9P | 439908-97-1P |
| | 439908-99-3P | 439909-01-0P | 439909-03-2P |
| | 439909-05-4P | 439909-07-6P | 439909-08-7P |
| | 439909-09-8P | 439909-10-1P | 439909-11-2P |
| | 439909-12-3P | 439909-14-5P | 439909-16-7P |
| | 439909-18-9P | 439909-20-3P | 439909-22-5P |
| | 439909-24-7P | 439909-26-9P | 439909-29-2P |
| | 439909-32-7P | 439909-34-9P | 439909-36-1P |
| | 439909-39-4P | 439909-41-8P | 439909-43-0P |
| | 439909-45-2P | 439909-47-4P | 439909-49-6P |
| | 439909-51-0P | 439909-53-2P | 439909-54-3P |
| | 439909-56-5P | 439909-58-7P | 439909-60-1P |
| | 439909-62-3P | 439909-64-5P | 439909-66-7P |
| | 439909-68-9P | 439909-70-3P | 439909-72-5P |
| | 439909-75-8P | 439909-79-2P | 439909-81-6P |
| | 439909-83-8P | 439909-85-0P | 439909-87-2P |
| | 439909-89-4P | 439909-91-8P | 439909-93-0P |
| | 439909-94-1P | 439909-95-2P | 439910-19-7P |


439910-21-1P 439910-25-5P 439910-27-7P
 439910-30-2P 439910-33-5P 439910-45-9P
 637744-43-5P 637744-64-0P 637744-67-3P
 637744-68-4P 637744-69-5P 637744-70-8P
 637744-71-9P 637744-72-0P 637744-76-4P
 637744-78-6P 637744-80-0P 637744-84-4P
 637744-85-5P 637744-89-9P 637744-90-2P
 637744-91-3P 637744-94-6P 637744-97-9P
 637744-99-1P 637745-13-2P 637745-15-4P
 637745-17-6P 637745-18-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel quinuclidine derivs. for therapeutic use in medicinal compns. as M3 muscarinic receptor antagonists)


RN 17656-14-3 CAPLUS

CN Carbamic acid, diphenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 17656-16-5 CAPLUS


CN Carbamic acid, ethylphenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 385367-14-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-68-0 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)(2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-71-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-fluorophenyl)methyl]phenylamino]carbonyloxy}-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-72-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[{[(2-methylphenyl)(phenylmethyl)amino]carbonyloxy}-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-73-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[(2-methylphenyl)methyl]amino]carbonyloxy-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-74-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(4-fluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-75-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)(phenylmethyl)amino]carbonyloxy}-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-76-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyloxy}-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● I -

RN 439907-53-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-52-5

CMF C22 H27 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-55-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-methyl-3-pentenyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-54-7
CMF C27 H35 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-57-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-56-9
CMF C30 H35 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439907-58-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



● Br⁻

RN 439907-59-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


RN 439907-61-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-hydroxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-60-5

CMF C23 H29 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-63-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(1-methylethyl)-3-[[(phenyl(methyl)amino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-62-7
CMF C24 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-65-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(phenyl(phenylmethyl)amino]carbonyl oxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-64-9
 CMF C24 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-67-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-[(phenyl(phenylmethyl)amino]carbonyl oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-66-1
 CMF C25 H30 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-69-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-[[(phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-68-3
CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-71-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxyethyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-70-7
 CMF C25 H33 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-73-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(5-ethoxy-5-oxopentyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-72-9
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-75-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-phenylbutyl)-3-[[[phenyl(methyl)amino]carbonyl]oxyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-74-1
CMF C31 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-77-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-fluorophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-76-3
 CMF C30 H34 F N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-79-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-hydroxypropyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-78-5

CMF C24 H31 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-81-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-80-9
CMF C27 H35 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-83-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-oxo-4-(2-thienyl)butyl]-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-82-1
 CMF C29 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-85-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-84-3
 CMF C30 H35 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-87-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-86-5

CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-89-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-88-7

CMF C30 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439907-90-1 CAPLUS

CN Carbanic acid, (4-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439907-92-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-fluorophenyl)(phenylmethyl)amino]carbonyl}oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-91-2

CMF C24 H28 F N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-94-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-fluorophenyl)(phenylmethyl)amino]carbonyl}oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-93-4

CMF C30 H34 F N2 O2

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2



RN 439907-95-6 CAPLUS
 CN Carbanic acid, (4-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439907-97-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-methylphenyl)(phenylmethyl)amino]carbonyloxy}-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-96-7
 CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-99-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-methylphenyl)(phenylmethyl)amino]carbonyl}oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-98-9
CMF C31 H37 N2 O2

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439908-00-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2-methoxyethoxy)ethyl]-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA
 INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439908-01-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenylethyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA
 INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439908-02-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
 1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-03-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-04-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


RN 439908-06-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-cyanophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-05-1
CMF C31 H34 N3 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-08-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1-naphthalenyl oxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-07-3
CMF C34 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-10-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(methylphenylamino)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-09-5
CMF C31 H38 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-12-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
1-[3-(phenylthio)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 439908-11-9
CMF C30 H35 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-14-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-oxo-4-phenylbutyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-13-1
 CMF C31 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-16-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(phenyl(phenylmethyl)amino)carbonyl]oxy]-
 1-[3-(2,4,6-trimethylphenoxy)propyl]-, (3R)-, salt with trifluoroacetic
 acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-15-3
 CMF C33 H41 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-18-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-chlorophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-17-5
 CMF C30 H34 Cl N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-20-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-(3-(trifluoromethyl)phenoxy]propyl-, (3*R*)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-19-7

CMF C31 H34 F3 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-22-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-((1,1'-biphenyl)-4-yloxy)propyl]-3-[[[phenylmethyl]amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-21-1
CMF C36 H39 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-24-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2,4-difluorophenoxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-23-3
CMF C30 H33 F2 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-26-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-methoxyphenoxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-25-5
CMF C31 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-28-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxyl]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-27-7
CMF C34 H41 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-30-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-29-9
CMF C31 H35 N2 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-32-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[2-(aminocarbonyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-31-3
CMF C31 H36 N3 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-34-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[3-(dimethylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-33-5

CMF C32 H40 N3 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-36-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-{4-(acetylamino)phenoxy}propyl]-3-[[[phenylmethyl]amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-35-7
CMF C32 H38 N3 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-38-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(methoxycarbonyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-37-9
CMF C32 H37 N2 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-40-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-nitrophenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-39-1
CMF C30 H34 N3 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-42-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(hydroxymethyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-41-5
CMF C31 H37 N2 O4

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-43-7 CAPLUS
CN Carbanic acid, phenyl(phenylmethyl)-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439908-45-9 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3S)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439908-47-1 CAPLUS
 CN Carbamic acid, butylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-50-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-49-3
 CMF C19 H29 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-52-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(4-methyl-3-pentenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-51-7
 CMF C24 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-54-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-53-9
 CMF C27 H37 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439908-55-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



● Br⁻

RN 439908-56-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439908-58-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(2-hydroxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-57-3

CMF C20 H31 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-60-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(1-methylethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-59-5
CMF C21 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-62-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-61-9
CMF C21 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-64-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(3-cyanopropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-63-1
 CMF C22 H32 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-66-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(cyclopropylmethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-65-3
 CMF C22 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-68-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(2-ethoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-67-5
CMF C22 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-70-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(5-ethoxy-5-oxopentyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-69-7
 CMF C25 H39 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-72-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(3-hydroxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-71-1
 CMF C21 H33 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-74-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-[3-(1H-pyrrrol-1-yl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439908-73-3
CMF C25 H36 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-76-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-[(butylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-75-5
 CMF C24 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-78-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-[4-oxo-4-(2-thienyl)butyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-77-7
 CMF C26 H35 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-80-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(4-phenylbutyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-79-9
CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439908-82-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy)-1-[3-(3-hydroxyphenoxy)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-81-3

CMF C27 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-84-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy)-1-heptyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-83-5

CMF C25 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-86-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439908-85-7
CMF C27 H37 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439908-87-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439908-88-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-[2-(2-methoxyethoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439908-89-1 CAPLUS
 CN Carbamic acid, butyl(4-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-90-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-[3-(4-fluorophenoxy)propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-91-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br-

RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-93-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-94-8 CAPLUS

CN Carbamic acid, phenyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-95-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[(phenyl(2-thienylmethyl)amino)carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-97-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (PCI) (CA INDEX NAME)

CM 1

CRN 439908-96-0
CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-99-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-98-2
CMF C28 H33 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-01-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-00-9
CMF C28 H31 N2 O2 S

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-03-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[(phenyl(2-thienylmethyl)aminol)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-02-1
CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-05-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[phenyl(2-thienylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-04-3
 CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-07-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[phenyl(2-thienylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-06-5
 CMF C26 H37 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439909-08-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyloxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439909-09-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-10-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-11-2 CAPLUS


CN Carbamic acid, phenyl(2-phenylethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439909-12-3 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-14-5 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-13-4
CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439909-16-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid


(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-15-6

CMF C31 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-18-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-17-8

CMF C30 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-20-3 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439909-19-0
CMF C31 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-22-5 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 439909-21-4
CMF C31 H35 N2 O2

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-24-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-23-6
CMF C31 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439909-26-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[phenyl(2-phenylethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-25-8

CMF C31 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-29-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[phenyl(2-phenylethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-28-1

CMF C29 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-32-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-31-6
CMF C29 H35 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-34-9 CAPLUS
 CN Carbamic acid, pentylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 439909-36-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[(pentylphenylamino)carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br-

RN 439909-39-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-38-3
 CMF C28 H39 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-41-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-40-7
CMF C27 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-43-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-42-9
 CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-45-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-44-1
 CMF C28 H37 N2 O2

Absolute stereochemistry.

Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-47-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439909-46-3
CMF C28 H39 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-49-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-{3-(3-hydroxyphenoxy)propyl}-3-[(pentylphenylamino)carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-48-5
 CMF C28 H39 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-51-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[(pentylphenylamino)carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-50-9
 CMF C26 H43 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-53-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-52-1
CMF C26 H37 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439909-54-3 CAPLUS
 CN Carbamic acid, 4-pentenylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-56-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-55-4
 CMF C22 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-58-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyloxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-57-6
CMF C28 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-60-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyloxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-59-8
CMF C27 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-62-3 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyloxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-61-2
CMF C28 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-64-5 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyloxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-63-4
CMF C28 H35 N2 O2

Absolute stereochemistry.

Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 Q2




BN 439909-66-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 439909-65-6
CMF C28 H37 N2 03

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 Q2




RN 439909-68-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[(4-pentenylphenylamino)carbonyl]oxy-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-67-8
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-70-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[(4-pentenylphenylamino)carbonyl]oxy-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-69-0
 CMF C26 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-72-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[(4-pentenylphenylamino)carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-71-4
CMF C20 H29 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-75-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439909-74-7
 CMF C26 H35 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-79-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439909-78-1
 CMF C22 H27 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-81-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(3-thienylmethyl)aminolcarbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-80-5
CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-83-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-82-7
 CMF C28 H33 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-85-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-84-9
 CMF C28 H31 N2 O2 S

Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-87-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[phenyl(3-thienylmethyl)aminolcarbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-86-1
CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-89-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[phenyl(3-thienylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-88-3
 CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-91-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[phenyl(3-thienylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-90-7
 CMF C26 H37 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-93-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-92-9

CMF C20 H25 N2 O2 S

Absolute stereochemistry.



CM 2


CRN 14477-72-6

CMF C2 F3 O2



RN 439909-94-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439909-95-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439910-19-7 CAPLUS

CN Carbamic acid, cyclopentyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439910-21-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[{cyclopentyl(2-thienylmethyl)amino}carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-20-0

CMF C21 H31 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439910-25-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{cyclopentyl(2-thienylmethyl)amino}carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-24-4
CMF C27 H37 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439910-27-7 CAPLUS
CN Carbamic acid, (2-furanylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439910-30-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-29-9
CMF C22 H27 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439910-33-5 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanyl methyl)phenylamino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439910-32-4
CMF C28 H33 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439910-45-9 CAPLUS
 CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester
 (9CI) (CA INDEX NAME)



RN 637744-43-5 CAPLUS
 CN Formic acid, compd. with 1-azabicyclo[2.2.1]heptyl N-phenyl-N-(phenylmethyl)carbamate (1:1) (CA INDEX NAME)

CM 1

CRN 439910-43-7
 CMF C20 H22 N2 O2




CM 2

CRN 64-18-6
 CMF C H2 O2



RN 637744-64-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-67-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-fluorophenyl)[(3-fluorophenyl)methyl]amino]carbonyloxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-68-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-fluorophenyl)[(3-fluorophenyl)methyl]amino]carbonyloxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 637744-69-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-methylphenyl)((2,4,5-trifluorophenyl)methyl)amino]carbonyl}oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 637744-70-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-fluorophenyl)((3,4,5-trifluorophenyl)methyl)amino]carbonyl}oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 637744-71-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyl}oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)-
 (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 637744-72-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyl}oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)-
 (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 637744-76-4 CAPLUS


CN Formic acid, compd. with (3R)-1-azabicyclo[2.2.2]octyl
N-[(5-bromo-2-thienyl)methyl]-N-(2,4,5-trifluorophenyl)carbamate (1:1)
(CA INDEX NAME)

CM 1

CRN 637744-75-3

CMF C19 H18 Br F3 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 637744-78-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-fluoro-2-methylphenyl)((3-methyl-2-thienyl)methyl)amino]carbonyloxy]-1-(2-phenoxyethyl)-, bromide (1:1),
(3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 637744-80-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-fluoro-4-methoxyphenyl)(3-thienylmethyl)amino]carbonyl}oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



● Br⁻

RN 637744-84-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[{(pentylphenylamino)carbonyl}oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-83-3

CME C22 H33 N2 O2

Absolute stereochemistry.



CM 2


CRN 14477-72-6
CMF C2 F3 O2



RN 637744-85-5 CAPLUS
CN Formic acid, compd. with 1-azabicyclo[2.2.2]octyl N-phenyl-N-(phenylmethyl)carbamate (1:1) (CA INDEX NAME)

CM 1

CRN 439910-45-9
CMF C21 H24 N2 O2




CM 2

CRN 64-18-6
CMF C H2 O2




RN 637744-89-9 CAPLUS
CN Carbanic acid, butyl(2,5-difluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 637744-90-2 CAPLUS
CN Carbamic acid, (2,6-difluorophenyl)-4-pentenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 637744-91-3 CAPLUS
CN Carbamic acid, cyclopentyl[(4,5-dimethyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 637744-94-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[[((5-bromo-2-thienyl)methyl)(2,4,5-trifluorophenyl)amino]carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-93-5
CME C28 H29 Br F3 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 637744-97-9 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluoro-2-methylphenyl)((3-methyl-2-thienyl)methyl)amino]carbonyloxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-96-8
CMF C29 H34 F N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 637744-99-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[(3-fluoro-4-methoxyphenyl)(3-thienylmethyl)amino]carbonyloxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-98-0

CMF C29 H32 F N2 O3 S

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 637745-13-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butyl(2,5-difluorophenyl)amino)carbonyloxy]-1-heptyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637745-12-1

CMF C25 H39 F2 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 637745-15-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-[(2,6-difluorophenyl)-4-pentenylamino]carbonyl oxy-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637745-14-3
CMF C23 H30 F2 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 637745-17-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(cyclopentyl(4,5-dimethyl-2-thienyl)methyl)amino]carbonyloxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637745-16-5
 CMF C21 H33 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2



RN 637745-18-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(3-(3-fluorophenyl)(3,4,5-trifluorophenyl)methyl)amino]carbonyloxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

L3 ANSWER 14 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:678653 CAPLUS
 DOCUMENT NUMBER: 139:207821
 TITLE: Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
 INVENTOR(S): Versi, Ebrahim
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 2003070233 | A1 | 20030828 | WO 2003-US4561 | 20030214 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2475374 | A1 | 20030828 | CA 2003-2475374 | 20030214 |
| AU 2003211078 | A1 | 20030909 | AU 2003-211078 | 20030214 |
| EP 1476146 | A1 | 20041117 | EP 2003-742765 | 20030214 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 200307772 | A | 20041207 | BR 2003-7772 | 20030214 |
| CN 1633283 | A | 20050629 | CN 2003-804160 | 20030214 |
| JP 2005526040 | T | 20050902 | JP 2003-569190 | 20030214 |
| EP 1915992 | A1 | 20080430 | EP 2008-101136 | 20030214 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR | | | | |
| US 20030191172 | A1 | 20031009 | US 2003-368091 | 20030218 |
| MX 2004PA08037 | A | 20041126 | MX 2004-PA8037 | 20040818 |
| ZA 2004006148 | A | 20060531 | ZA 2004-6148 | 20060317 |
| PRIORITY APPLN. INFO.: | | | US 2002-357888P | P 20020219 |
| | | | EP 2003-742765 | A3 20030214 |
| | | | WO 2003-US4561 | W 20030214 |


AB The invention provides a method for the use of a cyclooxygenase-2 inhibitor, alone or in combination with an antimuscarinic agent, for the treatment or prophylaxis of a urinary incontinence condition in a subject in need of such treatment or prevention, comprising administering to the subject an effective amount of the cyclooxygenase-2 inhibitor and, optionally, the antimuscarinic agent.

IT 171722-81-9, YM-46303

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase inhibitors and antimuscarinic agents for treatment of incontinence)

RN 171722-81-9 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester, hydrochloride (1:1) (CA INDEX NAME)



● HC1


REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:511328 CAPLUS
 DOCUMENT NUMBER: 139:85531
 TITLE: Preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives
 INVENTOR(S): Catena Ruiz, Juan Lorenzo; Farrerons Gallemi, Carles;
 Fernandez Serrat, Anna; Miquel Bono, Ignacio Jose;
 Balsa Lopez, Dolors; Lagunas Arnal, Carmen; Salcedo
 Roca, Carolina; Toledo Mesa, Natividad; Fernandez
 Garcia, Andres
 PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------------------|----------|-----------------|------------|
| WO 2003053966 | A2 | 20030703 | WO 2002-EP14470 | 20021218 |
| WO 2003053966 | A3 | 20031113 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2470956 | C | 20030703 | CA 2002-2470956 | 20021218 |
| AU 2002361158 | A1 | 20030709 | AU 2002-361158 | 20021218 |
| EP 1461336 | A2 | 20040929 | EP 2002-796673 | 20021218 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| BR 2002015348 | A | 20041116 | BR 2002-15348 | 20021218 |
| HU 2005000107 | A2 | 20050530 | HU 2005-107 | 20021218 |
| JP 2005516954 | T | 20050609 | JP 2003-5546821 | 20021218 |
| CN 1832948 | A | 20060913 | CN 2002-827836 | 20021218 |
| MX 2004PA06206 | A | 20041206 | MX 2004-PAG206 | 20040621 |
| NO 2004003064 | A | 20040917 | NO 2004-3064 | 20040719 |
| US 20050043349 | A1 | 20050224 | US 2004-499130 | 20041012 |
| PRIORITY APPLN. INFO.: | | | ES 2002-43 | A 20011220 |
| OTHER SOURCE(S): | MARPAT 139:85531 | | WO 2002-EP14470 | W 20021218 |
| GI | | | | |



AB The title compds. I (R1, R2 and R3 = H, OH, NO₂, SH, CN, F, Cl, Br, I,

COOH, CONH₂, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl,
 (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally
 substituted with one or several F, and (C1-C4)-alkyl optionally
 substituted with one or several F or OH; R₄ = cycloalkyl, Ph, heteroaryl
 or a bicyclic ring system; R₅ = cycloalkyl, (C5-C10)-alkyl, a substituted
 (C1-C10)-alkyl; and X⁻ = physiol. acceptable anion) were prepared. I is a
 selective muscarinic M₃ receptor antagonists vs. M₂ receptor and may be
 used for the treatment of urinary incontinence (particularly, the one
 caused by overactive bladder), irritable bowel syndrome, and respiratory
 disorders (particularly, chronic obstructive pulmonary disease, chronic
 bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic
 interventions. Thus, (R)-benzylphenylcarbamic acid 1-azabicyclo[2.2.2]oct-
 3-yl ester hydrochloride was treated with bromocyclopropane to give (R)-I
 (R₁, R₂, R₃ = H, R₄ = Ph, R₅ = cyclopropylmethyl, X = Br). The M₂/M₃ ratio
 of (R)-I (R₁, R₂, R₃ = H, R₄ = 4-FC₆H₄, R₅ = 3-phenoxypropyl, X = Br) was
 80.


IT 552830-52-1P 552830-53-2P 552830-54-3P
 552830-55-4P 552830-56-5P 552830-57-6P
 552830-58-7P 552830-59-8P 552830-60-1P
 552830-61-2P 552830-62-3P 552830-63-4P
 552830-64-5P 552830-65-6P 552830-66-7P
 552830-67-8P 552830-68-9P 552830-69-0P
 552830-70-3P 552830-71-4P 552830-72-5P
 552830-73-6P 552830-74-7P 552830-75-8P
 552830-76-9P 552830-77-0P 552830-78-1P
 552830-79-2P 552830-80-5P 552830-81-6P
 552830-82-7P 552830-83-8P 552830-84-9P
 552830-85-0P 552830-86-1P 552830-87-2P
 552830-88-3P 552830-89-4P 552830-90-7P
 552830-91-8P 552830-92-9P 552830-93-0P
 552830-94-1P 552830-95-2P 552830-96-3P
 552830-97-4P 552830-98-5P 552830-99-6P
 552831-00-2P 552831-01-3P 552831-02-4P
 552831-03-5P 552831-04-6P 552831-05-7P
 552831-06-8P 552831-07-9P 552831-08-0P
 552831-09-1P 552831-10-4P 552831-11-5P
 552831-12-6P 552831-13-7P 552831-14-8P
 552831-15-9P 552831-16-0P 552831-17-1P
 552831-18-2P 552831-19-3P 552831-20-6P
 552831-21-7P 552831-22-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as
 muscarinic receptor antagonists)

RN 552830-52-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-cyclopropyl-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, bromide (1:1), (3R)- (CA
 INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552830-53-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[(2-chlorophenyl)methyl]-3-
 [[(phenylmethyl)amino]carbonyloxy]-, chloride (1:1), (3R)- (CA
 INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552830-54-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[[3-(methylthio)-1H-1,2,4-triazol-5-
 yl]thio]methyl]-3-[[phenyl(phenylmethyl)amino]carbonyloxy]-, chloride
 (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552830-55-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxy-2-oxoethyl)-3-
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA
 INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552830-56-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-
 [[[3-methylphenyl](phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1),
 (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-57-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-[[[(3-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-58-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[[(4-fluorophenyl)methyl]phenylamino]carbonyl]oxy]-1-[2-(3-methylphenyl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-59-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(4-ethoxyphenyl)ethyl]-3-[{[(4-fluorophenyl)methyl]phenylamino}carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-60-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-fluorophenyl)methyl]phenylamino}carbonyloxy]-1-[2-(4-nitrophenyl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-61-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2,4-difluorophenyl)thio]ethyl]-3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-62-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-1-(3-phenoxypropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-63-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[{[(4-fluorophenyl)methyl](3-methylphenyl)amino]carbonyl}oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-64-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(3,4-dimethoxyphenyl)ethyl]-3-[{[(2-fluorophenyl)(4-fluorophenyl)methyl]amino]carbonyl}oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-65-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl}oxy]-1-[2-(4-methoxyphenyl)-2-oxoethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-66-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl}oxy]-1-[2-(1H-pyrrol-2-yl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-67-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-68-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(3-methoxyphenoxy)-2-oxoethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-69-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(cyclopentylamino)-2-oxoethyl]-3-[[[(2-fluorophenyl)(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-70-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-3-[[[(2-fluorophenyl)(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-71-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(4-(acetylamino)phenyl)thio]ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-72-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2,3-dimethylphenyl)thio]ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-73-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-1-[2-[(1-methyl-1H-imidazol-2-yl)thio]ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-74-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-1-[2-[(2-methoxyphenyl)sulfinyl]ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-75-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-1-[2-[(2-methoxyphenyl)thio]-2-oxoethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-76-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(benzoyloxy)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552830-77-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(benzoylamino)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552830-78-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-79-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(phenylsulfonyl)amino]ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552830-80-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-cyanophenoxy)propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-81-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-1-[3-(3-nitrophenoxy)propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-82-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-1-[3-[5-methyl-2-pyrimidinyl]oxy]propyl-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-83-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl}oxy]-1-[3-(2-pyridinylthio)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-84-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-benzoxazolylthio)propyl]-3-[{[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl}oxy]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-85-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)((4-fluorophenyl)methyl)amino]carbonyloxy]-1-[3-[(2-fluorophenyl)sulfonyl]propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-86-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[acetyl(4-chlorophenyl)amino]propyl]-3-[[[(2-fluorophenyl)((4-fluorophenyl)methyl)amino]carbonyloxy]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-87-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-[(4-fluorophenyl)[(phenylmethoxy)carbonyl]aminopropyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-88-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-oxo-3-(phenylamino)propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl^-

RN 552830-89-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(benzoyloxy)propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br^-


RN 552830-90-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[[4-(acetylamino)phenyl]thio]ethyl]-3-[[[(3-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

● Br⁻

RN 552830-91-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[[3,4-difluorophenyl)methyl]phenylamino]carbonyloxy]-1-[3-(4-fluorophenoxy)-2-hydroxypropyl]-, hydroxide, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● OH⁻

RN 552830-92-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[[[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyloxy]-,

chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-93-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-cyclohexylethyl)-3-[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyloxy]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-94-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyloxy]-1-[2-(phenylsulfonyl)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552830-95-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(3,4-difluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-[2-(phenylthio)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552830-96-3 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[(3,4-difluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-[3-[(4-fluorophenyl)thio]propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552830-97-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3,4-difluorophenyl)methyl](3-fluorophenyl)amino]carbonyloxy}-1-(2-phenoxyethyl)-, bromide (1:1), (3R)-(CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552830-98-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3,4-difluorophenyl)methyl](3-fluorophenyl)amino]carbonyloxy}-1-(3-phenylpropyl)-, bromide (1:1), (3R)-(CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552830-99-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-[{[(2-fluorophenyl)(3,4,5-trifluorophenyl)methyl]amino}carbonyloxy]-, bromide (1:1), (3R)-(CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552831-00-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl}oxy]-1-(phenylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552831-01-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl}oxy]-1-[2-(phenylthio)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552831-02-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl}oxy]-1-(3-phenoxypropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-03-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-difluorophenoxy)propyl]-3-[{[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl}oxy]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




● Cl⁻

RN 552831-04-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-methylphenyl)(2-thienylmethyl)amino]carbonyl}oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-05-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-methylphenyl)(2-thienylmethyl)amino]carbonyl}oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-06-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)(2-thienylmethyl)amino]carbonyl}oxy]-1-(phenylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-07-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[{[(3-fluorophenyl)(2-thienylmethyl)amino]carbonyl}oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-08-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(3-methyl-2-thienyl)methyl]phenylamino]carbonyl}oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-09-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-bromo-2-thienyl)methyl]phenylamino]carbonyl}oxy]-1-(cyclopropylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-10-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-bromo-2-thienyl)methyl]phenylamino]carbonyl}oxy]-1-[(phenylthio)methyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 552831-11-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-[[[(5-methyl-2-thienyl)methyl]phenylamino]carbonyloxy]oxy-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-12-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-chloro-2-thienyl)methyl](2-fluorophenyl)amino]carbonyloxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552831-13-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl]phenylamino]carbonyloxy]-1-(cyclopropylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 552831-14-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl]phenylamino]carbonyloxy]-1-[2-(phenylthio)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552831-15-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(5-bromo-2-thienyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-[(phenylthio)methyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 552831-16-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyloxy}-1-(cyclopropylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-17-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyl}oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-18-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyl}oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-19-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[(3-fluorophenyl)(3-thienylmethyl)amino]carbonyloxy-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-20-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(3-fluorophenyl)(3-thienylmethyl)amino]carbonyloxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-21-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(cyclohexylmethyl)phenylamino]carbonyl}oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 552831-22-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(cyclohexylmethyl)phenylamino]carbonyl}oxy]-1-(3-phenoxypropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


IT 552860-70-5 552860-71-6 552860-72-7
 552860-73-8 552860-75-0 552860-76-1
 552860-77-2 552860-78-3 552860-79-4
 552860-80-7 552860-81-8 552860-82-9
 552860-83-0

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as
 muscarinic receptor antagonists)

RN 552860-70-5 CAPLUS

CN Carbamic acid, (3-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-71-6 CAPLUS

CN Carbamic acid, (3-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-72-7 CAPLUS
CN Carbamic acid, [(4-fluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-73-8 CAPLUS
CN Carbamic acid, [(4-fluorophenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-75-0 CAPLUS
CN Carbamic acid, (2-fluorophenyl)[(4-fluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-76-1 CAPLUS
CN Carbamic acid, (3-fluorophenyl)[(4-fluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-77-2 CAPLUS
CN Carbamic acid, [(3,4-difluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-78-3 CAPLUS
 CN Carbamic acid, [(3,4-difluorophenyl)methyl](3-methylphenyl)-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 552860-79-4 CAPLUS
 CN Carbamic acid, [(3,4-difluorophenyl)methyl](2-fluorophenyl)-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




● HCl

RN 552860-80-7 CAPLUS

CN Carbamic acid, [(3,4-difluorophenyl)methyl](3-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-81-8 CAPLUS

CN Carbamic acid, (2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-82-9 CAPLUS

CN Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) (CA INDEX
NAME)

Absolute stereochemistry.




● HCl

RN 552860-83-0 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl
ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 385367-79-3P 552831-24-0P 552831-25-1P
 552831-26-2P 552831-27-3P 552831-28-4P
 552831-29-5P 552831-30-8P 552831-31-9P
 552831-32-0P 552831-33-1P 552831-34-2P
 552831-35-3P 552831-36-4P 552831-37-5P
 552831-38-6P 552831-39-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as muscarinic receptor antagonists)

RN 385367-79-3 CAPLUS

CN Carbanic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 552831-24-0 CAPLUS


CN Carbanic acid, (3-methylphenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 552831-25-1 CAPLUS
 CN Carbamic acid, (2-fluorophenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552831-26-2 CAPLUS
 CN Carbamic acid, (3-fluorophenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-27-3 CAPLUS
 CN Carbamic acid, [(4-methyl-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-28-4 CAPLUS

CN Carbamic acid, [(4-bromo-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-29-5 CAPLUS

CN Carbamic acid, [(5-methyl-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-30-8 CAPLUS

CN Carbamic acid, [(5-chloro-2-thienyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-31-9 CAPLUS

CN Carbamic acid, [(5-bromo-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-32-0 CAPLUS
CN Carbamic acid, [(5-bromo-2-thienyl)methyl](3-methylphenyl)-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



● HCl

RN 552831-33-1 CAPLUS
CN Carbamic acid, (3-fluorophenyl)(3-thienylmethyl)-, (3R)-1-
azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-34-2 CAPLUS
CN Carbamic acid, (2-fluorophenyl)[(3-methyl-2-thienyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




● HCl

RN 552831-35-3 CAPLUS

CN Carbamic acid, (2-fluorophenyl)[(5-methyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-36-4 CAPLUS

CN Carbamic acid, [(5-chloro-2-thienyl)methyl](3-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-37-5 CAPLUS

CN Carbamic acid, [(5-ethyl-2-thienyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-38-6 CAPLUS

CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-39-7 CAPLUS

CN Carbanic acid, (3-methylphenyl)(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● HCl

L3 ANSWER 16 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:615577 CAPLUS
 DOCUMENT NUMBER: 137:169536
 TITLE: Preparation of aryl-substituted tetrahydropyrimidines
 and related compounds as melanocortin-4 receptor
 binding compounds
 INVENTOR(S): Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 228 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|-----------------|-----------------|----------|
| WO 2002062766 | A2 | 20020815 | WO 2002-US3566 | 20020207 |
| WO 2002062766 | A3 | 20021003 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6699873 | B1 | 20040302 | US 2001-778468 | 20010207 |
| AU 2002250029 | A1 | 20020819 | AU 2002-250029 | 20020207 |
| EP 1363890 | A2 | 20031126 | EP 2002-718920 | 20020207 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 2001-778468 | A 20010207 | |
| | | US 1999-147288P | P 19990804 | |
| | | US 2000-223277P | P 20000803 | |
| | | US 2000-632309 | A2 20000804 | |
| | | WO 2002-US3566 | W 20020207 | |

OTHER SOURCE(S): MARPAT 137:169536
 GI



AB Title compds. I [wherein A and B = independently (un)substituted biaryl, (hetero)aryl, Ph, (cyclo)alkyl, (cyclo)alkoxy, alkenyl, alkynyl, OH, acyl(oxy), carbamoyl, amino, thiol, amidino, imino, NO₂, N₃, etc.; L1 and L2 = covalent bond or (un)substituted alkyl optionally interrupted by O, S, or N; r = covalent bond, CH, CH₂, CHR₁, CR₁R₂, or H; t = CH, CH₂, CHR₃, CR₃R₄, or H; s = CHR₅, CR₅R₆, or absent; R = H, (un)substituted alkyl,

arylalkyl, or heteroalkyl, and may optionally be linked to A, B, L1, or L2; R1-R6 = independently (un)substituted alkyl, halo, thiol, thioether, thioalkyl, alkoxy, and may be optionally linked to each other to form addnl. ring moieties, e.g., quinoxalinyl; or pharmaceutically acceptable salts thereof] were prepared as melanocortin-4 receptor binding (MC4-R) compds. For example, stirring a solution of α -tolunitrile with diisopropylamine and BuLi in hexanes at -78° under nitrogen for 1 h, followed by addition of HMPA and 1-chloromethylnaphthalene in THF, afforded 2-(2-naphthalen-1-ylethyl)benzonitrile. Heating the benzonitrile with 1,3-diaminopropane in the presence of H2S at 80° for 72 h gave the tetrahydropyrimidinyl cycloaddn. product II. The latter exhibited exemplary inhibition of MC4-R in a scintillation proximity assay. I are useful for the treatment of disorders associated with pigmentation, bones, or weight loss (no data).


IT 325826-44-6P, [2-(Naphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 325826-51-5P,
 [2-(2-Methylnaphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 326484-34-8P
 326484-38-2P 326484-48-4P 326484-49-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MC4-R binding compound; preparation of aryl-substituted tetrahydropyrimidines and related compds. as melanocortin-4 receptor binding compds. for treatment of pigmentation, bone, and weight loss disorders)


RN 325826-44-6 CAPLUS

CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 325826-51-5 CAPLUS

CN Carbamic acid, [2-[(2-methyl-1-naphthalenyl)methyl]thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 326484-34-8 CAPLUS

CN Carbamic acid, [2-[(1-naphthalenylmethyl)thiophenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-44-6

CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 326484-38-2 CAPLUS

CN Carbamic acid, [2-[(5-bromo-2-methoxyphenyl)methyl]thiophenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-37-1

CMF C22 H25 Br N2 O3 S



CM 2


CRN 64-18-6
CMF C H2 O2



RN 326484-48-4 CAPLUS
CN Carbamic acid, [2-[(2-naphthalenylmethyl)thio]phenyl]-,
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-47-3
CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6
CMF C H2 O2




RN 326484-49-5 CAPLUS
CN Carbamic acid, [2-[(2-methyl-1-naphthalenyl)methyl]thio]phenyl-,
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-51-5

CMF C26 H28 N2 O2 S



CM 2


CRN 64-18-6
CMF C H2 O2




L3 ANSWER 17 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:504786 CAPLUS
 DOCUMENT NUMBER: 137:79107
 TITLE: Preparation of quinuclidine carbamate derivatives as M3 antagonists
 INVENTOR(S): Buil Albero, Maria Antonia; Fernandez Forner, Maria
 Dolors; Prat Quinones, Maria
 PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-----------------|-----------------|----------|
| WO 2002051841 | A1 | 20020704 | WO 2001-EP15169 | 20011220 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2441896 | A1 | 20020704 | CA 2001-2441896 | 20011220 |
| AU 2002228015 | A1 | 20020708 | AU 2002-228015 | 20011220 |
| AU 2002228015 | B2 | 20070823 | | |
| EP 1345937 | A1 | 20030924 | EP 2001-989610 | 20011220 |
| EP 1345937 | B1 | 20050928 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2001016450 | A | 20030930 | BR 2001-16450 | 20011220 |
| EE 200300295 | A | 20031015 | EE 2003-295 | 20011220 |
| HU 2003003529 | A2 | 20040128 | HU 2003-3529 | 20011220 |
| HU 2003003529 | A3 | 20080328 | | |
| CN 1492868 | A | 20040428 | CN 2001-822829 | 20011220 |
| JP 2004530641 | T | 20041007 | JP 2002-552936 | 20011220 |
| NZ 526580 | A | 20050429 | NZ 2001-526580 | 20011220 |
| AT 305468 | T | 20051015 | AT 2001-989610 | 20011220 |
| ES 2248409 | T3 | 20060316 | ES 2001-989610 | 20011220 |
| RU 2296762 | C2 | 20070410 | RU 2003-122341 | 20011220 |
| US 20040266816 | A1 | 20041230 | US 2002-193622 | 20020710 |
| US 7208501 | B2 | 20070424 | | |
| US 20040242629 | A1 | 20041202 | US 2003-404395 | 20030331 |
| US 7312231 | B2 | 20071225 | | |
| IN 2003DN00939 | A | 20070105 | IN 2003-DN939 | 20030617 |
| MX 2003PA05583 | A | 20040505 | MX 2003-PA5583 | 20030619 |
| BG 107930 | A | 20040831 | BG 2003-107930 | 20030619 |
| ZA 2003004769 | A | 20040920 | ZA 2003-4769 | 20030619 |
| NO 2003002889 | A | 20030808 | NO 2003-2889 | 20030623 |
| HK 1055120 | A1 | 20060106 | HK 2003-107423 | 20031015 |
| US 20080021060 | A1 | 20080124 | US 2007-806927 | 20070605 |
| PRIORITY APPLN. INFO.: | | ES 2000-3084 | A 20001222 | |
| | | WO 2001-EP15169 | W 20011220 | |
| | | US 2002-193622 | A1 20020710 | |
| | | US 2003-404395 | A1 20030331 | |

OTHER SOURCE(S): MARPAT 137:79107
 GI



I



II

AB The title compds. I (R1 = unsubstituted, halo substituted, alkyl substituted, or cyano substituted Ph, 2-thienylmethyl, 2-thienyl, 2-furylmethyl, 2-furyl, 3-thienylmethyl, 3-thienyl, 3-furylmethyl, 3-furyl; R2 = benzyl, phenethyl, 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl or 3-thienylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbons atoms, or a cycloalkyl group of 3 to 6 carbon atoms; p = 1 or 2; the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asym. carbons) and their pharmaceutically acceptable salts II (A = CH₂, R3C:CH, CH:CR₃, CO, O, S, SO, SO₂, NR₃, CR₃R₄; B = O₂CR₃, CO₂R₃, cyano, etc.; R₃, R₄ = H, alkyl, R₃R₄ = alicyclic ring; m = 0-8, n = 0-4) were prepared as M₃ antagonists. Thus, (R)-3-hydroxy-1-azabicyclo[2.2.2]octane was treated with phenylbutylicarbamyl chloride to give the corresponding carbamate. The binding to receptor M₃ receptor IC50 of benzylphenylcarbamic acid (R)-1-azabicyclo[2.2.2]octyl-3-yl ester was 5.0 nM.


IT
385367-13-5P 439907-90-1P 439907-95-6P
439908-47-1P 439908-89-1P 439908-94-8P
439909-11-2P 439909-34-9P 439909-54-3P
439909-77-0P 439910-19-7P 439910-27-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinuclidine carbamate derivs. as M₃ antagonists)

RN 385367-13-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 439907-90-1 CAPLUS


CN Carbamic acid, (4-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439907-95-6 CAPLUS
 CN Carbamic acid, (4-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-47-1 CAPLUS
 CN Carbamic acid, butylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-89-1 CAPLUS
 CN Carbamic acid, butyl(4-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-94-8 CAPLUS
 CN Carbamic acid, phenyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-11-2 CAPLUS
 CN Carbamic acid, phenyl(2-phenylethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-34-9 CAPLUS
 CN Carbamic acid, pentylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-54-3 CAPLUS
 CN Carbamic acid, 4-pentenylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439909-77-0 CAPLUS
 CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439910-19-7 CAPLUS

CN Carbamic acid, cyclopentyl(2-thienymethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439910-27-7 CAPLUS

CN Carbamic acid, (2-furanyl methyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



| | | | |
|----|--------------|--------------|--------------|
| IT | 439907-53-6P | 439907-55-8P | 439907-57-0P |
| | 439907-58-1P | 439907-59-2P | 439907-61-6P |
| | 439907-63-8P | 439907-65-0P | 439907-67-2P |
| | 439907-69-4P | 439907-71-8P | 439907-73-0P |
| | 439907-75-2P | 439907-77-4P | 439907-79-6P |
| | 439907-81-0P | 439907-83-2P | 439907-85-4P |
| | 439907-87-6P | 439907-89-8P | 439907-92-3P |
| | 439907-94-5P | 439907-97-8P | 439907-99-0P |
| | 439908-00-6P | 439908-01-7P | 439908-02-8P |
| | 439908-03-9P | 439908-04-0P | 439908-06-2P |
| | 439908-08-4P | 439908-10-8P | 439908-12-0P |
| | 439908-14-2P | 439908-16-4P | 439908-18-6P |
| | 439908-20-0P | 439908-22-2P | 439908-24-4P |
| | 439908-26-6P | 439908-28-8P | 439908-30-2P |
| | 439908-32-4P | 439908-34-6P | 439908-36-8P |
| | 439908-38-0P | 439908-40-4P | 439908-42-6P |
| | 439908-45-9P | 439908-50-6P | 439908-52-8P |

439908-54-0P 439908-55-1P 439908-56-2P
 439908-58-4P 439908-60-8P 439908-62-0P
 439908-64-2P 439908-66-4P 439908-68-6P
 439908-70-0P 439908-72-2P 439908-74-4P
 439908-76-6P 439908-78-8P 439908-80-2P
 439908-82-4P 439908-84-6P 439908-86-8P
 439908-87-9P 439908-88-0P 439908-90-4P
 439908-91-5P 439908-92-6P 439908-93-7P
 439908-95-9P 439908-97-1P 439908-99-3P
 439909-01-0P 439909-03-2P 439909-05-4P
 439909-07-6P 439909-08-7P 439909-09-8P
 439909-10-1P 439909-12-3P 439909-14-5P
 439909-16-7P 439909-18-9P 439909-20-3P
 439909-22-5P 439909-24-7P 439909-26-9P
 439909-29-2P 439909-32-7P 439909-36-1P
 439909-37-2P 439909-39-4P 439909-41-8P
 439909-43-0P 439909-45-2P 439909-47-4P
 439909-49-6P 439909-51-0P 439909-53-2P
 439909-56-5P 439909-58-7P 439909-60-1P
 439909-62-3P 439909-64-5P 439909-66-7P
 439909-68-9P 439909-70-3P 439909-72-5P
 439909-75-8P 439909-79-2P 439909-81-6P
 439909-83-8P 439909-85-0P 439909-87-2P
 439909-89-4P 439909-91-8P 439909-93-0P
 439909-94-1P 439909-95-2P 439910-21-1P
 439910-25-5P 439910-30-2P 439910-33-5P
 439910-43-7P 439910-45-9P 439910-49-3P
 439910-50-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of quinuclidine carbamate derivs. as M3 antagonists)

RN 439907-53-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-52-5
CMF C22 H27 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-55-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-methyl-3-pentenyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-54-7
 CMF C27 H35 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-57-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-56-9
 CMF C30 H35 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439907-58-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



● Br⁻

RN 439907-59-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


RN 439907-61-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-hydroxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-60-5
CMF C23 H29 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-63-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(1-methylethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-62-7
CMF C24 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-65-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX
NAME)

CM 1

CRN 439907-64-9
CMF C24 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-67-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-66-1
 CMF C25 H30 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-69-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-68-3
 CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-71-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-70-7
CMF C25 H33 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-73-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(5-ethoxy-5-oxopentyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-72-9
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-75-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-phenylbutyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-74-1
 CMF C31 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-77-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-fluorophenoxy)propyl]-3-[(phenylmethyl)amino]carbonyloxy-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-76-3
CMF C30 H34 F N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-79-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-hydroxypropyl)-3-[[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-78-5
CMF C24 H31 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-81-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetoxy)butyl]-3-[[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-80-9
CMF C27 H35 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-83-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-oxo-4-(2-thienyl)butyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-82-1
CMF C29 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-85-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[phenyl(phenylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-84-3
 CMF C30 H35 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439907-87-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[phenyl(phenylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-86-5
 CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-89-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(methyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-88-7
CMF C30 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439907-92-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-fluorophenyl)(phenylmethyl)amino]carbonyloxy}-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-91-2

CMF C24 H28 F N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-94-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-fluorophenyl)(phenylmethyl)amino]carbonyloxy}-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-93-4

CMF C30 H34 F N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-97-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyloxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 439907-96-7
CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439907-99-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-methylphenyl)(phenylmethyl)amino]carbonyl}oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-98-9
 CMF C31 H37 N2 O2

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2



RN 439908-00-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2-methoxyethoxy)ethyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-01-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenylethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-02-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-03-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-04-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


RN 439908-06-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-cyanophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-05-1
CMF C31 H34 N3 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-08-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1-naphthalenyl oxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-07-3
CMF C34 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-10-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(methylphenylamino)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-09-5
CMF C31 H38 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-12-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-
1-[3-(phenylthio)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 439908-11-9
CMF C30 H35 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-14-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-oxo-4-phenylbutyl)-3-
 [[(phenyl(phenylmethyl)amino)carbonyl]oxy]-, (3R)-, salt with
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-13-1
 CMF C31 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-16-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(phenyl(phenylmethyl)amino)carbonyl]oxy]-
 1-[3-(2,4,6-trimethylphenoxy)propyl]-, (3R)-, salt with trifluoroacetic
 acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-15-3
 CMF C33 H41 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-18-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-chlorophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-17-5
 CMF C30 H34 Cl N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-20-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-(3-(trifluoromethyl)phenoxy]propyl-, (3*R*)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-19-7

CMF C31 H34 F3 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-22-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-((1,1'-biphenyl)-4-yloxy)propyl]-3-[[[phenylmethyl]amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-21-1
CMF C36 H39 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-24-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2,4-difluorophenoxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-23-3
CMF C30 H33 F2 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-26-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-methoxyphenoxy)propyl]-3-
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-25-5
CMF C31 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-28-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxyl]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-27-7
CMF C34 H41 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-30-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-29-9
CMF C31 H35 N2 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-32-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[2-(aminocarbonyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-31-3
CMF C31 H36 N3 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-34-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[3-(dimethylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-33-5

CMF C32 H40 N3 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-36-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-{4-(acetylamino)phenoxy}propyl]-3-[[[phenylmethyl]amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-35-7
CMF C32 H38 N3 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-38-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(methoxycarbonyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-37-9
CMF C32 H37 N2 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-40-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-nitrophenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-39-1
CMF C30 H34 N3 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-42-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(hydroxymethyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-41-5
CMF C31 H37 N2 O4

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439908-45-9 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-1-(3-phenylpropyl)-, bromide (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.




● Br-

RN 439908-50-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyloxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-49-3
CMF C19 H29 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-52-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(4-methyl-3-pentenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439908-51-7
CMF C24 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-54-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-53-9
 CMF C27 H37 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2



RN 439908-55-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




● Br⁻

RN 439908-56-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439908-58-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(2-hydroxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-57-3

CMF C20 H31 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-60-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(1-methylethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-59-5
CMF C21 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-62-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-61-9
CMF C21 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-64-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(3-cyanopropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-63-1
CMF C22 H32 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-66-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy)-1-(cyclopropylmethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-65-3
 CMF C22 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-68-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy)-1-(2-ethoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-67-5
 CMF C22 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-70-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(5-ethoxy-5-oxopentyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439908-69-7
CMF C25 H39 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-72-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(3-hydroxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-71-1
 CMF C21 H33 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-74-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-[3-(1H-pyrol-1-yl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-73-3
 CMF C25 H36 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-76-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-
[(butylphenylamino)carbonyloxy]-, (3R)-, salt with trifluoroacetic acid
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-75-5
CMF C24 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-78-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy)-1-(4-oxo-4-(2-thienyl)butyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-77-7
 CMF C26 H35 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-80-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy)-1-(4-phenylbutyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439908-79-9
 CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-82-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-[3-(3-hydroxyphenoxy)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439908-81-3
CMF C27 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-84-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-heptyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-83-5
 CMF C25 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439908-86-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-85-7
 CMF C27 H37 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439908-87-9 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-(2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br-

RN 439908-88-0 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyl]oxy]-1-[2-(2-methoxyethoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-90-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-[3-(4-fluorophenoxy)propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

RN 439908-91-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-93-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439908-95-9 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439908-97-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-96-0
CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439908-99-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-98-2
 CMF C28 H33 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-01-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-00-9
 CMF C28 H31 N2 O2 S

Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-03-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-02-1
CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439909-05-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-04-3

CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-07-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[phenyl(2-thienylmethyl)amino]carbonyl]oxyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-06-5

CMF C26 H37 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-08-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br-

RN 439909-09-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-


thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)
Absolute stereochemistry.



● Br⁻

RN 439909-10-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439909-12-3 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 439909-14-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-13-4

CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-16-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-15-6

CMF C31 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-18-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-17-8
CMF C30 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-20-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439909-19-0
 CMF C31 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-22-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 439909-21-4
 CMF C31 H35 N2 O2

Absolute stereochemistry.

Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-24-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-23-6
CMF C31 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439909-26-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[phenyl(2-phenylethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-25-8

CMF C31 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-29-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[phenyl(2-phenylethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-28-1

CMF C29 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-32-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-31-6
CMF C29 H35 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 439909-36-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[(pentylphenylamino)carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439909-37-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439909-39-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-38-3
 CMF C28 H39 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-41-8 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-40-7
CMF C27 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-43-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-42-9
 CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-45-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-44-1
 CMF C28 H37 N2 O2

Absolute stereochemistry.

Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-47-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439909-46-3
CMF C28 H39 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-49-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-{3-(3-hydroxyphenoxy)propyl}-3-[(pentylphenylamino)carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-48-5
 CMF C28 H39 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-51-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[(pentylphenylamino)carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-50-9
 CMF C26 H43 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-53-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[(pentylphenylamino)carbonyloxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-52-1
CMF C26 H37 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-56-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-55-4
 CMF C22 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-58-7 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-57-6
 CMF C28 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-60-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-59-8
CMF C27 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-62-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-61-2
 CMF C28 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-64-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-63-4
 CMF C28 H35 N2 O2


Absolute stereochemistry.

Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-66-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 439909-65-6
CMF C28 H37 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-68-9 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[(4-pentenylphenylamino)carbonyl]oxy-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-67-8
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-70-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[(4-pentenylphenylamino)carbonyl]oxy-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-69-0
 CMF C26 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-72-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-71-4
CMF C20 H29 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-75-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(4-pentenylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439909-74-7
 CMF C26 H35 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-79-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439909-78-1
 CMF C22 H27 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-81-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(3-thienylmethyl)aminolcarbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-80-5
CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-83-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-82-7
 CMF C28 H33 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-85-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-84-9
 CMF C28 H31 N2 O2 S

Absolute stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-87-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[phenyl(3-thienylmethyl)aminolcarbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-86-1
CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439909-89-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[phenyl(3-thienylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-88-3
 CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439909-91-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[phenyl(3-thienylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-90-7
 CMF C26 H37 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-93-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-92-9

CMF C20 H25 N2 O2 S

Absolute stereochemistry.



CM 2


CRN 14477-72-6

CMF C2 F3 O2



RN 439909-94-1 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br⁻

RN 439909-95-2 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻


RN 439910-21-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-20-0
CMF C21 H31 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439910-25-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-24-4
CMF C27 H37 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439910-30-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanyl methyl)phenylamino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 439910-29-9
CMF C22 H27 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6
CMF C2 F3 O2




RN 439910-33-5 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[([(2-furanylmethyl)phenylamino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 439910-32-4
 CMF C28 H33 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6
 CMF C2 F3 O2




RN 439910-43-7 CAPLUS
 CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.1]hept-4-yl ester
 (9CI) (CA INDEX NAME)



RN 439910-45-9 CAPLUS


CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester
(9CI) (CA INDEX NAME)



RN 439910-49-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-[3-(3-hydroxyphenoxy)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br⁻

RN 439910-50-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[(butylphenylamino)carbonyloxy]-1-[3-(4-fluorophenoxy)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 439908-43-7P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(preparation of quinuclidine carbamate derivs. as M3 antagonists)

RN 439908-43-7 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3S)-1-azabicyclo[2.2.2]oct-3-yl
ester (GCI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:10471 CAPLUS
DOCUMENT NUMBER: 136:69742

TITLE: Preparation of quinuclidinecarbamates derived from arylalkylamines as M3 muscarinic receptor antagonists
INVENTOR(S): Farrerons Gallemi, Carles; Catena Ruiz, Juan Lorenzo; Fernandez Serrat, Anna; Miquel Bono, Ignacio Jose; Balsa Lopez, Dolors; Bonilla Navarro, Jose Ignacio; Lagunas Arnal, Carmen; Salcedo Roca, Carolina; Fernandez Garcia, Andres

PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain
SOURCE: PCT Int. Appl., 30 pp.

DOCUMENT TYPE: Patent
LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2002000652 | A1 | 20020103 | WO 2001-ES252 | 20010625 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2414514 | A1 | 20020103 | CA 2001-2414514 | 20010625 |
| AU 2001066100 | A | 20020108 | AU 2001-66100 | 20010625 |
| EP 1300407 | A1 | 20030409 | EP 2001-943553 | 20010625 |
| EP 1300407 | B1 | 20040225 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2001012297 | A | 20030506 | BR 2001-12297 | 20010625 |
| HU 2003001414 | A2 | 20030929 | HU 2003-1414 | 20010625 |
| HU 2003001414 | A3 | 20080328 | | |
| JP 2004501916 | T | 20040122 | JP 2002-505776 | 20010625 |
| AT 260277 | T | 20040315 | AT 2001-943553 | 20010625 |
| PT 1300407 | T | 20040531 | PT 2001-943553 | 20010625 |
| ES 2213703 | T3 | 20040901 | ES 2001-943553 | 20010625 |
| CZ 294251 | B6 | 20041110 | CZ 2003-261 | 20010625 |
| AP 1420 | A | 20050614 | AP 2003-2722 | 20010625 |
| AU 2001266100 | B2 | 20050630 | AU 2001-266100 | 20010625 |
| AU 2001266100 | B9 | 20051006 | | |
| DE 20122417 | U1 | 20050908 | DE 2001-20122417 | 20010625 |
| NO 2002006211 | A | 20030226 | NO 2002-6211 | 20021223 |
| KR 751981 | B1 | 20070828 | KR 2002-717706 | 20021226 |
| MX 2003PA00141 | A | 20030527 | MX 2003-PA141 | 20030107 |
| BG 107474 | A | 20030930 | BG 2003-107474 | 20030117 |
| ZA 2003000644 | A | 20040210 | ZA 2003-644 | 20030123 |
| IN 2003CN00150 | A | 20050408 | IN 2003-CN150 | 20030124 |
| US 20040063950 | A1 | 20040401 | US 2003-312227 | 20030728 |
| US 6916828 | B2 | 20050712 | | |
| HK 1054934 | A1 | 20041021 | HK 2003-107175 | 20031006 |
| US 20040235887 | A1 | 20041125 | US 2004-875592 | 20040623 |
| US 7115629 | B2 | 20061003 | | |
| IN 2007CN00210 | A | 20070824 | IN 2007-CN210 | 20070118 |
| PRIORITY APPLN. INFO.: | | | ES 2000-1661 | A 20000627 |
| | | | EP 2001-943553 | A 20010625 |

OTHER SOURCE(S) :
GI

MARPAT 136:69742

WO 2001-ES252
IN 2003-CN150
US 2003-312227

W 20010625
A3 20030124
A1 20030728




AB The quinuclidinecarbamates I [R1, R2, R3 = H, OH, SH, CN, F, Cl, Br, I, (Cl-C4)-alkylthio, (Cl-C4)-alkoxyl, (Cl-C4)-alkoxy substituted by one or several F radicals, carbamoylamine, (Cl-C4)-alkyl and (Cl-C4)-alkyl substituted by one or several F or OH radicals; R4 = a substituted or non-substituted cycloalkyl or cycloaryl radical (a heterocycloalkyl radical or not)] were prepared as antagonists of the M3 muscarinic receptor, and selectively, the M2 receptor. The amine of the quinuclidine ring can also be forming quaternary ammonium salts or in an oxidized state (N-oxide). I can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmic operations. Thus, (R)-quinuclidinol was converted to the chloroformate and reacted with N-phenylbenzylamine to give (R)-I (R1 = R2 = R3 = H, R4 = Ph) (II). The M3 muscarinic receptor constant Ki of II was 0.31 nM.

IT 385367-12-4P 385367-13-5P 385367-14-6P
385367-15-7P 385367-16-8P 385367-17-9P
385367-18-0P 385367-19-1P 385367-20-4P
385367-21-5P 385367-22-6P 385367-23-7P
385367-24-8P 385367-25-9P 385367-26-0P
385367-27-1P 385367-28-2P 385367-29-3P
385367-30-6P 385367-31-7P 385367-32-8P
385367-33-9P 385367-34-0P 385367-35-1P
385367-36-2P 385367-37-3P 385367-38-4P
385367-39-5P 385367-40-8P 385367-41-9P
385367-42-0P 385367-43-1P 385367-44-2P
385367-45-3P 385367-46-4P 385367-47-5P
385367-48-6P 385367-49-7P 385367-50-0P
385367-51-1P 385367-52-2P 385367-53-3P
385367-54-4P 385367-55-5P 385367-56-6P
385367-57-7P 385367-58-8P 385367-59-9P
385367-60-2P 385367-61-3P 385367-62-4P
385367-63-5P 385367-64-6P 385367-65-7P
385367-66-8P 385367-67-9P 385367-68-0P
385367-69-1P 385367-70-4P 385367-71-5P
385367-72-6P 385367-73-7P 385367-74-8P
385367-75-9P 385367-76-0P 385367-78-2P
385367-79-3P 385424-09-9P 385424-10-2P
385424-11-3P 385424-12-4P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of quinuclidinecarbamates derived from arylalkylamines as quinuclidinecarbamates)

RN 385367-12-4 CAPLUS
CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester
(9CI) (CA INDEX NAME)




RN 385367-13-5 CAPLUS
CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 385367-14-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I-

RN 385367-15-7 CAPLUS
CN Carbamic acid, phenyl(phenylmethyl)-, 1-oxido-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 385367-16-8 CAPLUS
CN Carbamic acid, (2-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-17-9 CAPLUS
CN Carbamic acid, (3-chlorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-18-0 CAPLUS
CN Carbamic acid, (3-bromophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-19-1 CAPLUS
CN Carbamic acid, (2,6-difluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-20-4 CAPLUS
 CN Carbamic acid, (3,4-difluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-21-5 CAPLUS
 CN Carbamic acid, (3-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-22-6 CAPLUS
 CN Carbamic acid, (2,6-dimethylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-23-7 CAPLUS

CN Carbamic acid, (2,3-dihydro-1H-inden-5-yl)(phenylmethyl)-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-24-8 CAPLUS

CN Carbamic acid, (4-cyanophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-25-9 CAPLUS

CN Carbamic acid, (2-hydroxyphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-26-0 CAPLUS

CN Carbamic acid, (2-fluoro-5-methylphenyl)[(2-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-27-1 CAPLUS

CN Carbamic acid, [(2-bromophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-28-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-29-3 CAPLUS

CN Carbamic acid, (2,3-difluorophenyl)[(2-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-30-6 CAPLUS

CN Carbamic acid, [(4-chlorophenyl)methyl](2-fluoro-5-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-31-7 CAPLUS

CN Carbamic acid, [(3-chlorophenyl)[(2,3-difluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-32-8 CAPLUS


CN Carbamic acid, [(2,4-dichlorophenyl)methyl](2,4-difluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-33-9 CAPLUS
 CN Carbamic acid, [(2,4-difluorophenyl)methyl](3-methylphenyl)-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-34-0 CAPLUS
 CN Carbamic acid, (3-chlorophenyl)[(2-fluoro-4-methoxyphenyl)methyl]-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-35-1 CAPLUS
 CN Carbamic acid, (2-chlorophenyl)[(2,5-difluorophenyl)methyl]-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-36-2 CAPLUS

CN Carbamic acid, [(2-fluoro-5-methoxyphenyl)methyl]phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-37-3 CAPLUS

CN Carbamic acid, [(3,4-difluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-38-4 CAPLUS

CN Carbamic acid, [(4-chloro-3-fluorophenyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-39-5 CAPLUS

CN Carbamic acid, [(3-chloro-4-fluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-40-8 CAPLUS

CN Carbamic acid, [(3,4-dichlorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-41-9 CAPLUS

CN Carbamic acid, [(3,5-difluorophenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-42-0 CAPLUS

CN Carbamic acid, [(3-fluoro-4-methylphenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-43-1 CAPLUS

CN Carbamic acid, [(3-fluoro-4-methoxyphenyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-44-2 CAPLUS

CN Carbamic acid, (3-chlorophenyl)[(2,3,4-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-45-3 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,3,5-trifluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-46-4 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-47-5 CAPLUS

CN Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-48-6 CAPLUS

CN Carbamic acid, (4-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-49-7 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2-methylphenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-50-0 CAPLUS


CN Carbamic acid, phenyl[4-(trifluoromethyl)phenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-51-1 CAPLUS
 CN Carbamic acid, [(4-ethylphenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-52-2 CAPLUS
 CN Carbamic acid, [[4-(1,1-dimethylethyl)phenyl]methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-53-3 CAPLUS
 CN Carbamic acid, [[4-(hydroxymethyl)phenyl]methyl](2-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-54-4 CAPLUS
 CN Carbamic acid, [(4-cyanophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-55-5 CAPLUS
 CN Carbamic acid, [(4-(aminocarbonyl)phenyl)methyl]phenyl-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-56-6 CAPLUS
 CN Carbamic acid, (2-fluorophenyl)[(2-hydroxyphenyl)methyl]-,
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-57-7 CAPLUS

CN Carbamic acid, [(3-hydroxyphenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-58-8 CAPLUS

CN Carbamic acid, [(4-hydroxyphenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-59-9 CAPLUS


CN Carbamic acid, (3-chlorophenyl)[[3-(phenylmethoxy)phenyl]methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-60-2 CAPLUS
 CN Carbamic acid, phenyl[[(3-(trifluoromethoxy)phenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-61-3 CAPLUS
 CN Carbamic acid, [(4-(1-methylethoxy)phenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-62-4 CAPLUS
 CN Carbamic acid, (3-chlorophenyl)[[(3-methoxy-4-(phenylmethoxy)phenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-63-5 CAPLUS

CN Carbamic acid, (1,3-benzodioxol-5-ylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-64-6 CAPLUS

CN Carbamic acid, [(2,3-dihydro-1,4-benzodioxin-6-yl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-65-7 CAPLUS

CN Carbamic acid, (cyclopropylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-66-8 CAPLUS

CN Carbamic acid, (cyclobutylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-67-9 CAPLUS

CN Carbamic acid, (cyclopentylmethyl)(3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-68-0 CAPLUS

CN Carbamic acid, (cyclohexylmethyl)(2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-69-1 CAPLUS

CN Carbamic acid, (1-cyclohexen-1-ylmethyl)(2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-70-4 CAPLUS

CN Carbamic acid, (3-chlorophenyl)(3-cyclohexen-1-ylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-71-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-fluorophenyl)methyl]phenylamino}carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-72-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-73-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)methyl]amino]carbonyl]oxy]-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-74-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(4-fluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● I⁻

RN 385367-75-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[{[(2-fluorophenyl)(phenylmethyl)amino]carbonyloxy}-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● I⁻


RN 385367-76-0 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● I⁻


RN 385367-78-2 CAPLUS
 CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 385367-79-3 CAPLUS
 CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 385424-09-9 CAPLUS

CN Carbamic acid, [(4-methylcyclohexyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385424-10-2 CAPLUS

CN Carbamic acid, [(4-(1-methylethenyl)cyclohexyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385424-11-3 CAPLUS

CN Carbamic acid, (bicyclo[2.2.1]hept-2-ylmethyl)(3-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385424-12-4 CAPLUS

CN Carbamic acid, (bicyclo[2.2.1]hept-5-en-2-ylmethyl)phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:743993 CAPLUS
 DOCUMENT NUMBER: 136:134659
 TITLE: Synthesis and preliminary evaluation of a carbon-11-labelled agonist of the $\alpha 7$ nicotinic acetylcholine receptor
 AUTHOR(S): Dolle, Frederic; Valette, Heric; Hinnen, Francoise; Vaufrey, Francoise; Demphel, Stephane; Coulon, Christine; Ottaviani, Michele; Bottlaender, Michel; Crouzel, Christian
 CORPORATE SOURCE: Service Hospitalier Frederic Joliot, Departement de Recherche Medicale, CEA, Orsay, F-91401, Fr.
 SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals (2001), 44(11), 785-795
 PUBLISHER: John Wiley & Sons Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:134659
 GI




AB N-(4-bromophenyl)carbamic acid quinuclidin-3-yl ester I was prepared from [¹¹C]methane, 4-bromoaniline, and 3-quinuclidinol as a potential $\alpha 7$ -nicotinic acetylcholine receptor imaging agent. Chlorination of [¹¹C]methane followed by reaction with 98:2 nitrogen/oxygen over iron provided [¹¹C]phosgene; reaction of [¹¹C]phosgene with 4-bromoaniline generated an isocyanate in situ which reacted with 3-quinuclidinol to give I. 25-35 MCI (0.92-1.29 GBq) of I was obtained within 30 min of radiosynthesis (HPLC purification included) with specific radioactivities ranging from 500 to 800 mCi/ μ mol (18.5-29.6 GBq/ μ mol). Biodistribution studies in rats demonstrated a relatively good brain uptake of I (0.8-1.2% I.D./g tissue in various brain regions), but without preferential concentration in brain regions rich in $\alpha 7$ -subtype nicotinic receptors (e.g. hippocampus, pons and colliculi). No specific binding could be demonstrated in pre-saturation studies performed with both the cold compound and nicotine; therefore, this ligand is not suitable for further exploration in PET imaging.

IT 393138-35-7P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of a [¹¹C]-labeled quinuclidinyl bromophenylcarbamate as an $\alpha 7$ -nicotinic acetylcholine receptor agonist and potential PET imaging agent)

RN 393138-35-7 CAPLUS

CN Carbamic-11C acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



IT 195190-96-6P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(preparation of a quinuclidinyl bromophenylcarbamate as an
*α*7-nicotinic acetylcholine receptor agonist)

RN 195190-96-6 CAPLUS

CN Carbanic acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)



REFERENCE COUNT:



11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:115125 CAPLUS
 DOCUMENT NUMBER: 134:178566
 TITLE: Preparation of melanocortin-4 receptor binding compounds
 INVENTOR(S): Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|-------------|
| WO 2001010842 | A2 | 20010215 | WO 2000-US21327 | 20000804 |
| WO 2001010842 | A3 | 20010816 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2381008 | A1 | 20010215 | CA 2000-2381008 | 20000804 |
| EP 1204645 | A2 | 20020515 | EP 2000-953837 | 20000804 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| BR 2000012984 | A | 20020716 | BR 2000-12984 | 20000804 |
| JP 2003528810 | T | 20030930 | JP 2001-515309 | 20000804 |
| MX 2002PA01160 | A | 20020702 | MX 2002-PA1160 | 20020201 |
| AU 2004202804 | A1 | 20040722 | AU 2004-202804 | 20040624 |
| PRIORITY APPLN. INFO.: | | | US 1999-147288P | P 19990804 |
| | | | US 2000-223277P | P 20000803 |
| | | | AU 2000-66216 | A3 20000804 |
| | | | WO 2000-US21327 | W 20000804 |

OTHER SOURCE(S): MARPAT 134:178566
 GI



AB The title compds. of formula B-Z-E [wherein B = an anchor moiety; Z = a central moiety; E = an MC4-R interacting moiety], e.g. I [wherein P2, P3,

and P4 = independently CH, CF, CCl, CBr, C(alkyl), C(alkoxy), C(CN), C(OH), or Cl; W1 = covalent bond or CH₂; W2 = CH₂, CHR₃, or CR₃R₄; W3 = CH₂, CHR₅, or CR₅R₆; R = H or alkyl; Z1 = CH or covalently linked to Z2 to form a naphthyl ring; Z2 = CH, C(C.tplbond.CH), CCl, CBr, Cl, CF, or covalently linked to Z1 to form a naphthyl ring; Z3 = CH or C(OMe); R3-R6 = independently Me or Et; were prepared and tested as melanocortin-4 receptor (MC4-R) binding agonists and antagonists. For example, α -tolunitrile in THF was added to a solution of diisopropylamine in THF, which had been cooled to -78°C and treated with BuLi. HMPA and 1-chloromethylnaphthalene in THF were added, the reaction cooled and stirred for 1 h, and the reaction quenched with H₂O to give 2-(2-naphthalen-1-ylmethyl)benzonitrile. Treatment with H₂S and 1,3-diaminopropane, followed by heating to 80°C for 72 h and work up, gave II. In a scincillation proximity assay (SPA) using high-throughput receptor binding screening, II showed exemplary inhibition of MC4-R. The invention compds., primarily 2-(2-aryalkylsulfanylphenyl)-4,5-dihydro-1H-imidazole and 1,4,5,6-tetrahydropyrimidine derivs., are useful in the treatment of disorders associated with weight loss and pigmentation (no data).

IT 326486-03-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(inactive as MC4-R binding compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and pyrimidines and analogs)


RN 326486-03-7 CAPLUS

CN Carbanic acid, (2-ethoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326486-02-6

CMF C16 H22 N2 O3



CM 2

CRN 64-18-6

CMF C H2 O2




IT 325826-44-6P, [2-(Naphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 325826-51-5P, [2-(2-Methylnaphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 326484-34-8P 326484-38-2P 326484-48-4P 326484-49-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and

pyrimidines and analogs)
RN 325826-44-6 CAPLUS
CN Carbamic acid, [2-[(1-naphthalenylmethyl)thiophenyl]-,
1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 325826-51-5 CAPLUS
CN Carbamic acid, [2-[(2-methyl-1-naphthalenyl)methyl]thiophenyl]-,
1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 326484-34-8 CAPLUS
CN Carbamic acid, [2-[(1-naphthalenylmethyl)thiophenyl]-,
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-44-6
CME C25 H26 N2 O2 S



CM 2


CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 326484-38-2 CAPLUS
CN Carbamic acid, [2-[(5-bromo-2-methoxyphenyl)methyl]thio]phenyl-,
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-37-1
CMF C22 H25 Br N2 O3 S



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH


RN 326484-48-4 CAPLUS
CN Carbamic acid, [2-[(2-naphthalenylmethyl)thio]phenyl]-,

1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-47-3

CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2

O= CH OH


RN 326484-49-5 CAPLUS

CN Carbamic acid, [2-[(2-methyl-1-naphthalenyl)methyl]thio]phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-51-5

CMF C26 H28 N2 O2 S




CM 2

CRN 64-18-6

CMF C H2 O2

O= CH OH


L3 ANSWER 21 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:558084 CAPLUS
DOCUMENT NUMBER: 129:285907
TITLE: Selective muscarinic antagonists. II. Synthesis and
antimuscarinic properties of biphenylcarbamate
derivatives
AUTHOR(S): Naito, Ryo; Takeuchi, Makoto; Morihira, Koichiro;
Hayakawa, Masahiko; Ikeda, Ken; Shibanuma, Tadao;
Isomura, Yasuo
CORPORATE SOURCE: Institute for Drug Discovery Research, Yamanouchi
Pharmaceutical Co., Ltd., Tsukuba, 305-8585, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1998), 46(8),
1286-1294
CODEN: CFBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:285907
AB A novel series of biphenylcarbamate derivs. were synthesized and
evaluated for binding to M1, M2 and M3 receptors and for antimuscarinic
activities. Receptor binding assays indicated that biphenyl-2-ylcarbamate
derivs. had high affinities for M1 and M3 receptors and good selectivities
for M3 receptor over M2 receptor, indicating that the biphenyl-2-yl group
is a novel hydrophobic replacement for the benzhydryl group in the
muscarinic antagonist field. In this series, quinuclidin-4-yl
biphenyl-2-ylcarbamate monohydrochloride (81, YM-46303) exhibited the
highest affinities for M1 and M3 receptors, and selectivity for M3 over M2
receptor. Compared to oxybutynin, YM-46303 showed approx. ten times
higher inhibitory activity on bladder pressure in reflexly-evoked rhythmic
contraction, and about 5-fold greater selectivity for urinary bladder
contraction against salivary secretion in rats. Moreover, selective
antagonistic activity was also observed in vitro. Further evaluation of
antimuscarinic effects on bradycardia and pressor in pithed rats, and on
tremor in mice, showed that YM-46303 can be useful for the treatment of
urinary urge incontinence as a bladder-selective M3 antagonist with potent
activities and fewer side effects.
IT 171722-78-4P 171722-79-5P 171722-85-3P
171723-61-8P 171723-67-4P 214192-45-7P
214192-46-8P 214192-47-9P 214192-48-0P
214192-49-1P 214192-50-4P 214192-51-5P
214192-52-6P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
effector, except adverse); BSU (Biological study, unclassified); PRP
(Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(synthesis and antimuscarinic properties of biphenylcarbamate
derivs.)
RN 171722-78-4 CAPLUS
CN Carbanic acid, [1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171722-79-5 CAPLUS


CN Carbamic acid, [2-(1H-pyrrol-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171722-85-3 CAPLUS

CN Carbamic acid, [2-(phenylmethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 171723-61-8 CAPLUS

CN Carbamic acid, (2-cyclohexylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-60-7

CMF C20 H28 N2 O2




CM 2

CRN 144-62-7
CME C2 H2 O4




RN 171723-67-4 CAPLUS
CN Carbamic acid, [2-(phenylthio)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214192-45-7 CAPLUS
CN Carbamic acid, (2-phenoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214192-46-8 CAPLUS
CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester), monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 214192-47-9 CAPLUS

CN Carbamic acid, (2-ethylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214192-48-0 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214192-49-1 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 214192-50-4 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-3-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 195191-11-8

CMF C20 H22 N2 O2



CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 214192-51-5 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214192-52-6 CAPLUS


CN Carbamic acid, [2-(2-cyclohexen-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl

ester, ethanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-89-0

CMF C20 H26 N2 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




IT 171722-81-9, YM 46303 171723-89-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and antimuscarinic properties of biphenylylcarbamate
derivs.)

RN 171722-81-9 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester,
hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 171723-89-0 CAPLUS

CN Carbamic acid, [2-(2-cyclohexen-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl

ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:430068 CAPLUS
 DOCUMENT NUMBER: 129:108992
 TITLE: Preparation of 3-acyloxy-1-azabicyclo[2.2.1]heptane
 1-oxides as centrally active muscarinic agents.
 INVENTOR(S): Sabb, Annmarie L.; Stein, Reinhardt P.
 PATENT ASSIGNEE(S): American Home Products Corp., USA
 SOURCE: U.S., 8 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------|------------|----------|-----------------|----------|
| US 5773458 | A | 19980630 | US 1997-953601 | 19971017 |
| PRIORITY APPLN. INFO.: | | | US 1997-953601 | 19971017 |
| OTHER SOURCE(S): MARPAT | 129:108992 | | | |

GI



I

AB Title compds. (I; R = H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl; Y = O, S, NR2; R2 = H, alkyl), were prepared for treatment of cognitive disorders associated with decreased levels of acetylcholine production or release

(no data). Thus, (exo)-1-azabicyclo[2.2.1]heptan-3-ol in THF/pyridine was treated with MeNCO to give the carbamate derivative, which was treated with m-chlorobenzoic acid in CH2Cl2 to give (exo)-methylcarbamic acid 1-oxy-1-azabicyclo[2.2.1]hept-3-yl ester.


IT 209786-34-5P 209786-35-6P 209786-36-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-acyloxy-1-azabicyclo[2.2.1]heptane 1-oxides as centrally active muscarinic agents)

RN 209786-34-5 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3S,4R)-1-oxido-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 209786-35-6 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3S,4R)-1-oxido-1-azabicyclo[2.2.1]hept-3-

yl ester, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 209786-36-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3S,4R)-1-oxido-1-azabicyclo[2.2.1]hept-3-yl ester, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




IT 174001-79-7P 174001-80-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-acyloxy-1-azabicyclo[2.2.1]heptane 1-oxides as centrally active muscarinic agents)

RN 174001-79-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 174001-80-0 CAPLUS

CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:


14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:617010 CAPLUS
 DOCUMENT NUMBER: 127:293132
 TITLE: Preparation of 1-azabicycloheptane derivatives for treatment of neurological illness.
 INVENTOR(S): Sabb, Annmarie L.; Stein, Reinhardt P.
 PATENT ASSIGNEE(S): American Home Products Corp., USA
 SOURCE: U.S., 6 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--------|------------|-----------------|----------|
| US 5668144 | A | 19970916 | US 1996-742425 | 19961030 |
| PRIORITY APPLN. INFO.: | | | US 1996-742425 | 19961030 |
| OTHER SOURCE(S): | MARPAT | 127:293132 | | |

GI




AB Title compds. (I; R = H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl; Y = O, S, NR2; R2 = H, alkyl), were prepared. Thus, (-)-(exo)-1-azabicyclo[2.2.1]heptane-3-ol, MeSCN, and pyridine were stirred at 60° in THF to give methylcarbamic acid (-)-(exo)-1-azabicyclo[2.2.1]hept-3-yl ester. The latter reversed scopolamine-induced hyperactivity in mice with a min. ED of 30 mg/kg.

IT 174001-79-7P 174001-80-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1-azabicycloheptane derivs. as muscarinic agents)

RN 174001-79-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 174001-80-0 CAPLUS

CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



L3 ANSWER 24 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:579721 CAPLUS
 DOCUMENT NUMBER: 127:234255
 TITLE: Preparation of azabicyclic esters of carbamic acids
 for use as nicotinic acetylcholine receptor agonists
 INVENTOR(S): Macor, John; Wu, Edwin
 PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------------|-----------------|----------|
| WO 9730998 | A1 | 19970828 | WO 1997-SE294 | 19970221 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG | | | | |
| ZA 9701082 | A | 19970825 | ZA 1997-1082 | 19970210 |
| CA 2246051 | A1 | 19970828 | CA 1997-2246051 | 19970221 |
| AU 9722387 | A | 19970910 | AU 1997-22387 | 19970221 |
| AU 706944 | B2 | 19990701 | | |
| EP 885221 | A1 | 19981223 | EP 1997-905544 | 19970221 |
| EP 885221 | B1 | 20020612 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| CN 1211983 | A | 19990324 | CN 1997-192461 | 19970221 |
| CN 1063749 | B | 20010328 | | |
| BR 9707616 | A | 19990727 | BR 1997-7616 | 19970221 |
| HU 9901273 | A2 | 19990728 | HU 1999-1273 | 19970221 |
| HU 9901273 | A3 | 20000628 | | |
| NZ 331145 | A | 20000228 | NZ 1997-331145 | 19970221 |
| JP 2000050452 | T | 20000509 | JP 1997-530075 | 19970221 |
| RU 2172739 | C2 | 20010827 | RU 1998-117804 | 19970221 |
| IL 125620 | A | 20010913 | IL 1997-125620 | 19970221 |
| CZ 289110 | B6 | 20011114 | CZ 1998-2659 | 19970221 |
| AT 219081 | T | 20020615 | AT 1997-905544 | 19970221 |
| IN 1997DE00438 | A | 20050311 | IN 1997-DE438 | 19970221 |
| US 5998429 | A | 19991207 | US 1997-836143 | 19970613 |
| NO 9803711 | A | 19980813 | NO 1998-3711 | 19980813 |
| US 6054464 | A | 20000425 | US 1999-276689 | 19990326 |
| HK 1017357 | A1 | 20010803 | HK 1999-102514 | 19990609 |
| PRIORITY APPLN. INFO.: | | SE 1996-683 | A 19960223 | |
| | | WO 1997-SE294 | W 19970221 | |
| | | US 1997-836143 | A1 19970613 | |

OTHER SOURCE(S): MARPAT 127:234255
 GI




AB Azabicyclic carbamic esters, A-X-C(Y)-NH-Z {A = 1-azabicyclo[2.2.1]heptan-3-yl, 7-azabicyclo[2.2.1]heptan-2-yl, 1-azabicyclo[2.2.2]octan-3-yl, 2-azabicyclo[2.2.2]octan-5-yl; X = O, S; Y = O, S; Z = Ph, aryl, heteroaryl}, were prepared for use as nicotinic acetylcholine receptor agonists useful for treatment or prophylaxis of psychotic disorders and intellectual impairment disorders such as Alzheimer's disease, cognition deficit, autism, or attention deficit hyperactivity disorder. Thus, carbamic ester I was prepared in 60% yield by condensation of 3-quinuclidinol and 4-bromophenyl isocyanate. The prepared carbamic esters were tested for binding affinity for the α_7 nicotinic acetylcholine receptor.

IT 195190-96-6P 195190-97-7P 195190-98-8P
 195190-99-9P 195191-00-5P 195191-01-6P
 195191-03-8P 195191-04-9P 195191-05-0P
 195191-06-1P 195191-07-2P 195191-08-3P
 195191-09-4P 195191-10-7P 195191-11-8P
 195191-12-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azabicyclic esters of carbamic acids for use as nicotinic acetylcholine receptor agonists)


RN 195190-96-6 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
 (CA INDEX NAME)




RN 195190-97-7 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
 (CA INDEX NAME)




RN 195190-98-8 CAPLUS

CN Carbamic acid, (3-dichlorophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 195190-99-9 CAPLUS


CN Carbamic acid, (4-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
 (CA INDEX NAME)




RN 195191-00-5 CAPLUS
CN Carbamic acid, (2-fluorophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)




RN 195191-01-6 CAPLUS
CN Carbamic acid, (3-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)




RN 195191-03-8 CAPLUS
CN Carbamic acid, (4-cyanophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)




RN 195191-04-9 CAPLUS
CN Carbamic acid, 2-pyridinyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 195191-05-0 CAPLUS
CN 1-Azabicyclo[2.2.1]heptan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)



RN 195191-06-1 CAPLUS
 CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 195191-07-2 CAPLUS
 CN Carbamic acid, 1-naphthalenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
 (CA INDEX NAME)




RN 195191-08-3 CAPLUS
 CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 195191-09-4 CAPLUS
 CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester), (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 195191-10-7 CAPLUS
 CN Carbamic acid, 4-pyridinyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 195191-11-8 CAPLUS
 CN Carbamic acid, N-[1,1'-biphenyl]-3-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)



RN 195191-12-9 CAPLUS
 CN Carbamic acid, 3-quinolinyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




IT 195191-13-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of azabicyclic esters of carbamic acids for use as nicotinic acetylcholine receptor agonists)
 RN 195191-13-0 CAPLUS
 CN Carbamic acid, (2,6-dichloro-4-pyridinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 25 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:428265 CAPLUS
DOCUMENT NUMBER: 127:156253
TITLE: WAY-131256 is an orally active, efficacious, and in vivo functionally selective M₁ agonist
AUTHOR(S): Sabb, Annmarie L.; Stein, Reinhardt P.; Vogel, Robert L.; Tasse, Rene; Amburn, Susan; Fairman, Denise K.; Kowal, Dianne; Malhotra, Deepa; Boast, Carl A.; Bartolomeo, Adam; Morris, Herman; Sailer, Tracy; Moyer, John A.; Abou-Gharios, Magid; Ho, Douglas M.
CORPORATE SOURCE: CNS Medicinal Chemistry and CNS Disorders Division, Wyeth-Ayerst Research, Princeton, NJ, 08543-8000, USA
SOURCE: Drug Development Research (1997), 40(2), 185-192
CODEN: DDREDK; ISSN: 0272-4391
PUBLISHER: Wiley-Liss
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Computer modeling of carbachol docked in the human m₁ receptor binding pocket has been used to discover a series of carbamate and thiocarbamate chiral, conformationally restricted analogs of carbachol based on azabicyclo[2.2.1]heptan-3-ol. These mols. have been evaluated for affinity and efficacy at human muscarinic receptors (m₁-m₅) transfected into a CHO cell line. None of these compds. was selective in binding. Thiocarbamate analogs had greater affinity for the m₁ receptor subtype, but lower efficacy based on comparison of their ability to induce phosphoinositide (PI) turnover. Carbamate analogs had lower affinity for m₁ receptors than thiocarbonates and varied in efficacy from 10% to 100% of the carbachol response in phosphoinositide (PI) turnover. One of these analogs, 3S,4R-azabicyclo[2.2.1]heptan-3-methylcarbamate (WAY-131256) (I) has been characterized as an m₁/m₂ agonist *in vitro*. I was equi-efficacious to the standard m₁ agonist, xanomeline (Phase III) *in vivo* in a scopolamine-impaired radial arm maze paradigm (MED 1 mg/kg, 5.88 mmol/kg for VI and MED 1 mg/kg, 3.55 mmol/kg for xanomeline) and was approx. equal to xanomeline in an AF64A-impaired radial arm maze paradigm. Despite its lack of m₁ selectivity *in vitro*, *in vivo* expts. on I indicated no significant effect on blood pressure or heart rate at 10 mg/kg (58.78 mmol/kg) (i.p.), and no peripheral side effects attributed to stimulation of either the m₂ or m₃ receptors (salivation, lacrimation, and chromodacryorrhea) up to doses of 30 mg/kg, 176.2 mmol/kg. These results may be explained by different receptor densities in various brain regions not accounted for in a transfected cell line or by metabolism of I to a m₁ selective agonist *in vivo*. The results are discussed in relation treatment of Alzheimer's disease.
IT 174001-79-7 174001-80-0
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(WAY-131256 is orally active and efficacious and *in vivo* functionally selective M₁ muscarinic agonist in relation to structure-activity relations of carbamate and thiocarbamate analogs and treatment of Alzheimer's disease)
RN 174001-79-7 CAPLUS
CN Carbanic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 174001-80-0 CAPLUS

CN Carbamic acid, cyclopropyl-, (1*S*,3*S*,4*R*)-1-azabicyclo[2.2.1]hept-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L3 ANSWER 26 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:416851 CAPLUS

DOCUMENT NUMBER: 127:34136

TITLE: 1-Azabicycloheptane derivatives and their pharmaceutical use as central muscarinic agents

INVENTOR(S): Sabb, Annmarie Louise; Stein, Reinhardt Peter
PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9717348 | A1 | 19970515 | WO 1996-US17569 | 19961030 |
| W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR,
LK, LR, LT, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT,
UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG | | | | |
| CA 2236836 | A1 | 19970515 | CA 1996-2236836 | 19961030 |
| AU 9675518 | A | 19970529 | AU 1996-75518 | 19961030 |
| EP 861256 | A1 | 19980902 | EP 1996-937872 | 19961030 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, FI, RO | | | | |
| JP 20000500139 | T | 20000111 | JP 1997-518247 | 19961030 |
| PRIORITY APPLN. INFO.: | | | US 1995-6337P | P 19951108 |
| | | | WO 1996-US17569 | W 19961030 |

OTHER SOURCE(S): MARPAT 127:34136
GI




AB Title compds. I [R = H, alkyl, haloalkyl, cycloalkyl, alkenyl, or alkynyl; Y = O, S, or NR2; R2 = H or alkyl] and their pharmaceutically acceptable salts are useful as centrally active muscarinic agents. The compds. are useful for treatment of senile memory loss, Parkinson's disease, Down's syndrome, and other neurol. conditions related to acetylcholine deficiency. For instance, reaction of (-)-exo-1-azabicyclo[2.2.1]heptan-3-ol with Me isocyanate in THF and pyridine at 60° gave 55% title compound II. In a rat maze assay, II reversed scopolamine-induced disruption of performance with a min. ED of 1 mg/kg i.p.

IT 174001-79-7P, exo-Cyclopropylcarbamic acid 1-azabicyclo[2.2.1]hept-3-yl ester 174001-80-0P, (-)-exo-Cyclopropylcarbamic acid 1-azabicyclo[2.2.1]hept-3-yl ester
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azabicycloheptane derivs. as central muscarinic agonists)

RN 174001-79-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 174001-80-0 CAPLUS

CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L3 ANSWER 27 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:205340 CAPLUS

DOCUMENT NUMBER: 126:199461

ORIGINAL REFERENCE NO.: 126:38563a

TITLE: Preparation of 2-alkoxyphenylcarbamoyloxyquinuclidinium chlorides as topical anesthetics

INVENTOR(S): Durinda, Jan; Gregan, Fridrich; Kralova, Katarina; Racanska, Eva

PATENT ASSIGNEE(S): Farmaceuticka Fakulta UK, Slovakia; Prirodovedecka Fakulta UK

SOURCE: Slovakia, 3 pp.

CODEN: SLXXFO

DOCUMENT TYPE: Patent


LANGUAGE: Slovak

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|----------|--------------------|-----------------|----------|
| SK 278236 | B6 | 19960508 | SK 1992-2057 | 19920701 |
| PRIORITY APPLN. INFO.: | | | SK 1992-2057 | 19920701 |
| OTHER SOURCE(S): | CASREACT | 126:199461; MARPAT | 126:199461 | |

GI



AB The title compds. [I; R = Cl-8 alkyl], useful as topical anesthetics, were prepared. Thus, reaction of 2-hexyloxyphenyl isocyanate with 3-quinuclidinol in PhMe afforded 70% I [R = n-hexyl] which showed IC50 of 1.00 mM/L against oxygen formation in spinach chloroplasts suspension.

IT 151643-45-7P 151643-46-8P 151643-47-9P

151643-48-0P 151643-49-1P 151643-50-4P


151643-51-5P 151643-52-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-alkoxyphenylcarbamoyloxyquinuclidinium chlorides as topical anesthetics)

RN 151643-45-7 CAPLUS


CN Carbamic acid, (2-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-46-8 CAPLUS


CN Carbamic acid, (2-ethoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-47-9 CAPLUS


CN Carbamic acid, (2-propoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151643-48-0 CAPLUS

CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-49-1 CAPLUS
CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-50-4 CAPLUS
CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151643-51-5 CAPLUS
CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-52-6 CAPLUS

CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 28 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 19961643737 CAPLUS

DOCUMENT NUMBER: 125:275652

ORIGINAL REFERENCE NO.: 125:51549a,51552a

TITLE: Preparation of carbamate derivatives as selective
muscarine M3 receptor antagonists

INVENTOR(S): Takeuchi, Makoto; Naito, Makoto; Hayakawa, Masahiko;
Ikeda, Masaru; Isomura, Yasuo

PATENT ASSIGNEE(S): Yamanouchi Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.

DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|----------|
| JP 08198751 | A | 19960806 | JP 1995-6142 | 19950119 |
| PRIORITY APPLN. INFO.: | | | JP 1995-6142 | 19950119 |

OTHER SOURCE(S): MARPAT 125:275652

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = O, alkylene optionally interrupted by NR1; R1 = H, lower alkyl, lower alkoxy carbonyl; Y = (un)substituted phenyl; ring B = bridged and saturated N-containing heterocyclyl] and their pharmacol.
acceptable


salts are prepared I possessing muscarine M3 receptor antagonism are useful for prevention and treatment of urinary system, respiratory, and digestive system diseases (no data). Thus, 1-phenyl-1-cyclobutanecarboxylic acid was reacted with diphenylphosphoryl azide in the presence of Et3N and then reacted with 3-quinuclidinol to give the title compound (II).

IT 182489-33-4P 182489-50-5P 182489-60-7P
182489-70-9P 182489-85-6P 182489-91-4P
182490-39-7P 182490-50-2P 182490-56-8P
182490-63-7P 182490-71-7P 182490-83-1P
182490-93-3P 182491-09-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of carbamate derivs. as selective muscarine M3 receptor antagonists)


RN 182489-33-4 CAPLUS

CN Carbamic acid, (1-phenylcyclopentyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester
(9CI) (CA INDEX NAME)




RN 182489-50-5 CAPLUS


CN Carbamic acid, (1-phenylcyclohexyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester
(9CI) (CA INDEX NAME)




RN 182489-60-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1-azabicyclo[2.2.2]oct-3-yloxy)carbonyl]amino]-4-phenyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 182489-70-9 CAPLUS
CN Carbamic acid, (tetrahydro-4-phenyl-2H-pyran-4-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182489-85-6 CAPLUS
CN Carbamic acid, (4-phenyl-4-piperidinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182489-91-4 CAPLUS
CN Carbamic acid, (1-methyl-4-phenyl-4-piperidinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-39-7 CAPLUS
CN Carbamic acid, (1-phenylcyclobutyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester
(9CI) (CA INDEX NAME)




RN 182490-50-2 CAPLUS
CN Carbamic acid, (1-phenylcyclopropyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester
(9CI) (CA INDEX NAME)



RN 182490-56-8 CAPLUS
CN Carbamic acid, [1-(4-chlorophenyl)cyclobutyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-63-7 CAPLUS
CN Carbamic acid, [1-(4-chlorophenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-71-7 CAPLUS


CN Carbamic acid, [1-(4-methylphenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-83-1 CAPLUS
CN Carbamic acid, [1-(4-chlorophenyl)cyclohexyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 182490-93-3 CAPLUS
CN Carbamic acid, (1-phenylcyclobutyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester (9CI) (CA INDEX NAME)



RN 182491-09-4 CAPLUS
CN Carbamic acid, [1-(4-nitrophenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




IT 182489-31-2P 182489-34-5P 182489-36-7P
182489-38-9P 182489-41-4P 182489-44-7P
182489-47-0P 182489-51-6P 182489-55-0P
182489-61-8P 182489-65-2P 182489-71-0P
182489-86-7P 182489-92-5P 182490-01-3P
182490-04-6P 182490-08-0P 182490-12-6P
182490-24-0P 182490-28-4P 182490-33-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)
(preparation of carbamate derivs. as selective muscarine M3 receptor antagonists)

RN 182489-31-2 CAPLUS

CN Carbamic acid, (1-phenylcyclobutyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 182489-34-5 CAPLUS

CN Carbamic acid, (1-phenylcyclopentyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-33-4

CMF C19 H26 N2 O2



CM 2


CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 182489-36-7 CAPLUS
CN Carbamic acid, (1-phenylcyclopropyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 182489-38-9 CAPLUS
CN Carbamic acid, [1-(4-chlorophenyl)cyclobutyl]-, 1-azabicyclo[2.2.2]oct-3-
yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 182489-41-4 CAPLUS
CN Carbamic acid, [1-(4-chlorophenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-
yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 182489-44-7 CAPLUS
CN Carbamic acid, [1-(4-methylphenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-
yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 182489-47-0 CAPLUS
 CN Carbamic acid, [1-(4-methoxyphenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 182489-51-6 CAPLUS
 CN Carbamic acid, (1-phenylcyclohexyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-50-5
 CMF C20 H28 N2 O2



CM 2


CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 182489-55-0 CAPLUS

CN Carbamic acid, [1-(4-chlorophenyl)cyclohexyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 182489-61-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-azabicyclo[2.2.2]oct-3-yloxy)carbonyl]amino-4-phenyl-, 1,1-dimethylethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-60-7

CMF C24 H35 N3 O4



CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 182489-65-2 CAPLUS

CN Carbamic acid, (1-phenylcyclobutyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 182489-71-0 CAPLUS

CN Carbanic acid, (tetrahydro-4-phenyl-2H-pyran-4-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-70-9

CME C19 H26 N2 O3



CM 2

CRN 110-17-8

CME C4 H4 O4

Double bond geometry as shown.




RN 182489-86-7 CAPLUS

CN Carbanic acid, (4-phenyl-4-piperidinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-85-6


CME C19 H27 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 182489-92-5 CAPLUS
CN Carbamic acid, (1-methyl-4-phenyl-4-piperidinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 182489-91-4
CMF C20 H29 N3 O2




CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 182490-01-3 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[(1-phenylcyclobutyl)amino]carbonyl]oxy-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 182490-04-6 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-4-[(1-phenylcyclobutyl)amino]carbonyloxy-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 182490-08-0 CAPLUS
 CN Carbamic acid, [1-(4-nitrophenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 182490-12-6 CAPLUS
CN Carbamic acid, (1-phenylcyclobutyl)-, 1-oxido-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 182490-24-0 CAPLUS
CN Carbamic acid, (1-phenylcyclopentyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester (9CI) (CA INDEX NAME)



RN 182490-28-4 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(1-phenylcyclopentyl)amino]carbonyl]oxy]-, iodide (9CI) (CA INDEX NAME)



● I⁻

RN 182490-33-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-4-[[[(1-phenylcyclopentyl)amino]carbonyl]oxy]-, bromide (9CI) (CA INDEX NAME)



● Br⁻

L3 ANSWER 29 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:502473 CAPLUS

DOCUMENT NUMBER: 125:158489

ORIGINAL REFERENCE NO.: 125:29411a, 29414a

TITLE: The comparative genotoxicological study of new local anesthetics, 3-(2-alkoxyphenylcarbamoyloxy)quinuclidinium chlorides, on *Salmonella typhimurium*, *Saccharomyces cerevisiae*, *Vicia faba*, *Hordeum vulgare* and *Drosophila melanogaster*

AUTHOR(S): Miadokova, E.; Vlckova, V.; Duhova, V.; Trebaticka, M.; Groimus, J.; Bohmova, B.; Podstavkova, S.; Rauko, P.; Plesnikova, I.; Vlcek, D.

CORPORATE SOURCE: Department Genetics, Comenius University, Bratislava, Slovakia

SOURCE: Cell Biology and Toxicology (1996), 12(3), 135-145

CODEN: CBTOE2; ISSN: 0742-2091

PUBLISHER: Kluwer
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Potential genotoxicity of five new local anesthetics, derivs. of phenylcarbamic acid differing in the length of the alkyl chain of the alkoxy substituent, was studied on five test systems. There was a direct relation with increased toxic effect in bacteria and yeast as a function of the elongation of the alkyl chain of the alkoxy substituents of the phenylcarbamic acid esters. No structure-toxicity relation was found after application of 3-(2-alkoxyphenylcarbamoyloxy)-quinuclidinium chlorides on plants and *Drosophila*. All anesthetics were nonmutagenic to *Salmonella typhimurium* strains TA98, TA98, TA100, and TA102 in the absence and in the presence of S9 mix. Pentyloxy and heptyloxy derivs. increased rates of genetic changes in *Saccharomyces cerevisiae*, mainly revertants at the isoleucine locus. Pentyloxy and hexyloxy derivs. increased the frequency of chromosome aberrations in *Vicia faba* root-tip meristems. No chlorophyll mutations were detected after treatment of *Hordeum vulgare* with pentyloxy, hexyloxy and heptyloxy derivs. No sex-linked recessive lethals were scored in *Drosophila melanogaster* males. The rates of aneuploids induced in their germ cells were significantly increased after treatment with butoxy and octyloxy derivs. However, the local toxic and genotoxic effects of test anesthetics on the microorganisms of the anesthetized tissues may be of some importance. In particular, the genotoxic effect exhibited in fungi by the heptyloxy derivative, a potent local anesthetic, was remarkable.

IT 180423-60-3 180423-61-4 180423-62-5


180423-63-6 180423-64-7 180423-65-8D, alkoxy derivs.

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)

(genotoxicol. study of local anesthetics 3-(2-alkoxyphenylcarbamoyloxy)quinuclidinium chlorides)

RN 180423-60-3 CAPLUS


CN Carbanic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 180423-61-4 CAPLUS


CN Carbanic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 180423-62-5 CAPLUS

CN Carbanic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-4-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




• HC1

RN 180423-63-6 CAPLUS
CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-4-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



• HCl


RN 180423-64-7 CAPLUS
CN Carboxic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-4-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 180423-65-8 CAPLUS

CN Carbanic acid, (2-hydroxyphenyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L3 ANSWER 30 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:276839 CAPLUS
 DOCUMENT NUMBER: 124:310199
 ORIGINAL REFERENCE NO.: 124:57339a,57342a
 TITLE: Phytotoxic and clastogenic effects of new local
 anesthetics, 3-(2-alkoxyphenylcarbamoyloxy)quinuclidiu
 m chlorides, on Vicia sativa L.
 AUTHOR(S): Duhova, Viola; Blaskovicova, Martina; Miadokova, Eva
 CORPORATE SOURCE: Faculty Science, Comenius University, Bratislava,
 SK-842 15, Slovakia
 SOURCE: Biologia (Bratislava) (1996), 51(1), 37-41
 CODEN: BLOAAO; ISSN: 0006-3088
 PUBLISHER: Slovak Academic Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Phytotoxic and clastogenic effects of 5 new local anesthetics, derivs. of
 alkoxyphenylcarbamic acid, differing in the length of the alkyl chain of
 the alkoxy substituent, on V. sativa were assessed. The phytotoxic effect
 was increased as a function of concentration used, and the rank order of
 derivs.
 was: heptyloxy < octyloxy < butoxy < pentyloxy < hexyloxy. Test compds.
 did not exhibit any clastogenic effect. With the exception of hexyloxy
 derivative, they did not reduce the mitotic activity of V. sativa.
 IT 151643-48-0 151643-49-1 151643-50-4
 151643-51-5 151643-52-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (phytotoxic and clastogenic effects of, on Vicia sativa)
 RN 151643-48-0 CAPLUS
 CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-49-1 CAPLUS
 CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-50-4 CAPLUS
CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-51-5 CAPLUS
CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-52-6 CAPLUS
CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 31 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:63508 CAPLUS

DOCUMENT NUMBER: 124:194015

ORIGINAL REFERENCE NO.: 124:35607a,35610a

TITLE: Synthesis of esters of aliphatic and aromatic carbamic acids. A comparative study of properties and local anesthetic activity of these compounds

AUTHOR(S): Gregan, F.; Remko, M.; Racanska, E.; Csolei, J.

CORPORATE SOURCE: Fac. Pharmacy, Comenius Univ., Bratislava, 832 32, Slovakia

SOURCE: Bollettino Chimico Farmaceutico (1995), 134(8), 454-8

CODEN: BCFAAI; ISSN: 0006-6648

PUBLISHER: Societa Editoriale Farmaceutica

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Four basic esters of cyclohexanecarbamic acid and their salts with hydrochloride were synthesized and evaluated for local anesthetic activity. It was found that also aliphatic carbamates studied exhibit local anesthetic activity comparable with the activity of analogous esters of aromatic (2-methoxyphenyl) carbamic acid. Our comparative investigation shows that the presence of aromatic group in the ester of carbamic acid influences local anesthetic activity, however the occurrence of aromatic moiety is not necessary condition for their activity.

IT 151643-45-7P 174228-24-1P 174228-25-2P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and local anesthetic activity and properties of esters of aliphatic and aromatic carbamic acids)

RN 151643-45-7 CAPLUS


CN Carbamic acid, (2-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 174228-24-1 CAPLUS

CN Carbamic acid, cyclohexyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 174228-25-2 CAPLUS

CN Carbamic acid, cyclohexyl-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 32 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 19951006746 CAPLUS

DOCUMENT NUMBER: 124:202023

ORIGINAL REFERENCE NO.: 124:37345a,37348a

TITLE: 1-Azabicycloheptane derivatives with central
muscarinic activity

INVENTOR(S): Sabb, Annmarie L.; Stein, Reinhardt P.

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: U.S., 7 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--------|------------|-----------------|----------|
| ----- | ----- | ----- | ----- | ----- |
| US 5468875 | A | 19951121 | US 1994-362695 | 19941222 |
| PRIORITY APPLN. INFO.: | | | US 1994-362695 | 19941222 |
| OTHER SOURCE(S): | MARPAT | 124:202023 | | |
| GI | | | | |



AB Title compds. I [R = H, alkyl, haloalkyl, cycloalkyl, alkenyl or alkynyl; Y = O, S or NR2 where R2 = H or alkyl] and pharmaceutically acceptable salts are centrally active muscarinic agents, and are particularly active at M1 receptors. For example, reaction of (+)-exo-1-azabicyclo[2.2.1]heptan-3-ol with MeNCO in THF containing pyridine at 50-60° gave (+)-exo-I [Y = O, R = Me]. This compound had an MED of 1 mg/kg for reversal of scopolamine-disrupted performance by rats in the 8-arm radial maze test.


IT 174001-79-7P 174001-80-0P 174001-83-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);
(preparation of azabicycloheptane derivs. as central muscarinic agents)

RN 174001-79-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 174001-80-0 CAPLUS

CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 174001-83-3 CAPLUS

CN Carbamic acid, cyclopropyl-, 1-azabicyclo[2.2.1]hept-3-yl ester, exo-(+)-
(9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



L3 ANSWER 33 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:994203 CAPLUS

DOCUMENT NUMBER: 124:55800

ORIGINAL REFERENCE NO.: 124:10544h,10545a

TITLE: Preparation of novel heterocyclyl pyridyl- or phenyl(methyl)carbamate derivatives as selective antagonists for muscarine M3 receptor

INVENTOR(S): Takeuchi, Makoto; Naito, Ryo; Morihira, Koichiro; Hayakawa, Masahiko; Ikeda, Ken; Isomura, Yasuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------------|-----------------|----------|
| WO 9521820 | A1 | 19950817 | WO 1995-JP168 | 19950208 |
| W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN | | | | |
| RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2182568 | A1 | 19950817 | CA 1995-2182568 | 19950208 |
| AU 9515909 | A | 19950829 | AU 1995-15909 | 19950208 |
| AU 685225 | B2 | 19980115 | | |
| EP 747355 | A1 | 19961211 | EP 1995-907855 | 19950208 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| CN 1140447 | A | 19970115 | CN 1995-191543 | 19950208 |
| HU 76289 | A2 | 19970728 | HU 1996-2188 | 19950208 |
| PRIORITY APPLN. INFO.: | | | | |
| | | JP 1994-16829 | A | 19940210 |
| | | JP 1994-35064 | A | 19940304 |
| | | JP 1994-102579 | A | 19940517 |
| | | JP 1994-221335 | A | 19940916 |
| | | JP 1994-267412 | A | 19941031 |
| | | WO 1995-JP168 | W | 19950208 |

OTHER SOURCE(S): MARPAT 124:55800

GI For diagram(s), see printed CA Issue.

AB Carbamates derivs. represented by general formula [I]; ring A = a benzene or pyridine ring; ring B = a saturated nitrogenous heterocycle which may be substituted on the nitrogen atom or cross-linked, i.e. Q = Q2; wherein Z = N(O)qR2, N+R3R4A-; Z1 = N(O)q, N+R5A-; wherein A- = anion; R2 = H, alkyl, alkenyl, alkynyl, cycloalkylalkyl, (un)substituted aralkyl, heterocyclylalkyl having 1 or 2 heteroatoms and optional substituents on the heterocyclic ring and optionally condensed on the ring; R3 = alkyl, alkenyl, alkynyl, (un)substituted aralkyl, heterocyclylalkyl having 1 or 2 heteroatoms and optional substituents on the heterocyclic ring and optionally condensed on the ring; R4 = alkyl, alkenyl, alkynyl, R5 = alkyl, alkenyl, alkynyl, aralkyl; m, n = an integer of 1-4, provided that m + n = 3-5; p = an integer of 1-3; q = 0,1; r, s, t = an integer of 0-3, provided that r + s + t = 2 or 3; wherein R1 = optionally substituted Ph, C3-8 cycloalkyl or cycloalkenyl, or 5- or 6-membered nitrogenous heterocyclic group; X = a single bond or CH2; Y = a single bond, CO, optionally hydroxylated methylene, or -S(O)l; wherein l = an integer of 0, 1 or 2, salts, hydrates, or solvates thereof, useful for the treatment of prevention of digestive, respiratory or urol. diseases, are prepared In particular, a remedy or preventive for chronic obstructive lung diseases, chronic bronchitis, asthma, rhinitis, nervous pollakiurea (frequent urination), nervous bladder, nocturnal enuresis, unstable bladder, bladder


contracture, chronic cystitis, urinary incontinence, pollakiurea (frequent urination), irritable bowel syndrome, spasmody colitis, or diverticulitis which is related to muscarine M3 receptor contains the said carbamate I as the active ingredient. Thus, 2.89 g (PhO)₂P(O)N₃ was added dropwise to a solution of 1.98 g 2-biphenylcarboxylic acid and 1.11 g Et₃N in 50 mL toluene, stirred at 60° for 1.5 h, followed by adding 1.27 g 3-quinuclidinol, and the resulting mixture was refluxed for 6 h to give, after workup and silica gel chromatog., 2.47 g 3-quinuclidinyl N-(2-biphenyl)carbamate (II). The latter compound (0.46 g) was stirred with MeI in 2-butanone at room temperature for 5.5 h to give 0.58 g 3-[(N-(2-biphenyl)carbamoyloxy)-1-methylquinuclidinium iodide (III). II and III showed a binding affinity with the dissociation constant K_i of 0.94 and 0.56 nM, resp., for muscarine M3 receptor preparation from submaxillary gland membrane and that of 25.9 and 14.4 nM, resp., for muscarine M2 receptor preparation from heart membrane and the binding affinity ratio of the muscarine M2 and M3 receptor was 27.6 and 25.7 for II and III, resp. II and III inhibited 50% the gallamine-induced contraction of a respiratory tract of guinea pig at 0.0045 and 0.0038 mg/kg i.v., resp., vs. 0.0008 mg/kg i.v. for atropine.

IT 171722-78-4P 171722-79-5P 171722-80-8P
 171722-81-9P 171722-82-0P 171722-83-1P
 171722-85-3P 171722-87-5P 171723-33-4P
 171723-49-2P 171723-50-5P 171723-52-7P
 171723-55-0P 171723-56-1P 171723-57-2P
 171723-58-3P 171723-59-4P 171723-61-8P
 171723-62-9P 171723-63-0P 171723-65-2P
 171723-67-4P 171723-69-6P 171723-70-9P
 171723-73-2P 171723-74-3P 171723-75-4P
 171723-76-5P 171723-77-6P 171723-78-7P
 171723-79-8P 171723-83-4P 171723-84-5P
 171723-85-6P 171723-86-7P 171723-87-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel heterocycl pyridyl(methyl)- or phenyl(methyl)carbamate derivs. as selective antagonists for muscarine M3 receptor)

RN 171722-78-4 CAPLUS


CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 171722-79-5 CAPLUS

CN Carbamic acid, [2-(1H-pyrrol-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 171722-80-8 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 3-(((1,1'-biphenyl)-2-ylamino)carbonyloxy)-
 1-methyl-, iodide (9CI) (CA INDEX NAME)



● I⁻


RN 171722-81-9 CAPLUS
 CN Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester,
 hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 171722-82-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 4-[{[{1,1'-biphenyl}-2-ylamino)carbonyl]oxy}-1-methyl-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 171722-83-1 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 4-[{[{1,1'-biphenyl}-2-ylamino)carbonyl]oxy}-1-methyl-, bromide (9CI) (CA INDEX NAME)



● Br⁻

RN 171722-85-3 CAPLUS
CN Carbamic acid, [2-(phenylmethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 171722-87-5 CAPLUS
 CN Carbamic acid, (2-phenyl-3-pyridinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
 ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171722-86-4
 CMF C19 H21 N3 O2




CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 171723-33-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 4-[[{([1,1'-biphenyl]-2-ylamino)carbonyl}oxy]-
 1-ethyl-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 171723-49-2 CAPLUS
CN Carbanic acid, (2-benzoylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171723-50-5 CAPLUS
CN Carbanic acid, (2'-methyl[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 171723-52-7 CAPLUS
 CN Carbamic acid, (2'-nitro[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-51-6
 CMF C20 H21 N3 O4




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 171723-55-0 CAPLUS
 CN Carbamic acid, (2'-hydroxy[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-56-1 CAPLUS

CN Carbamic acid, (2'-hydroxy[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-55-0

CMF C20 H22 N2 O3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 171723-57-2 CAPLUS


CN Carbamic acid, (2'-amino[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (10:19) (9CI) (CA INDEX NAME)



● 19/10 HCl

RN 171723-58-3 CAPLUS


CN Carbamic acid, [2-(hydroxyphenylmethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171723-59-4 CAPLUS

CN Carbamic acid, [2-(2-cyclopenten-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




HCl

BN 171723-61-8 CAPIUS


RN 171725-01-6 CARLOS
CN Carbamic acid, (2-cyclohexylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CRN 171723-60-7
CMF C20 H28 N2 O2




CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 171723-62-9 CAPLUS
CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-oxido-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 171723-63-0 CAPLUS
CN Carbamic acid, [2-(phenylsulfonyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 171723-65-2 CAPLUS
CN Carbamic acid, [2-(phenylsulfinyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl

ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-64-1

CMF C20 H22 N2 O3 S



CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 171723-67-4 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 171723-69-6 CAPLUS

CN Carbamic acid, [2-(1-piperidinyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-68-5

CMF C19 H27 N3 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 171723-70-9 CAPLUS
CN Carbamic acid, [2-(1-piperidinyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-68-5
CMF C19 H27 N3 O2




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 171723-73-2 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 4-[{({1,1'-biphenyl}-2-ylamino)carbonyl}oxy]-1-(2-propenyl)-, bromide (9CI) (CA INDEX NAME)




● Br⁻

RN 171723-74-3 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 4-[(1-(1-methylethyl)-2-ylamino)carbonyloxy]-1-(1-phenylpropyl)-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 171723-75-4 CAPLUS
 CN 1-Azoniabicyclo[2.2.2]octane, 4-[(1-(1-propyl)-2-ylamino)carbonyloxy]-1-(1-phenylpropyl)-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 171723-76-5 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 4-[{[{1,1'-biphenyl}-2-ylamino]carbonyl}oxy]-3-methyl-1-(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)




● Br⁻


RN 171723-77-6 CAPLUS
CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-78-7 CAPLUS
CN Carbamic acid, [2-(1H-pyrrol-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 171723-79-8 CAPLUS
CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester (9CI) (CA INDEX NAME)




RN 171723-83-4 CAPLUS
CN Carbamic acid, (2'-amino[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-84-5 CAPLUS

CN Carbamic acid, (2-benzoylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)




RN 171723-85-6 CAPLUS

CN Carbamic acid, [2-(hydroxyphenylmethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-86-7 CAPLUS

CN Carbamic acid, [2-(2-cyclopenten-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 171723-87-8 CAPLUS

CN Carbamic acid, [2-(phenylsulfonyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



IT 171723-51-6 171723-88-9 171723-89-0


171723-90-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction in preparation of novel heterocyclyl pyridyl(methyl)- or phenyl(methyl)carbamate derivs. as selective antagonists for muscarine M3 receptor)


RN 171723-51-6 CAPLUS

CN Carbamic acid, (2'-nitro[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-88-9 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-89-0 CAPLUS

CN Carbamic acid, [2-(2-cyclohexen-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 171723-90-3 CAPLUS

CN Carbamic acid, (2'-methoxy[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 34 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:905942 CAPLUS

DOCUMENT NUMBER: 124:86796

ORIGINAL REFERENCE NO.: 124:16314h,16315a

TITLE: Identification of a Series of 3-(Benzyoxy)-1-azabicyclo[2.2.2]octane Human NK1 Antagonists
AUTHOR(S): Swain, Christopher J.; Sewart, Eileen M.; Cascieri, Margaret A.; Fong, Tung M.; Herbert, Richard; MacIntyre, D Euan; Merchant, Kevin J.; Owen, Simon N.; Owens, Andrew P.; et al.

CORPORATE SOURCE: Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Harlow/Essex, CM20 2QR, UK

SOURCE: Journal of Medicinal Chemistry (1995), 38(24), 4793-805

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:86796

AB The synthesis and *in vitro* and *in vivo* evaluation of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane NK1 antagonists are described. While a number of 3,5-disubstituted benzyl ethers afford high affinity, the 3,5-bis(trifluoromethyl)benzyl was found to combine high *in vitro* affinity with good oral activity. Detailed structure-activity relationship studies in conjunction with data from mol. modeling and mutagenesis work have allowed the construction of a model of the pharmacophore. Specific interactions that have been identified include an interaction between His-197 and one of the rings of the benzhydryl, a lipophilic pocket containing His-265 that the benzyl ether occupies, and a possible hydrogen bond between Asp-165 and the oxygen of the benzyl ether.

IT 172140-26-0P 172140-31-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of (benzyloxy)-1-azabicyclo[2.2.2]octane NK1 antagonists)

RN 172140-26-0 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(diphenylmethyl)-, phenylcarbamate (ester), cis-, (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 172140-31-7 CAPLUS


CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(diphenylmethyl)-, phenylcarbamate (ester), cis-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 172140-26-0

CMF C27 H28 N2 O2

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4




L3 ANSWER 35 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:574252 CAPLUS
 DOCUMENT NUMBER: 122:310505
 ORIGINAL REFERENCE NO.: 122:56365a,56368a
 TITLE: Effects of 3-(2-alkoxyphenylcarbamoyloxy)chinuclidium chlorides on repair-deficient strains of Chlamydomonas reinhardtii
 AUTHOR(S): Miadokova, E.; Sepakova, K.; Podstavkova, S.; Vlcek, D.
 CORPORATE SOURCE: Faculty of Sciences, Comenius University, Bratislava, 84215, Slovakia
 SOURCE: Biologia Plantarum (1995), 37(1), 15-19
 CODEN: BPABAJ; ISSN: 0006-3134
 PUBLISHER: Institute of Experimental Botany, Academy of Sciences of the Czech Republic
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The effect of five 3-(2-alkoxyphenylcarbamoyloxy)chinuclidium chlorides (alkoxy = butoxy - octyloxy) on survival of a wild-type strain and repair-deficient strains of Chlamydomonas reinhardtii was studied. There was a direct relationship with increased toxic effects in the algal strains as a function of the elongation of the alkyl chain of the alkoxy substituents of the phenylcarbamate acid derivs. Repair-deficient strains were more sensitive than the wild-type strain. The recombination-deficient strain uvsl0 expressed the highest sensitivity to the test agents. This suggests that a gene responsible for recombination repair is involved in an important role in DNA repair of damages induced in C. reinhardtii by the phenylcarbamate esters.
 IT 151643-48-0 151643-49-1 151643-50-4
 151643-51-5 151643-52-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (effect of 3-(2-alkoxyphenylcarbamoyloxy)chinuclidium chlorides on repair-deficient strains of Chlamydomonas reinhardtii)
 RN 151643-48-0 CAPLUS
 CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-49-1 CAPLUS
 CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-50-4 CAPLUS
CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-51-5 CAPLUS
CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-52-6 CAPLUS
CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 36 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:457282 CAPLUS

DOCUMENT NUMBER: 121:57282

ORIGINAL REFERENCE NO.: 121:10325a,10328a

TITLE: Quinuclidine-based NK-1 antagonists I:

3-benzyloxy-1-azabicyclo[2.2.2]octanes

AUTHOR(S): Seward, Eileen M.; Swain, Christopher J.; Merchant, Kevin J.; Owen, Simon N.; Sabin, Verity; Cascieri, Margaret A.; Sadowski, Sharon; Strader, Catherine; Baker, Raymond


CORPORATE SOURCE: Neurosci. Res. Cent., Merck Sharp Dohme Res. Lab., Harlow/Essex, CM20 2QR, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (1993), 3(6), 1361-6

DOCUMENT TYPE: CODEN: BMCL8; ISSN: 0960-894X

LANGUAGE: Journal
English

GI




AB Analogs I [R = Ph, X = NHCH₂, NHCH₂CH₂, NHCO, OCO, etc.; RX = (un)substituted benzyloxy] of CP-96,345 (II) were prepared and their affinity for the human NK1 receptor tested. The 3-benzyloxy derivs. had significant affinity for the human NK1 receptor. 3,5-Disubstitution of the benzyl ether has been identified to be essential for high affinity.

IT 155618-06-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and NK-1 antagonist activity of)

RN 155618-06-7 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(diphenylmethyl)-, phenylcarbamate
(ester), (2S-cis)- (9CI) (CA INDEX NAME)



L3 ANSWER 37 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:134470 CAPLUS

DOCUMENT NUMBER: 120:134470

ORIGINAL REFERENCE NO.: 120:23691a,23694a

TITLE: Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as serotonin receptor antagonists

INVENTOR(S): Turconi, Marco; Donetti, Arturo; Montagna, Ernesto; Nicola, Massimo; Uberti, Annamaria; Micheletti, Rosamaria; Giachetti, Antonio

PATENT ASSIGNEE(S): Boehringer Ingelheim Italia S.p.A., Italy

SOURCE: U.S., 13 pp. Cont-in-part of U.S. Ser. No. 768,497, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|--|--|
| US 5223511 | A | 19930629 | US 1992-845891 | 19920304 |
| US 5358954 | A | 19941025 | US 1993-33675 | 19930316 |
| US 5552408 | A | 19960903 | US 1995-432338 | 19950501 |
| PRIORITY APPLN. INFO.: | | | IT 1987-21997
US 1988-243949
US 1990-552353
US 1991-768497
US 1992-845891
US 1993-33675
US 1994-267682 | A 19870923
B1 19880913
B1 19900712
B2 19910930
A3 19920304
A 19930316
A 19940628 |

OTHER SOURCE(S): MARPAT 120:134470
GI



I

AB The title compds. I (R = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; R2 = H, halogen, C1-6 alkoxy; R5 = H, C1-6 alkyl, CR6:NR7; R6 = H, C1-4 alkyl, NH2; R7 = H, C1-C6 alkyl; Y = O, NH), which are serotonin receptor antagonists, useful as antiemetics and gastric prokinetic agents, are prepared and I-containing formulation presented. Thus, N-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-3-hexyl-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride (m.p. 214-215°) was prepared and demonstrated 50% elimination of cisplatin-induced nausea in dogs at 1.3 µg/kg.


IT 123259-51-8P 152994-90-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of serotonin receptor antagonists)


RN 123259-51-8 CAPLUS

CN Carbanic acid, (2-aminophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)



RN 152994-90-6 CAPLUS

CN Carbanic acid, (2-nitrophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 38 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:30656 CAPLUS

DOCUMENT NUMBER: 120:30656

ORIGINAL REFERENCE NO.: 120:5785a,5788a

TITLE: Synthesis and local anesthetic activities of
3-(2-alkoxyphenylcarbamoyloxy)quinuclidinium chlorides

AUTHOR(S): Gregan, F.; Durinda, J.; Racanska, E.; Zamocka, J.

CORPORATE SOURCE: Fac. Pharm., Comenius Univ., Bratislava, Czech.


SOURCE: Pharmazie (1993), 48(6), 465-6

CODEN: PHARAT; ISSN: 0031-7144

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I


AB The title compds. I (R = alkyl) were prepared by treating 3-quinuclidinol with alkoxyphenyl isocyanates. Local anesthetic activities and algicde min. inhibitory concns. were determined Mol. structure biol. activity relationships were discussed.

IT 151643-45-7P 151643-46-8P 151643-47-9P
151643-48-0P 151643-49-1P 151643-50-4P
151643-51-5P 151643-52-6P 151643-53-7P
151643-54-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and local anesthetic and algicidal activity of)

RN 151643-45-7 CAPLUS


CN Carbanic acid, (2-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-46-8 CAPLUS


CN Carbamic acid, (2-ethoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-47-9 CAPLUS


CN Carbamic acid, (2-propoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-48-0 CAPLUS


CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151643-49-1 CAPLUS

CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-50-4 CAPLUS
CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-51-5 CAPLUS
CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151643-52-6 CAPLUS
CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-53-7 CAPLUS


CN Carbamic acid, [2-(nonyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-54-8 CAPLUS

CN Carbamic acid, [2-(decyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 39 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:459028 CAPLUS

DOCUMENT NUMBER: 113:59028

ORIGINAL REFERENCE NO.: 113:9987a,9990a

TITLE: Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT₃ receptor antagonists

AUTHOR(S): Turconi, Marco; Nicola, Massimo; Gil Quintero, Myrna; Maiocchi, Luciano; Micheletti, Rosella; Giraldo, Ettore; Donetti, Arturo

CORPORATE SOURCE: Dep. Med. Chem., Ist. De Angeli, Milan, I-20139, Italy

SOURCE: Journal of Medicinal Chemistry (1990), 33(8), 2101-8


CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:59028

GI



I


AB A series of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid ester and amides containing a basic azabicycloalkyl or azacycloalkyl moiety, e.g., I and its analogs, were prepared and tested for their serotonin receptor-antagonist activity.

IT 123259-51-8


RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation reaction of, with trichloromethyl chloroformate,
benzimidazolecarboxylate from)

RN 123259-51-8 CAPLUS


CN Carbamic acid, (2-aminophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)
(CA INDEX NAME)



L3 ANSWER 40 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1989:628221 CAPLUS
 DOCUMENT NUMBER: 111:228221
 ORIGINAL REFERENCE NO.: 111:37829a,37832a
 TITLE: New photoaffinity labels for rat brain muscarinic acetylcholine receptors
 AUTHOR(S): Ilien, Brigitte; Mejean, Annick; Hirth, Christian
 CORPORATE SOURCE: Fac. Pharm., Univ. Louis Pasteur, Illkirch, 67401, Fr.
 SOURCE: Biochemical Pharmacology (1989), 38(17), 2879-87
 CODEN: BCPCA6; ISSN: 0006-2952
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Localization of the ligand binding site on muscarinic acetylcholine receptors is 1 of the new fields of interest opened by the recent determination of their primary structures. Owing to their interesting photochemical properties, aryl diazonium salts may be considered as appropriate tools for tagging the agonist/antagonist binding domain and to get precise identification and positioning of covalently labeled residues along the primary sequence of these receptors. A series of aryl diazonium derivs. and some of their azido-analogs were synthesized and their reversible muscarinic binding component was assessed through competition expts. involving either the whole population of receptor sites (³H]QNB assay) or the super high affinity of their agonist binding sites (³H]OXO-M assay). Three compds. fulfilled the criteria for efficient photolabels, allowing substantial and irreversible occupation of the receptor sites to be obtained. Interestingly, the 2 diazonium derivs. which were selected have been previously described as potent photoprobes of the peripheral nicotinic receptor of acetylcholinesterase, though displaying lower binding affinities for these acetylcholine binding proteins than for the muscarinic receptors. These findings, together with the all-to-none photolabeling efficiency observed for a quinuclidine derivative, substituted either by an azido or a diazonium group, are discussed. Finally, the apparent lack of binding selectivity of these new photoaffinity probes towards muscarinic receptor affinity states or subtypes should allow comparative studies of the acetylcholine binding site on different muscarinic receptor proteins, obtained either through purification procedures or expression of sep. gene products.
 IT 123733-03-9P
 RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deprotection of)
 RN 123733-03-9 CAPLUS
 CN Carbamic acid, (4-aminophenyl)phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester
 (9CI) (CA INDEX NAME)



IT 123733-02-8P
 RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 123733-02-8 CAPLUS
 CN Carbamic acid, (4-nitrophenyl)phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester
 (9CI) (CA INDEX NAME)




IT 122842-65-3P 123732-97-8P

RL: PREP (Preparation)

(preparation of and photoaffinity labeling by, of brain muscarinic acetylcholine receptors)


RN 122842-65-3 CAPLUS

CN Carbamic acid, (4-azidophenyl)phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester
(9CI) (CA INDEX NAME)




RN 123732-97-8 CAPLUS

CN Benzenediazonium, 4-[(1-azabicyclo[2.2.2]oct-3-yloxy)carbonyl]phenylamino- (CA INDEX NAME)



L3 ANSWER 41 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1989:594763 CAPLUS
 DOCUMENT NUMBER: 111:194763
 ORIGINAL REFERENCE NO.: 111:32379a,32382a
 TITLE: Benzimidazoline-2-oxo-1-carboxylic acid derivatives
 useful as serotonin receptor antagonists
 INVENTOR(S): Turconi, Marco; Donetti, Arturo; Micheletti,
 Rosamaria; Uberti, Annamaria; Nicola, Massimo;
 Giachetti, Antonio
 PATENT ASSIGNEE(S): Istituto De Angeli S.p.A., Italy
 SOURCE: Eur. Pat. Appl., 28 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--------|------------|-----------------|------------|
| EP 309423 | A2 | 19890329 | EP 1988-830375 | 19880919 |
| EP 309423 | A3 | 19891129 | | |
| EP 309423 | B1 | 19940615 | | |
| R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| PL 151434 | B1 | 19900928 | PL 1988-274751 | 19880919 |
| DD 285354 | A5 | 19901212 | DD 1988-319929 | 19880919 |
| PL 152951 | B1 | 19910228 | PL 1988-279346 | 19880919 |
| IL 87795 | A | 19930221 | IL 1988-87795 | 19880919 |
| ES 2054872 | T3 | 19940816 | ES 1988-830375 | 19880919 |
| JP 01106882 | A | 19890424 | JP 1988-236179 | 19880920 |
| JP 06031225 | B | 19940427 | | |
| CA 1337347 | C | 19951017 | CA 1988-577840 | 19880920 |
| AU 8822378 | A | 19890323 | AU 1988-22378 | 19880921 |
| AU 610040 | B2 | 19910509 | | |
| DK 8805261 | A | 19890324 | DK 1988-5261 | 19880922 |
| DK 172226 | B1 | 19980112 | | |
| FI 8804350 | A | 19890324 | FI 1988-4350 | 19880922 |
| FI 89920 | B | 19930831 | | |
| FI 89920 | C | 19931210 | | |
| NO 8804202 | A | 19890328 | NO 1988-4202 | 19880922 |
| NO 169286 | B | 19920224 | | |
| NO 169286 | C | 19920603 | | |
| HU 48250 | A2 | 19890529 | HU 1988-4970 | 19880922 |
| HU 200770 | B | 19900828 | | |
| ZA 8807083 | A | 19900530 | ZA 1988-7083 | 19880922 |
| SU 1676451 | A3 | 19910907 | SU 1988-4356601 | 19880922 |
| CZ 279864 | B6 | 19950712 | CZ 1988-6307 | 19880922 |
| SK 278812 | B6 | 19980304 | SK 1988-6307 | 19880922 |
| LV 11035 | B | 19960820 | LV 1995-33 | 19950217 |
| PRIORITY APPLN. INFO.: | | | IT 1987-21997 | A 19870923 |
| OTHER SOURCE(S): | MARPAT | 111:194763 | | |
| GI | | | | |



AB Title compds. I [R = H, Cl-6 alkyl, Cl-6 alkynyl; R1,R2 = H, halo, CF₃, Cl-6 alkyl, Cl-6 alkoxy, Cl-6 alkylthio, Cl-6 acyl, CO₂H, Cl-6 alkoxy carbonyl, OH, NO₂, (mono- or di- Cl-4 alkyl-substituted)NH₂, Cl-6 acylamino, Cl-6 alkoxy carbonylamino, (N-mono- or di- Cl-4 alkyl-substituted) carbamoyl, (N-mono- or di- Cl-4 alkyl-substituted) aminosulfonylamino; Y = O, NR₃; R₃ = H, Cl-6 alkyl, Cl-6 alkoxy-substituted PhCH₂; A = 1-azabicyclo[2.2.2]octanyl, 1-azabicyclo[3.3.1]nonan-4-yl, Q₁, Q₂; p = 0 or 1; r = 0-3; R₄ = H, Cl-4 alkyl; R₅ = H, Cl-6 alkyl, C₃-8 cycloalkyl, C₃-8 cycloalkyl-Cl-4 alkyl, (substituted)phenyl-Cl-4 alkyl; R₆ = H, Cl-4 alkyl, NH₂; R₆ = H, Cl-6 alkyl] are prepared from 1,2-phenylenediamines II, benzimidazoles III (R⁷ = metal), or III (R⁷ = COX; X = leaving group). Treatment of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carbonyl chloride with endo-8-Me-8-azabicyclo[3.2.1]octan-3-amine in THF gave I [R = R₁ = R₂ = H; YA = endo-8-Me-8-azabicyclo[3.2.1]oct-3-ylamino]. The latter showed ED₅₀ s' of 0.3 µg/kg i.v. and 0.4 µg/kg i.v. for bradycardia and hypotension in 5-HT-treated rats, resp. Tablets were formulated containing I 250, lactose 270, corn starch 76, and Mg stearate 4 mg.


IT 123259-51-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of serotonin antagonists)

RN 123259-51-8 CAPLUS

CN Carbamic acid, (2-aminophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




L3 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:549839 CAPLUS
DOCUMENT NUMBER: 111:149839
ORIGINAL REFERENCE NO.: 111:24913a,24916a
TITLE: Direct and energy-transfer photolabeling of brain
muscarinic acetylcholine receptors
AUTHOR(S): Ilien, Brigitte; Hirth, Christian
CORPORATE SOURCE: Fac. Pharm., Univ. Louis Pasteur, Illkirch, Fr.
SOURCE: European Journal of Biochemistry (1989), 183(2), 331-7
CODEN: EJBCAI; ISSN: 0014-2956
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Efficient photolabeling of muscarinic acetylcholine receptors was done by using either 2 aryl diazonium salts or an azido derivative. These probes did not discriminate between muscarinic binding subtypes or affinity states and became irreversibly bound to the receptor sites, in an entirely atropine-protectable manner, upon UV irradiation. The extent of labeling was dependent both on probe concentration and on time of irradiation and reached up to

80% of the receptor population, under optimal alkylating conditions. In contrast to the azido derivative, both diazonium salts behave as potent irreversible labels of muscarinic receptors, provided energy-transfer photolabeling conditions were followed. Such an indirect activation of diazonium ligands, through an energy transfer from photoexcited tryptophan residues, has been previously found to increase the site-specificity and the rate of labeling of other acetylcholine binding proteins. Analogies in the photolabeling process of acetylcholinesterase or of nicotinic and muscarinic receptors by the 2 diazonium salts are discussed. The findings suggest that these new probes may be promising tools to investigate the location and the topog. of the agonist-antagonist binding domain on purified muscarinic receptors, through amino acid and/or sequence analyses of radioactive, photolabeled residues.

IT 122842-65-3
RL: ANST (Analytical study)
(photolabeling by, of muscarinic acetylcholine receptors of brain)
RN 122842-65-3 CAPLUS
CN Carbamic acid, (4-azidophenyl)phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester
(9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1976:432768 CAPLUS

DOCUMENT NUMBER: 85:32768

ORIGINAL REFERENCE NO.: 85:5313a,5316a

TITLE: Synthesis and pharmacological properties of new compounds related to 2-aminochromone


AUTHOR(S): Payard, Marc; Paris, Joelle; Couquelet, Jacques; Bastide, Janine; Lapalus, Philippe; Alves, Pierrette; Mongourd, Nicole

CORPORATE SOURCE: Lab. Pharm. Chim., Fac. Pharm., Clermont-Ferrand, Fr. SOURCE: European Journal of Medicinal Chemistry (1976), 11(1), 13-18


DOCUMENT TYPE: CODEN: EJMCA5; ISSN: 0223-5234
Journal
LANGUAGE: French

OTHER SOURCE(S): CASREACT 85:32768

GI



AB Acylaminochromones I ($R = \text{substituted phenyl, aralkyl, pyridyl, heterocyclic substituted methyl, substituted amino, alkoxy}$) (38 compds.) were prepared by Curtius rearrangement of 2-chromonecarbonyl azide in the presence of carboxylic acids, alcs., or amines. I have analgesic, anticonvulsant, and antilipemic properties and the 2-aminochromone moiety confers very low toxicity.


IT 59629-45-7PRL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)**RN** 59629-45-7 CAPLUS**CN** Carbamic acid, (4-oxo-4H-1-benzopyran-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

L3 ANSWER 44 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:111296 CAPLUS
 DOCUMENT NUMBER: 78:111296
 ORIGINAL REFERENCE NO.: 78:17871a,17874a
 TITLE: Penicillin saccharimides
 PATENT ASSIGNEE(S): Gist-Brocades N. V.
 SOURCE: Neth. Appl., 28 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Dutch
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|------------|
| NL 7207022 | A | 19721205 | NL 1972-7022 | 19720525 |
| US 3726861 | A | 19730410 | US 1971-149819 | 19710603 |
| US 3726860 | A | 19730410 | US 1971-149847 | 19710603 |
| US 3734906 | A | 19730522 | US 1971-149795 | 19710603 |
| US 3734903 | A | 19730522 | US 1971-149848 | 19710603 |
| PRIORITY APPLN. INFO.: | | | US 1971-149795 | A 19710603 |
| | | | US 1971-149819 | A 19710603 |
| | | | US 1971-149847 | A 19710603 |
| | | | US 1971-149848 | A 19710603 |

- GI For diagram(s), see printed CA Issue.
 AB The penicillins I (R1 = Me2NCH2CH2S, 3-quinuclidinylloxy, BuNH,
 PhCMe2CH2NMe, 3-morpholinopropylamino, PhMeNNH, 1-methyl-4-pyrolidino-
 1,2,5,6-tetrahydropyridin-3-yl) were prepared by treating II with R1H.
 IT 40278-39-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 40278-39-5 CAPLUS
 CN Carbamic acid, [2-[(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-
 yl)carbonyl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-,
 1-azabicyclo[2.2.2]oct-3-yl ester, [2S-(2a,5a,6b)]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 45 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1970:464632 CAPLUS

DOCUMENT NUMBER: 73:64632

ORIGINAL REFERENCE NO.: 73:10583a,10586a

TITLE: Carbanilic acid esters of cyclic amino alcohols. III. Esters of ecgonine, tropine, and some related bicyclic alcohols as local anesthetics

AUTHOR(S): Nilsson, J. Lars G.; Dahlbom, Richard; Akerman, Bengt

CORPORATE SOURCE: Dep. Org. Chem., Farm. Fak., Stockholm, Swed.

SOURCE: Acta Pharmacologica Suecica (1970), 7(3), 239-46

CODEN: APXSAS; ISSN: 0001-6675

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A number of carbanilic acid esters of ecgonine methyl ester, pseudoecgonine methyl ester, tropine, pseudotropine, 3 α -granatanol, and 3-quinuclidinol were prepared and tested for local anesthetic activity. Primary screening data reveal that some of the compds. have very high activity.


IT 29440-70-8 29440-71-9 29440-72-0

RL: PROC (Process)

(local anesthetic action of)

RN 29440-70-8 CAPLUS


CN Carbanilic acid, 2-chloro-6-methyl-, 3-quinuclidinyl ester, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 29440-71-9 CAPLUS

CN Carbanilic acid, o-methyl-, 3-quinuclidinyl ester (8CI) (CA INDEX NAME)




RN 29440-72-0 CAPLUS


CN Carbanilic acid, 2,6-dimethyl-, 3-quinuclidinyl ester (8CI) (CA INDEX NAME)



L3 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1968:435886 CAPLUS
 DOCUMENT NUMBER: 69:35886
 ORIGINAL REFERENCE NO.: 69:6683a,6686a
 TITLE: Some quinuclidine derivatives with potential
 antimalarial activity
 AUTHOR(S): Nilsson, J. Lars G.; Wagermark, Jorgen; Dahlbom,
 Richard
 CORPORATE SOURCE: Kungl. Farm. Inst., Stockholm, Swed.
 SOURCE: Acta Pharmacologica Suecica (1968), 5(2), 71-6
 DOCUMENT TYPE: CODEN: APXSAS; ISSN: 0001-6675
 LANGUAGE: Journal
 English
 GI For diagram(s), see printed CA Issue.
 AB A series of carbamates and Schiff bases were prepared with a structural
 similarity to quinine. To 3.3 g. 3-quinuclidinol in 50 ml. dry PhMe was
 added 0.6 g. powdered Na and the mixture refluxed 2 hrs. to form the
 alcoholate. N,N-Diphenylcarbamoyl chloride (6 g.) dissolved in 25 ml.
 PhMe was then slowly added, and the mixture stirred and refluxed 1 hr. to
 yield 74% 3-quinuclidinyl N,N-diphenylcarbamate, m. 79-80°. The
 following I were similarly prepared (R, % yield, and m.p. given):
 phenothiazino, 85, 183-4°; N-ethylanilino, 44, 190-2°;
 indolino, 82, 125°. II were synthesized by the usual procedure
 (same date given): diphenylmethyl, 62, 108°; 9-fluorenyl, 35,
 189-90°; cyclohexyl, 80, 75-6°. The carbamates showed
 strong anticholinergic activity both centrally and peripherally.
 IT 17656-14-3P 18692-63-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 17656-14-3 CAPLUS
 CN Carbanic acid, diphenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA
 INDEX NAME)



RN 18692-63-2 CAPLUS
 CN Carbanic acid, N-ethyl-, 3-quinuclidinyl ester, monohydrochloride (8CI)
 (CA INDEX NAME)



● HCl

L3 ANSWER 47 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1967:464199 CAPLUS

DOCUMENT NUMBER: 67:64199

ORIGINAL REFERENCE NO.: 67:12067a,12070a

TITLE: 3,4,5-Trimethoxyphenylcarbamic acid esters of some cyclic amino alcohols

AUTHOR(S): Dahlbom, Richard; Karlén, Bo; Nilsson, Lars

CORPORATE SOURCE: Kungl. Farm. Inst., Stockholm, Swed.

SOURCE: Acta Pharmaceutica Suecica (1967), 4(3), 211-16

CODEN: APSXAS; ISSN: 0001-6675

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Ten 3,4,5-trimethoxyphenyl-carbamic acid esters of cyclic amino alc. were prepared by the Curtius rearrangement. Thus, a solution of 0.02 mole 3,4,5-trimethoxybenzoyl azide and 0.03 mole amino alc. in dry benzene was refluxes 2 hrs. Quaternary ammonium salts were prepared by dissolving 0.015 mole amino ester in 20 ml. acetone and adding 5 ml. MeBr. The mixture was kept overnight at room temperature I prepared are (R₁, m.p., and % yield given):


N-methyl-3-piperidyl, 99-100°, 46 [MeBr salt, m. 234-5° (decomposition)], 88; N-ethyl-3-piperidyl, 81-2.5° [50, MeBr salt m. 187-8° (decomposition)], 69; N-methyl-4-piperidyl, 142-3.5°, 64 [MeBr salt m.p. 183.5-84° (decomposition)] 95; 1-azabicyclo[2.2.2]oct-3-yl, 173-4°, 78; 2-methyl-2-azabicyclo[1.3.2]oct-5-yl(axial), 175-7°, 77; 2-methyl-2-azabicyclo[1.3.2]oct-5-yl(equatorial) II, 215-16°, 91; 2-methyl-2-azabicyclo[1.3.3]non-5-yl(axial), 126-7°, 64; 4-methyl-2,5-methano-2H-furo[3,2-b]pyrrol-6-yl (IIa), 142.5-44°, 57; 2-methyl-4-carbomethoxy-2-azabicyclo[1.3.2]oct-5-yl(axial CO₂Me) (III), 164-5°, 73; 2-methyl-4-carbomethoxy-2-azabicyclo[1.3.2]oct-5-yl(equatorial). The new compds. were tested in mice and only II and III showed some local anesthetic activity. 12 references.

IT 15436-52-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 15436-52-9 CAPLUS

CN Carbanilic acid, 3,4,5-trimethoxy-, 3-quinuclidinyl ester (8CI) (CA INDEX NAME)



L3 ANSWER 48 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1966:465412 CAPLUS
DOCUMENT NUMBER: 65:65412
ORIGINAL REFERENCE NO.: 65:12163d-g
TITLE: New quinuclidine derivatives
AUTHOR(S): Tondeur, R.; Urbain, M.
CORPORATE SOURCE: Lab. Rech. Labaz, Brussels, Belg.
SOURCE: Chim. Therap (1966), 19(66(4)), 207-8
DOCUMENT TYPE: Journal
LANGUAGE: French

GI For diagram(s), see printed CA Issue.

AB Quinuclidin-3-ol (Sternbach and Kaiser, CA 48, 6437d) gave 3-quinuclidinyl benzoate-HCl, m. 225° (Mikhлина and Rubetsov, CA 54, 22632h), p-nitrobenzoate-HCl, m. 258-60° (loc. cit.), and p-aminobenzoate-HCl, (I.HCl), m. 220°. I.HCl (359 mg.) heated 2 hrs. at 45-50° in 2 cc. H2O with 200 mg. ClCO2Et, and then left overnight in an ice chest gave a crystalline precipitate of IIa.HCl; yield 400 mg., m.

225° (H2O). To a mixture of 266 mg. I (base) in 3 cc. C6H6 and 68 mg. NMe3 in C6H6, was added with stirring, 136.5 mg. ClCO2Bu. The product was collected and recrystd. from Me2COAcOEt to give 91 mg. IIb.HCl, m. 222°. To a Grignard reagent from 0.48 g. Mg and 3.1 g. PhBr in 10 cc. Et2O was added during 20 min. 0.88 g. Me quinuclidine-3-carboxylate in 10 cc. Et2O, after refluxing 1 hr. the mixture was treated with 25 cc. saturated

NH4Cl and 25 g. ice. The aqueous layer was washed with Et2O, and the combined Et2O solns. on evaporation gave 520 mg. unidentified amorphous substance. From the aqueous layer was filtered 1.28 g. diphenyl-3-quinuclidinylcarbinol-HCl (IIIa.HCl), m. 285-90° (EtOH); IIIa m. 239°. In the similar preparation of bis(p-methoxyphenyl)-3-quinuclidinylcarbinol (IIb), the aqueous solution of reaction product, after extraction with Et2O, was made alkaline with NH4OH


and extracted with CHCl3. The extract yielded 3.5 g. IIb (base), m. 198-200° (AcOEt). An organic solution of IIb treated with an Et2O solution of HCl gas gave 3-bis[(p-methoxyphenyl)methylene] quinuclidine HCl salt, m. 243° (MeOH-Me2CO). I, IIa, and IIIa had slight spasmolytic activity.

IT 859037-31-3P, Carbanilic acid, p-carboxy-, N-ethyl 3-quinuclidinyl ester, hydrochloride

RL: PREP (Preparation)
(preparation of)

RN 859037-31-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● HC1


L3 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1965:472047 CAPLUS
 DOCUMENT NUMBER: 63:72047
 ORIGINAL REFERENCE NO.: 63:13276g-h,13277a-b
 TITLE: N-Benzodioxanylcarbamates
 PATENT ASSIGNEE(S): Lakeside Laboratories, Inc.
 SOURCE: 6 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|----------|---------------|-----------------|----------|
| ----- | ----- | ----- | ----- | ----- |
| GB 998878 | 19650721 | GB 1961-39225 | 19611102 | 19610125 |
| PRIORITY APPLN. INFO.: | | | | |
| GI For diagram(s), see printed CA Issue. | | | | |
| AB Title compds. (I) where n = 0-3 and R = dialkylamino or a cyclic amino structure, were prepared from 2-benzodioxanyl isocyanate (II) and amino alcs. II was prepared from benzodioxane-2-carbonyl chloride (III) and NaN ₃ . Thus, 20 g. III in 100 cc. dry PhMe was added to 42.5 g. NaN ₃ in 100 cc. dry PhMe at 50°, the mixture refluxed 15 hrs., the salts filtered off, and the resulting II solution refluxed 1 hr. with 19.2 g. N-benzyl-3-hydroxypiperidine. PhMe was distilled at reduced pressure, the residue dissolved in 300 cc. dry Et ₂ O, and treated with ethereal HCl. The precipitate was washed with 100 cc. MeCN to yield 19.3 g. I (n = 0, R = N-benzyl-3-piperidinyl) hydrochloride (IV), m. 211-12°. Similarly prepared were the following I [n, R, salt, m.p. of salt, hrs. reflux, and % yield (if reported) given]: 3, NET ₂ , hydrochloride, 136-7°, 2, 56; 1, N-ethyl-2-pyrrolidinyl, acid fumarate, 167-8° (decomposition), 2, 38; 0, 3-quinuclidinyl, acid fumarate, 176-7° (decomposition), 2; 3, 4-d-(1-phenyl-2-propyl)piperazino, di-acid fumarate, 188-90°, 2, 69.5; 3, 4-methylpiperazino, di-acid fumarate, 191-3° (EtOH), 2; 0, N-methyl-3-piperidinyl, free base, 142-4° (Et ₂ O-n-hexane), 1. IV (15.4 g.) in 200 cc. MeOH hydrogenated 20 min. at 60 psi. in the presence of 3 g. 10% Pd-C gave 10.2 g. I (n = 0, R = 3-piperidinyl) hydrochloride, m. 170-1° (MeCN-Et ₂ O). I have analgetic properties and are skeletal muscle relaxants and mild tranquilizers. | | | | |
| IT 2318-38-9B, 3-Quinuclidinol, 1,4-benzodioxan-2-carbamate (ester) | | | | |
| 2456-61-3P, 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester, fumarate (1:1) | | | | |
| RL: PREP (Preparation)
(preparation of) | | | | |
| RN 2318-38-9 CAPLUS | | | | |
| CN 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester (7CI, 8CI) (CA INDEX NAME) | | | | |



RN 2456-61-3 CAPLUS
 CN 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester, fumarate (1:1)
 (8CI) (CA INDEX NAME)


CRN 2318-38-9
CMF C16 H20 N2 O4



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L3 ANSWER 50 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1965:416892 CAPLUS
 DOCUMENT NUMBER: 63:16892
 ORIGINAL REFERENCE NO.: 63:2982a-c
 TITLE: Aminoalkyl N-[2-(1,4-benzodioxyl)]carbamates
 INVENTOR(S): Judd, Claude I.
 PATENT ASSIGNEE(S): Colgate-Palmolive Co.
 SOURCE: 4 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|----------|-----------------|----------|
| US 3185692 | | 19650525 | US 1962-205849 | 19610125 |
| PRIORITY APPLN. INFO.: US | | | | |
| GI For diagram(s), see printed CA Issue. | | | | |
| AB Esters of the general formula I are prepared and can be used as skeletal muscle relaxants. Thus, a solution of 20 g. 1,4-benzodioxane-2-carbonyl chloride in 100 ml. PhMe is added at 50° to a mixture of 42.5 g. Na ₃ in 100 ml. PhMe, the mixture is refluxed .apprx.1 1/2 hrs. and filtered, 42.5 g. Na ₃ is added, and the mixture is refluxed 16 hrs. and filtered. The filtrate is treated with 0.1 mole N-methyl-3-hydroxypiperidine, the mixture is refluxed 1 hr., and the solvent is distilled in vacuo to give 14.9 g. 1-methyl-3-piperidyl N-[2-(1,4-benzodioxyl)]carbamate, m. 142-4° (ether-hexane), HCl salt m. 136° (decomposition). Similarly prepared are the following I (R, m.p. acid fumarate, and m.p. di acid fumarate given): 1-benzyl-3-piperidyl, --, --, HCl salt m. 211-12°; 3-[4-d-(1-phenyl-2-propyl)-1-piperazinyl]propyl, --, 188-90° (decomposition); 1-ethyl-2-pyrrolidylmethyl, 167-8° (decomposition); γ-(4-pyridyl)propyl, 139-40° (MeCN), --; 3-(4-methylpiperazino)propyl, --, 191-3° (EtOH); 3-quinuclidinyl, 176-7° (decomposition), --; Et ₂ N(CH ₂) ₃ , --, --, HCl salt m. 136-7°. | | | | |
| IT | 2318-38-9P, 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester | | | |
| | 2456-61-3P, 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester, fumarate (1:1) | | | |
| RL | PREP (Preparation)
(preparation of) | | | |
| RN | 2318-38-9 CAPLUS | | | |
| CN | 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester (7CI, 8CI) (CA INDEX NAME) | | | |




RN 2456-61-3 CAPLUS
 CN 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester, fumarate (1:1)
 (8CI) (CA INDEX NAME)

CM 1

CRN 2318-38-9

CMF C16 H20 N2 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST | 276.34 | 454.91 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -40.00 | -40.00 |

STN INTERNATIONAL LOGOFF AT 11:23:01 ON 05 JUN 2008